| MDL | - |
|---|---|
| Molecular Weight | 853.91 |
| Molecular Formula | C47H51NO14 |
| SMILES | O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O |
|
Traditional Cytotoxic Agents |
Paclitaxel (20 nM; 48 hours) induces programmed cell death and exists a block at the G2/M phase of the cell cycle
[1]
.
Paclitaxel (20 nM; 48 hours) induces a consistent increase in the level of p53
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Apoptosis Analysis [1]
| Cell Line: | MCF-7, MDA-MB-231 cells |
| Concentration: | 20 nM |
| Incubation Time: | 48 hours |
| Result: | Induced programmed cell death. |
Cell Cycle Analysis [1]
| Cell Line: | MCF-7, MDA-MB-231 cells |
| Concentration: | 20 nM |
| Incubation Time: | 48 hours |
| Result: | >60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament. |
Western Blot Analysis [1]
| Cell Line: | MCF-7 cells (harboring wild-type p53) |
| Concentration: | 20 nM |
| Incubation Time: | 48 hours |
| Result: | Induced a consistent increase in the level of p53. |
Paclitaxel (1-20 mg/kg; i.p.; 1 time/2 days for five cycles) obviously induces liver metastases at the low-Paclitaxel group with little influence on primary tumor growth [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | MDA-231 xenograft-bearing mice [3] |
| Dosage: | 1, 20 mg/kg |
| Administration: | Intraperitoneal injection; five cycles (1 time/2 days) |
| Result: | Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group. |
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00730353 | Hoosier Cancer Research Network|Pfizer |
Esophageal Cancer
|
August 2008 | Phase 2 |
| NCT03377491 | NovoCure Ltd. |
Pancreas Adenocarcinoma
|
May 10, 2018 | Phase 3 |
| NCT02041338 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Cancer|Neoadjuvant Chemotherapy
|
January 2014 | Phase 2 |
| NCT02483104 | AbbVie |
Ovarian Cancer
|
July 2015 | Phase 1 |
| NCT00653952 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Sequus Pharmaceuticals|ALZA |
Ovarian Neoplasms
|
May 1997 | Phase 3 |
| NCT00080418 | INSYS Therapeutics Inc |
Neoplasm
|
July 2003 | Phase 1 |
| NCT01079481 | Samsung Medical Center |
Small Cell Lung Cancer
|
December 2009 | Phase 1 |
| NCT00033696 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
September 2001 | Phase 2 |
| NCT04656041 | Massachusetts General Hospital|Ipsen |
Gastroesophageal Junction Adenocarcinoma|Esophagogastric Cancer
|
June 29, 2021 | Phase 2 |
| NCT00126581 | National Cancer Institute (NCI) |
Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Malignant Pericardial Effusion|Malignant Pleural Effusion|Minimally Invasive Lung Adenocarcinoma|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7
|
August 15, 2005 | Phase 2 |
| NCT03644186 | ETOP IBCSG Partners Foundation|Pfizer|Hoffmann-La Roche |
Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer
|
April 16, 2019 | Phase 2 |
| NCT00014118 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
March 2001 | Phase 2 |
| NCT01204125 | Sanofi|SOLTI Breast Cancer Research Group |
Breast Cancer Female
|
September 2010 | Phase 2 |
| NCT03432598 | BeiGene |
Locally Advanced Lung Cancer; Metastatic Lung Cancer
|
August 24, 2017 | Phase 2 |
| NCT02451956 | Samsung Medical Center |
Advanced Gastric Cancer
|
January 7, 2015 | Phase 2 |
| NCT03292822 | Cairo University |
Squamous Cell Carcinoma
|
November 1, 2017 | Early Phase 1 |
| NCT01653470 | Bristol-Myers Squibb |
Cancer
|
October 12, 2012 | Phase 1 |
| NCT03607955 | Washington University School of Medicine|Aravive, Inc. |
Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer
|
June 30, 2021 | Phase 1 |
| NCT04736823 | Akeso |
NSCLC
|
February 1, 2021 | Phase 2 |
| NCT05552651 | Tao Jiang|Air Force Military Medical University, China |
Esophageal Squamous Cell Carcinoma
|
September 20, 2022 | Phase 2 |
| NCT00033657 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
May 2002 | Phase 2 |
| NCT01204996 | Centocor, Inc. |
Cancer
|
May 2010 | Phase 1 |
| NCT02109328 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Bladder Cancer|Transitional Cell Carcinoma
|
August 28, 2014 | Phase 2 |
| NCT00049257 | Jonsson Comprehensive Cancer Center|Bristol-Myers Squibb |
Prostate Cancer
|
October 2002 | Phase 2 |
| NCT01263145 | National Cancer Institute (NCI) |
Adult Solid Neoplasm|Recurrent Breast Carcinoma|Stage IV Breast Cancer
|
January 5, 2011 | Phase 1 |
| NCT04661696 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd. |
Ovarian Cancer
|
December 9, 2020 | Phase 2 |
| NCT00874848 | HiberCell, Inc. |
NSCLC
|
August 2009 | Phase 2 |
| NCT01200342 | M.D. Anderson Cancer Center|Genta Incorporated |
Melanoma
|
December 2010 | Phase 2 |
| NCT05047250 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
June 15, 2022 | Phase 3 |
| NCT00825201 | City of Hope Medical Center|National Cancer Institute (NCI)|National Comprehensive Cancer Network |
Ovarian Cancer|Peritoneal Cavity Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
January 2009 | Phase 1 |
| NCT00520975 | National Cancer Institute (NCI) |
Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer
|
November 2007 | Phase 3 |
| NCT02985333 | Sun Yat-sen University |
Relapse+Refractory Multiple Myeloma
|
January 2014 | Phase 2 |
| NCT02263495 | Asan Medical Center|Eisai Inc.|Dong-A ST Co., Ltd.|Samyang Biopharmaceuticals Corporation |
Metastatic Breast Cancer
|
December 19, 2014 | Phase 2 |
| NCT03246074 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Rigel Pharmaceuticals|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) |
Ovarian Cancer
|
April 3, 2018 | Phase 1 |
| NCT00003160 | Theradex|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
September 1997 | Phase 2 |
| NCT02364713 | Mayo Clinic|National Cancer Institute (NCI) |
Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Primary Peritoneal Carcinosarcoma|Primary Peritoneal Clear Cell Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Primary Peritoneal Transitional Cell Carcinoma|Primary Peritoneal Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
March 13, 2015 | Phase 2 |
| NCT00033410 | California Cancer Consortium|National Cancer Institute (NCI) |
Lung Cancer
|
March 2002 | Phase 1 |
| NCT00006108 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT04821765 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophagus Cancer|Chemoradiotherapy|Oligometastatic Disease|Immunotherapy
|
October 1, 2020 | Phase 2 |
| NCT05450042 | University Hospital, Essen |
Peripheral Arterial Disease|Flow-mediated Dilation|Drug Eluting Balloon|Infrainguinal Peripheral Arterial Disease
|
April 6, 2022 | Not Applicable |
| NCT03604991 | National Cancer Institute (NCI) |
Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
January 17, 2019 | Phase 2|Phase 3 |
| NCT00856492 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
April 2010 | Phase 2 |
| NCT00434252 | Genentech, Inc. |
Melanoma
|
February 2007 | Phase 2 |
| NCT02923739 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Adenocarcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
May 5, 2017 | Phase 2 |
| NCT01023347 | Samyang Biopharmaceuticals Corporation |
Non Small Cell Lung Cancer
|
June 2008 | Phase 2 |
| NCT01015222 | M.D. Anderson Cancer Center |
Advanced Cancer
|
November 2009 | Phase 1 |
| NCT04079192 | Biosensors Europe SA |
Coronary Artery Disease|In-Stent Restenosis
|
August 7, 2020 | Not Applicable |
| NCT02595554 | Sun Yat-sen University |
Cervical Carcinoma Stage IIB
|
November 2015 | Phase 3 |
| NCT03783442 | BeiGene |
Esophageal Squamous Cell Carcinoma (ESCC)
|
December 11, 2018 | Phase 3 |
| NCT01593020 | M.D. Anderson Cancer Center|Eisai Inc. |
Breast Cancer
|
August 3, 2012 | Phase 2 |
| NCT04840290 | Tang-Du Hospital |
Non Small Cell Lung Cancer
|
June 1, 2019 | Phase 3 |
| NCT03245892 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb |
High Grade Serous Ovarian|Fallopian Tube|Primary Peritoneal Cancer
|
August 4, 2017 | Phase 1 |
| NCT04982237 | Akeso |
Cervical Cancer
|
August 27, 2021 | Phase 3 |
| NCT01094184 | Hoffmann-La Roche |
Breast Cancer
|
March 2010 | Phase 4 |
| NCT01980472 | Grupo de Investigación y Divulgación Oncológica |
Non-small Cell Lung Cancer (NSCLC)
|
August 2013 | Phase 2 |
| NCT04127019 | Fudan University |
Primary Breast Cancer
|
June 1, 2010 | Phase 3 |
| NCT00533949 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Cancer and Leukemia Group B|NRG Oncology |
Lung Cancer|Radiation Toxicity
|
November 2007 | Phase 3 |
| NCT05287308 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd. |
Breast Cancer
|
March 2022 | Not Applicable |
| NCT00602797 | University of Nebraska|National Cancer Institute (NCI) |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer
|
December 2007 | Phase 2 |
| NCT00393068 | SCRI Development Innovations, LLC|Genentech, Inc. |
Esophageal Cancer
|
February 2007 | Phase 2 |
| NCT00002568 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer
|
June 1994 | Phase 3 |
| NCT01572038 | Hoffmann-La Roche |
Breast Neoplasms
|
June 1, 2012 | Phase 3 |
| NCT01171170 | Dutch Society of Physicians for Pulmonology and Tuberculosis |
Non Small Cell Lung Cancer
|
January 2011 | Phase 2 |
| NCT00307255 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2006 | Phase 1 |
| NCT04053205 | GeneScience Pharmaceuticals Co., Ltd.|Shanghai East Hospital|The First Affiliated Hospital, Zhejiang University School of Medicine|Fujian Tumor Hospital|Sir Run Run Shaw Hospital|The Affiliated Tumor Hospital of Harbin Medical University|Union Hospital of Tongji Medical College, Huazhong University of Science and Technology|Sixth Affiliated Hospital, Sun Yat-sen University|Tongji Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|The First Hospital of Jilin University|The First Affiliated Hospital with Nanjing Medical University|The First Affiliated Hospital of Zhengzhou University |
Advanced Gastric or Gastroesophageal Junction Cancer
|
August 2019 | Phase 1|Phase 2 |
| NCT03872947 | Toray Industries, Inc |
Solid Tumor|Colorectal Cancer|Cholangiocarcinoma|Bladder Cancer|Ovarian Cancer|Gastric Cancer|Palpable Subcutaneous Malignant Lesions|Renal Cell Carcinoma|Melanoma|Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer
|
April 26, 2019 | Phase 1 |
| NCT02229058 | Sun Yat-sen University |
Gastric Cancer
|
February 2012 | Phase 2 |
| NCT01705483 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
Pharmacokinetics of ASP9853|Non-hematologic Malignancies
|
August 28, 2012 | Phase 1 |
| NCT03587311 | National Cancer Institute (NCI) |
Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube High Grade Serous Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma
|
June 29, 2018 | Phase 2 |
| NCT00702299 | University of Arizona|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
September 2007 | Phase 1 |
| NCT04921527 | Chipscreen Biosciences, Ltd. |
Ovarian Cancer|Relapsed or Refractory|Chiauranib|Paclitaxel
|
December 20, 2021 | Phase 3 |
| NCT04806945 | Shanghai Henlius Biotech |
Cervical Cancer
|
September 30, 2022 | Phase 3 |
| NCT00596830 | Pfizer |
Carcinoma, Squamous Cell|Carcinoma, Adenosquamous|Carcinoma, Large Cell|Carcinoma, Non-Small-Cell Lung
|
April 2008 | Phase 3 |
| NCT00003877 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Breast Cancer
|
September 1998 | Phase 1|Phase 2 |
| NCT00028938 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Lung Cancer
|
January 1, 2002 | Phase 3 |
| NCT00654758 | AbbVie |
Non-small Cell Lung Cancer
|
December 2007 | Phase 1 |
| NCT00494182 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Squamous Cell Carcinoma of the Hypopharynx|Metastatic Squamous Cell Carcinoma of the Larynx|Metastatic Squamous Cell Carcinoma of the Oral Cavity|Metastatic Squamous Cell Carcinoma of the Oropharynx|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma
|
April 25, 2007 | Phase 2 |
| NCT02365805 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Breast Cancer
|
April 2014 | Phase 2 |
| NCT03314935 | Incyte Corporation |
Biliary Tract Cancer (BTC)|Colorectal Cancer (CRC)|Endometrial Cancer|Gastroesophageal Cancer (GC)|Ovarian Cancer|Solid Tumors
|
November 21, 2017 | Phase 1|Phase 2 |
| NCT03920839 | Incyte Corporation |
Advanced and+or Metastatic Solid Tumors|Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer|Advanced+Metastatic Unresectable Malignant Pleural Mesothelioma
|
July 15, 2019 | Phase 1 |
| NCT01764022 | Biocad |
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
|
October 2012 | Phase 3 |
| NCT03850444 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
August 1, 2016 | Phase 3 |
| NCT05207709 | SOLTI Breast Cancer Research Group|Novartis|Alliance Foundation Trials, LLC. |
Metastatic Breast Cancer
|
March 28, 2022 | Phase 3 |
| NCT03242096 | InnoRa GmbH |
Coronary Restenosis
|
July 21, 2017 | Not Applicable |
| NCT00866528 | GlaxoSmithKline |
Lung Cancer, Non-Small Cell
|
July 9, 2009 | Phase 1 |
| NCT05158062 | Kosei Hasegawa, MD, PhD|Saitama Medical University International Medical Center |
Carcinoma, Ovarian Epithelial
|
April 20, 2022 | Phase 2 |
| NCT00278148 | Nathan Pennell, MD, PhD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center |
Lung Cancer
|
October 2005 | Phase 1|Phase 2 |
| NCT00002734 | National Cancer Institute (NCI) |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
March 1996 | Phase 1 |
| NCT00097227 | Eli Lilly and Company|Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
November 2004 | Phase 2 |
| NCT01644890 | Nippon Kayaku Co., Ltd. |
Breast Cancer Nos Metastatic Recurrent
|
July 2012 | Phase 3 |
| NCT02560298 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma|Stage IIIB Anal Canal Cancer|Stage IV Anal Canal Cancer
|
February 1, 2016 | Phase 2 |
| NCT03367182 | Yonsei University |
Ovarian Cancer
|
September 1, 2017 | |
| NCT00088829 | Georgetown University|National Cancer Institute (NCI) |
Breast Cancer
|
April 2001 | Phase 2 |
| NCT03942068 | Henan Cancer Hospital |
Ovarian Cancer
|
September 1, 2019 | Phase 2 |
| NCT00005644 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer
|
May 2000 | Phase 2 |
| NCT00436566 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Cancer|Cardiac Toxicity
|
March 16, 2007 | Phase 2 |
| NCT03792074 | Sinocelltech Ltd. |
Non-squamous Cell Non-small Cell Lung Cancer
|
February 2019 | Phase 3 |
| NCT01740336 | Genentech, Inc. |
Breast Cancer
|
February 6, 2013 | Phase 2 |
| NCT00028873 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
September 2001 | Phase 2 |
| NCT04627870 | Acotec Scientific Co., Ltd|Beijing Tiantan Hospital |
Intracranial Atherosclerosis|Stroke
|
May 26, 2021 | Not Applicable |
| NCT04672928 | Innovent Biologics (Suzhou) Co. Ltd. |
Small Cell Lung Carcinoma
|
December 21, 2020 | Phase 1 |
| NCT00429299 | GlaxoSmithKline |
Neoplasms, Breast
|
August 2006 | Phase 2 |
| NCT01980277 | Institut Paoli-Calmettes |
Breast Cancer
|
January 2014 | Phase 1|Phase 2 |
| NCT00016406 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
May 2001 | Phase 3 |
| NCT04730219 | Tianjin Medical University Second Hospital |
Muscle Invasive Bladder Cancer|Urothelial Carcinoma
|
July 11, 2020 | Phase 2 |
| NCT00011999 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
March 2001 | Phase 2 |
| NCT04175912 | National Cancer Institute (NCI) |
Metastatic Cholangiocarcinoma|Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Cholangiocarcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma
|
January 31, 2020 | Phase 2 |
| NCT02776917 | Barbara Parker, MD|Oncternal Therapeutics, Inc|University of California, San Diego |
Breast Neoplasms
|
August 15, 2018 | Phase 1 |
| NCT03595059 | AbbVie |
Advanced Solid Tumors
|
July 13, 2018 | Phase 1 |
| NCT00003158 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
February 1998 | Phase 2 |
| NCT03875092 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
April 21, 2017 | Phase 3 |
| NCT02250599 | Sun Yat-sen University |
Nasopharyngeal Neoplasms
|
August 2014 | Phase 2 |
| NCT05189730 | Sichuan Cancer Hospital and Research Institute |
Esophageal Squamous Cell Carcinoma
|
July 1, 2021 | Phase 2 |
| NCT04814485 | Tianjin Medical University Cancer Institute and Hospital |
Pancreatic Cancer
|
April 22, 2021 | Phase 2 |
| NCT03691090 | Jiangsu HengRui Medicine Co., Ltd. |
Advanced Esophageal Cancer
|
December 3, 2018 | Phase 3 |
| NCT02001272 | Hospices Civils de Lyon |
Ovarian Cancer
|
December 2013 | Phase 2 |
| NCT00955305 | National Cancer Institute (NCI) |
Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer|Bronchioloalveolar Lung Carcinoma
|
March 2010 | Phase 2 |
| NCT02336087 | City of Hope Medical Center|National Cancer Institute (NCI) |
Pancreatic Adenocarcinoma|Unresectable Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7
|
January 14, 2016 | Phase 1 |
| NCT05145218 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recurrent Platinum-resistant Ovarian Cancer
|
September 28, 2021 | Phase 3 |
| NCT04739800 | National Cancer Institute (NCI)|NRG Oncology |
Fallopian Tube Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Platinum-Refractory Fallopian Tube Carcinoma|Platinum-Refractory Ovarian Carcinoma|Platinum-Refractory Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Mucinous Adenocarcinoma|Recurrent Fallopian Tube Transitional Cell Carcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian High Grade Serous Adenocarcinoma|Recurrent Ovarian Low Grade Serous Adenocarcinoma|Recurrent Ovarian Mucinous Adenocarcinoma|Recurrent Ovarian Seromucinous Carcinoma|Recurrent Ovarian Transitional Cell Carcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Transitional Cell Carcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma|Refractory Fallopian Tube Clear Cell Adenocarcinoma|Refractory Fallopian Tube Endometrioid Adenocarcinoma|Refractory Fallopian Tube High Grade Serous Adenocarcinoma|Refractory Fallopian Tube Mucinous Adenocarcinoma|Refractory Fallopian Tube Transitional Cell Carcinoma|Refractory Fallopian Tube Undifferentiated Carcinoma|Refractory Low Grade Fallopian Tube Serous Adenocarcinoma|Refractory Ovarian Clear Cell Adenocarcinoma|Refractory Ovarian Endometrioid Adenocarcinoma|Refractory Ovarian High Grade Serous Adenocarcinoma|Refractory Ovarian Low Grade Serous Adenocarcinoma|Refractory Ovarian Mucinous Adenocarcinoma|Refractory Ovarian Seromucinous Carcinoma|Refractory Ovarian Transitional Cell Carcinoma|Refractory Ovarian Undifferentiated Carcinoma|Refractory Primary Peritoneal Clear Cell Adenocarcinoma|Refractory Primary Peritoneal Endometrioid Adenocarcinoma|Refractory Primary Peritoneal High Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Transitional Cell Carcinoma|Refractory Primary Peritoneal Undifferentiated Carcinoma
|
April 28, 2021 | Phase 2 |
| NCT01196429 | National Cancer Institute (NCI)|NRG Oncology |
Ovarian Clear Cell Cystadenocarcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer
|
August 2010 | Phase 2 |
| NCT00470366 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor
|
March 2007 | Phase 2 |
| NCT00511459 | Amgen |
Locally Recurrent and Metastatic Breast Cancer
|
July 2007 | Phase 2 |
| NCT00977574 | National Cancer Institute (NCI)|NRG Oncology |
Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Cancer|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
September 14, 2009 | Phase 2 |
| NCT00020761 | Jonsson Comprehensive Cancer Center |
Esophageal Cancer|Gastric Cancer
|
April 2000 | Phase 2 |
| NCT00003555 | State University of New York - Upstate Medical University|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 1998 | Phase 1 |
| NCT00139633 | The Oregon Clinic|Bristol-Myers Squibb|MedImmune LLC |
Esophageal Cancer
|
July 2000 | Phase 2 |
| NCT00561795 | GlaxoSmithKline |
Primary Peritoneal Carcinoma|Tumor|Epithelial Ovarian Cancer|Uterine Disease|Cervix Diseases|Neoplasms, Ovarian|Cancer
|
September 2007 | Phase 2 |
| NCT04732598 | Japanese Foundation for Cancer Research|Chugai Pharmaceutical |
Breast Cancer
|
January 21, 2021 | Phase 3 |
| NCT00005087 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
March 2000 | Phase 2 |
| NCT03907475 | National Cancer Institute (NCI) |
Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
June 25, 2019 | Phase 2 |
| NCT04296175 | Fudan University |
Triple-negative Breast Cancer
|
September 18, 2018 | Phase 3 |
| NCT05281003 | Fudan University|Merck Sharp & Dohme LLC |
Esophageal Squamous Cell Carcinoma
|
September 1, 2022 | Phase 2 |
| NCT02474173 | National Cancer Institute (NCI) |
Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma
|
January 15, 2016 | Phase 1 |
| NCT02509286 | University Hospital Schleswig-Holstein|Clinical Trials Unit Freiburg|University of Freiburg|University of Leipzig|University of Luebeck|University of Hamburg-Eppendorf |
Esophageal Adenocarcinoma (UICC TNM7)|Adenocarcinoma of the Esophagogastric Junction
|
January 2016 | Phase 3 |
| NCT01138046 | GlaxoSmithKline |
Neoplasms, Breast
|
April 2010 | Phase 2 |
| NCT01538108 | N.M.B. Medical Applications Ltd |
Obstructive Lesions of Arteriovenous Dialysis Fistulae
|
July 2012 | Not Applicable |
| NCT04001829 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8
|
June 27, 2019 | Phase 2 |
| NCT02944396 | AbbVie |
Non-Small Cell Lung Cancer
|
December 23, 2016 | Phase 1 |
| NCT00538395 | King Faisal Specialist Hospital & Research Center |
Breast Cancer
|
September 2007 | Not Applicable |
| NCT01120158 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
September 2009 | Phase 2 |
| NCT01973309 | OncoMed Pharmaceuticals, Inc.|Mereo BioPharma |
Metastatic Breast Cancer
|
September 2013 | Phase 1 |
| NCT00001442 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Head and Neck Neoplasm|Squamous Cell Carcinoma
|
July 1995 | Phase 1 |
| NCT01728441 | Provascular GmbH|William Cook Europe |
Peripheral Artery Disease
|
October 2012 | Not Applicable |
| NCT00077246 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
September 2003 | Phase 1|Phase 2 |
| NCT05388500 | Institut de cancérologie Strasbourg Europe |
HER2-positive Breast Cancer
|
December 15, 2022 | Phase 3 |
| NCT03742102 | AstraZeneca |
Triple Negative Breast Neoplasms
|
December 21, 2018 | Phase 1|Phase 2 |
| NCT00526890 | Roswell Park Cancer Institute |
Lung Cancer
|
October 2006 | Phase 2 |
| NCT00729612 | Greg Otterson|National Comprehensive Cancer Network|Celgene Corporation|Ohio State University Comprehensive Cancer Center |
Lung Cancer
|
August 14, 2008 | Phase 2 |
| NCT00542191 | Leo W. Jenkins Cancer Center |
Breast Cancer
|
July 2007 | Phase 2 |
| NCT01663727 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
August 27, 2012 | Phase 3 |
| NCT01133925 | A.O. Ospedale Papa Giovanni XXIII|Case Western Reserve University|Medtronic Vascular |
Coronary Artery Disease
|
May 2008 | Phase 4 |
| NCT03492047 | Ain Shams University|Nasser Institute For Research and Treatment |
Peripheral Neuropathy Due to Chemotherapy
|
April 1, 2018 | Phase 1|Phase 2 |
| NCT05459129 | Hoffmann-La Roche |
Squamous Cell Carcinoma of the Head and Neck
|
February 28, 2023 | Phase 1|Phase 2 |
| NCT03282825 | Dong Wha Pharmaceutical Co. Ltd. |
Advanced Breast Cancer
|
March 28, 2017 | Phase 1 |
| NCT00314678 | John P. Fruehauf|GlaxoSmithKline|University of California, Irvine |
Epithelial Ovarian Cancer|Primary Peritoneal Cancer
|
September 2005 | Phase 2 |
| NCT00055835 | Southwest Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer|Urethral Cancer
|
November 2002 | Phase 2 |
| NCT03600090 | Taizhou EOC Pharma Co., Ltd. |
Solid Tumor, Adult
|
October 16, 2018 | Phase 1 |
| NCT00580983 | University of Michigan Rogel Cancer Center |
Head and Neck Cancer
|
August 2003 | Not Applicable |
| NCT04331067 | Washington University School of Medicine|Bristol-Myers Squibb |
Triple Negative Breast Cancer
|
November 19, 2020 | Phase 1|Phase 2 |
| NCT01138137 | OHSU Knight Cancer Institute |
Ovarian Carcinoma, Stage 3 or 4|Epithelial Ovarian Carcinoma|Primary Peritoneal Carcinoma
|
June 2010 | Phase 1 |
| NCT04561739 | Xijing Hospital |
De Novo Stenosis|Coronary Artery Disease
|
February 1, 2021 | Not Applicable |
| NCT00016913 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Prostate Cancer
|
May 2001 | Phase 2 |
| NCT01084876 | Celltrion |
Metastatic Breast Cancer
|
June 2010 | Phase 3 |
| NCT01853748 | Dana-Farber Cancer Institute |
Breast Cancer
|
May 2013 | Phase 2 |
| NCT02728492 | NewVac LLC|Janssen Pharmaceutica N.V., Belgium |
Non-small Cell Lung Cancer|Epithelial Ovarian Cancer
|
August 2013 | Phase 1 |
| NCT02916511 | Fudan University |
Esophageal Squamous Cell Carcinoma
|
September 1, 2016 | Phase 2 |
| NCT04077255 | National Cancer Center, Korea|Korean Cancer Study Group |
Adenocarcinoma of the Stomach
|
September 1, 2019 | Phase 2 |
| NCT04564157 | Fundación GECP |
Non-Small Cell Lung Cancer|Adjuvant Chemotherapy
|
January 13, 2021 | Phase 3 |
| NCT04269200 | AstraZeneca|The Gynecologic Oncology Group (GOG) Foundation Inc|The European Network for Gynaecological Oncological Trial groups (ENGOT) |
Endometrial Neoplasms
|
May 21, 2020 | Phase 3 |
| NCT00616967 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
May 2008 | Phase 2 |
| NCT02037529 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Breast Adenocarcinoma|HER2+Neu Negative|Invasive Breast Carcinoma|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
January 17, 2014 | Phase 3 |
| NCT00003159 | Medical Research Council|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI) |
Lung Cancer
|
August 1997 | Phase 3 |
| NCT00607048 | Hoffmann-La Roche |
Neoplasms
|
November 2007 | Phase 1 |
| NCT04332367 | Abramson Cancer Center of the University of Pennsylvania |
Non-small Cell Lung Cancer
|
December 19, 2019 | Phase 2 |
| NCT01069796 | ARCAGY+ GINECO GROUP |
Triple Negative Metastatic Breast Cancer
|
April 2010 | Phase 2 |
| NCT00027937 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific
|
August 2001 | Phase 2 |
| NCT02630823 | Washington University School of Medicine|Merck Sharp & Dohme LLC |
Endometrial Cancer|Endometrial Carcinoma|Neoplasms, Endometrial
|
February 5, 2016 | Phase 1 |
| NCT04276389 | Beijing Anzhen Hospital |
Coronary Artery Disease
|
August 1, 2017 | Not Applicable |
| NCT00373256 | Pfizer |
Breast Neoplasms
|
November 2006 | Phase 3 |
| NCT03410784 | National Cancer Institute, Naples|Mario Negri Institute for Pharmacological Research |
Ovarian Cancer
|
April 1, 2018 | Phase 2 |
| NCT00102622 | M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Ovarian Cancer
|
December 1, 2004 | Phase 1 |
| NCT00009763 | University of California, Davis|National Cancer Institute (NCI) |
Breast Cancer
|
March 2001 | Phase 1 |
| NCT02737709 | Sun Yat-sen University |
Non-small Cell Lung Cancer
|
March 2016 | Phase 2 |
| NCT00003327 | Theradex|National Cancer Institute (NCI) |
Head and Neck Cancer
|
September 1997 | Phase 2 |
| NCT02172846 | Washington University School of Medicine |
Carcinoma, Non-Small-Cell Lung
|
May 22, 2014 | Phase 1 |
| NCT03064854 | Novartis Pharmaceuticals|Novartis |
Non-small Cell Lung Cancer
|
May 24, 2017 | Phase 1 |
| NCT05624099 | Fujian Cancer Hospital |
Esophageal Neoplasms|Esophageal Diseases|Digestive System Neoplasms
|
December 1, 2022 | Phase 2 |
| NCT01583426 | German Breast Group|Celgene Corporation|Roche Pharma AG |
Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|Tubular Breast Cancer Stage III|HER-2 Positive Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Cancer
|
July 2012 | Phase 3 |
| NCT02628951 | Samsung Medical Center |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
May 26, 2016 | Phase 2 |
| NCT00003943 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Carcinoma of Unknown Primary|Lung Cancer
|
September 1998 | Phase 2 |
| NCT01822314 | Fondazione Michelangelo |
Breast Cancer
|
April 2013 | Phase 3 |
| NCT00006378 | Case Comprehensive Cancer Center|National Cancer Institute (NCI)|American College of Radiology |
Lung Cancer
|
December 1999 | Phase 2 |
| NCT01003158 | AstraZeneca |
Neoplasms|Metastatic Cancer|Breast Cancer
|
October 2009 | Phase 1 |
| NCT00661193 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
December 2008 | Phase 2 |
| NCT00042809 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
May 2002 | Phase 1 |
| NCT05193604 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pancreatic Carcinoma
|
March 24, 2022 | Phase 1 |
| NCT01238133 | National Cancer Institute (NCI) |
Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
December 2010 | Phase 1 |
| NCT04498689 | Fudan University |
Metastatic Pancreatic Cancer
|
August 1, 2019 | Phase 2 |
| NCT02135822 | Chinese PLA General Hospital |
Advanced Pancreatic Cancer
|
May 2014 | Phase 2 |
| NCT05381038 | National University Hospital, Singapore|The N.1 Institute for Health (N.1)|Cancer Science Institute of Singapore |
Solid Tumor|Gastrointestinal Cancer|Breast Cancer
|
June 2022 | Phase 1|Phase 2 |
| NCT02039674 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Carcinoma
|
February 21, 2014 | Phase 1|Phase 2 |
| NCT02302807 | Hoffmann-La Roche |
Bladder Cancer
|
January 13, 2015 | Phase 3 |
| NCT05481645 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Advanced Endometrial Cancer
|
August 26, 2022 | Phase 2 |
| NCT00003643 | European Organisation for Research and Treatment of Cancer - EORTC |
Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor
|
October 1998 | Phase 2|Phase 3 |
| NCT04943445 | Latin American Cooperative Oncology Group |
Squamous Cell Carcinoma of Larynx
|
February 8, 2022 | Phase 2 |
| NCT01953445 | Washington University School of Medicine |
Breast Neoplasms
|
August 2014 | Phase 2 |
| NCT01086579 | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS |
Coronary Artery Disease
|
March 2010 | Not Applicable |
| NCT00005819 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
April 2000 | Phase 1 |
| NCT02101788 | National Cancer Institute (NCI)|NRG Oncology |
Borderline Ovarian Serous Tumor|Micropapillary Serous Carcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Low Grade Ovarian Serous Adenocarcinoma|Recurrent Primary Peritoneal Serous Adenocarcinoma
|
April 11, 2014 | Phase 2|Phase 3 |
| NCT05383196 | Antonio Giordano, MD|Cardiff Oncology|Dana-Farber Cancer Institute |
Breast Cancer|Invasive Breast Cancer|Unresectable Breast Carcinoma|Locally Advanced Breast Cancer|Metastatic Breast Cancer|Inflammatory Breast Cancer|Triple Negative Breast Cancer (TNBC)|Hormone Receptor+Growth Factor Receptor-Negative Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Negative Breast Carcinoma
|
September 30, 2022 | Phase 1|Phase 2 |
| NCT00030368 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
November 2001 | Phase 1 |
| NCT02775435 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
June 9, 2016 | Phase 3 |
| NCT00561119 | Samsung Medical Center|Korean Cancer Study Group |
Advanced Breast Cancer
|
May 2007 | Phase 3 |
| NCT00016900 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer
|
December 2000 | Phase 2 |
| NCT03462212 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Istituto Di Ricerche Farmacologiche Mario Negri|Foundation Medicine |
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
|
March 17, 2021 | Phase 1|Phase 2 |
| NCT00639522 | Nanjing Sike Pharmaceutical Co., Ltd. |
Gastric Carcinoma
|
May 2008 | Phase 1 |
| NCT00614484 | Loma Linda University |
Locally Advanced Non-Small Cell Lung Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT02542293 | AstraZeneca |
Non Small Cell Lung Carcinoma NSCLC
|
November 3, 2015 | Phase 3 |
| NCT00408655 | National Cancer Institute (NCI) |
Ovarian Sarcoma|Ovarian Stromal Cancer|Recurrent Endometrial Carcinoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage III Endometrial Carcinoma|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Endometrial Carcinoma|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific
|
February 2007 | Phase 1 |
| NCT05506943 | Compass Therapeutics |
Biliary Tract Cancer|Cholangiocarcinoma|Gall Bladder Cancer|Ampullary Cancer
|
September 2022 | Phase 2|Phase 3 |
| NCT02430311 | AstraZeneca |
Advanced Solid Tumours
|
June 10, 2015 | Phase 1 |
| NCT00832494 | Antisoma Research |
Non-Small Cell Lung Cancer
|
September 2004 | Phase 1|Phase 2 |
| NCT00002913 | National Cancer Institute (NCI) |
Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer
|
December 1996 | Phase 1 |
| NCT00479817 | Amgen |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
July 5, 2007 | Phase 2 |
| NCT01721746 | Bristol-Myers Squibb |
Unresectable or Metastatic Melanoma
|
December 21, 2012 | Phase 3 |
| NCT04366596 | Peking Union Medical College Hospital |
Hypertension, Renovascular
|
October 1, 2019 | Phase 3 |
| NCT05415709 | Ohio State University Comprehensive Cancer Center |
Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8
|
June 13, 2022 | Early Phase 1 |
| NCT01446016 | The Methodist Hospital Research Institute |
Breast Neoplasms|Breast Cancer
|
September 2011 | Phase 2 |
| NCT00511849 | Pfizer |
Neoplasms
|
November 2005 | Phase 1 |
| NCT00003128 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|GOG Foundation |
Sarcoma
|
November 1997 | Phase 3 |
| NCT00603941 | Daiichi Sankyo, Inc. |
Anaplastic Thyroid Cancer
|
January 2008 | Phase 1|Phase 2 |
| NCT00756470 | M.D. Anderson Cancer Center|GlaxoSmithKline |
Breast Cancer
|
October 2008 | Phase 2 |
| NCT02640755 | AstraZeneca|Quintiles, Inc. |
Solid Malignancies
|
January 28, 2016 | Phase 1 |
| NCT00003086 | Louisiana State University Health Sciences Center Shreveport |
Breast Cancer
|
March 1997 | Phase 1|Phase 2 |
| NCT05228743 | Tianjin Medical University Cancer Institute and Hospital |
Gastric Cancer
|
September 1, 2020 | Not Applicable |
| NCT01345851 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
March 23, 2011 | Not Applicable |
| NCT00039039 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|National Cancer Institute (NCI) |
Lung Cancer
|
February 2000 | Phase 3 |
| NCT04329065 | University of Washington|United States Department of Defense |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8
|
April 20, 2022 | Phase 2 |
| NCT00003054 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Sarcoma
|
August 1997 | Phase 2 |
| NCT01159418 | Southern Europe New Drug Organization|Novartis |
Advanced Solid Tumors
|
June 2008 | Phase 1 |
| NCT03193918 | Arog Pharmaceuticals, Inc. |
Esophagogastric Adenocarcinoma
|
April 14, 2017 | Phase 1 |
| NCT02019277 | Hoffmann-La Roche |
Breast Cancer
|
December 5, 2013 | Phase 3 |
| NCT02654119 | University of Nebraska|National Cancer Institute (NCI) |
HER2 Positive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7
|
December 11, 2015 | Phase 2 |
| NCT00194779 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
October 2003 | Phase 2 |
| NCT02187991 | US Oncology Research|Millennium Pharmaceuticals, Inc. |
Breast Cancer|Breast Carcinoma|Breast Tumors|Malignant Neoplasm of Breast
|
February 12, 2015 | Phase 2 |
| NCT03301350 | University of Wisconsin, Madison |
Breast Cancer|Triple Negative Breast Cancer
|
November 7, 2017 | Phase 2 |
| NCT01280058 | National Cancer Institute (NCI) |
Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer
|
December 2010 | Phase 2 |
| NCT05411237 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
Kaposi Sarcoma|HIV-1-infection
|
December 2022 | Phase 3 |
| NCT01897441 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
June 2013 | Not Applicable |
| NCT00002949 | University of Chicago|National Cancer Institute (NCI) |
Bladder Cancer|Cervical Cancer|Endometrial Cancer|Vaginal Cancer
|
July 1996 | Phase 1 |
| NCT00288041 | National Cancer Institute (NCI) |
Ciliary Body and Choroid Melanoma, Medium+Large Size|Extraocular Extension Melanoma|Iris Melanoma|Recurrent Intraocular Melanoma|Recurrent Melanoma|Stage IV Melanoma
|
October 2005 | Phase 2 |
| NCT03704077 | Bristol-Myers Squibb |
Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction
|
October 31, 2019 | Phase 2 |
| NCT00393315 | University Hospital, Saarland|B. Braun Melsungen AG |
In-Stent Restenosis
|
November 2005 | Phase 2 |
| NCT03935256 | Loyola University |
Endometrial Cancer
|
March 5, 2019 | Phase 2 |
| NCT00004077 | Medical Research Council|National Cancer Institute (NCI) |
Testicular Germ Cell Tumor
|
May 1996 | Phase 2 |
| NCT01057342 | Swiss Group for Clinical Cancer Research |
Lung Cancer
|
January 2010 | Phase 2 |
| NCT00006081 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
June 2000 | Phase 2 |
| NCT00273507 | Rigshospitalet, Denmark |
Non-small Cell Lung Cancer
|
January 1998 | Phase 3 |
| NCT01276041 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|University of Pennsylvania |
Breast Cancer
|
January 5, 2011 | Phase 2 |
| NCT03594747 | BeiGene |
Non-Small Cell Lung Cancer
|
July 30, 2018 | Phase 3 |
| NCT03635567 | Merck Sharp & Dohme LLC |
Cervical Cancer
|
October 25, 2018 | Phase 3 |
| NCT02890511 | Daehwa Pharmaceutical Co., Ltd. |
Solid Tumor|Stage IV Gastric Cancer
|
August 2010 | Phase 1|Phase 2 |
| NCT00942357 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IA Uterine Corpus Cancer AJCC v7|Stage IB Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7
|
June 29, 2009 | Phase 3 |
| NCT01726452 | Cancer Trials Ireland|Southampton Clinical Trials Unit|Region H Rigshospitalet|Centre Hospitalier Régional, Universitaire de Lille |
Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Oesophago-gastric Junction|Oesophageal Tumours|Junctional Tumours|Oesophageal Cancer
|
January 24, 2013 | Phase 3 |
| NCT00499291 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Cancer
|
September 2006 | Not Applicable |
| NCT00733408 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer
|
April 23, 2008 | Phase 2 |
| NCT03798626 | Novartis Pharmaceuticals|Novartis |
Colorectal Cancer|Gastroesophageal Cancer|Renal Cell Carcinoma
|
May 22, 2019 | Phase 1 |
| NCT00024310 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Unspecified Adult Solid Tumor, Protocol Specific
|
September 2001 | Phase 1 |
| NCT00034177 | Achieve Life Sciences |
Urologic Neoplasms
|
April 2002 | Phase 2 |
| NCT02279134 | Zefen Xiao|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Neoplasms|Esophageal Cancer
|
October 2014 | Phase 2|Phase 3 |
| NCT02367352 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Tumors|Ovarian Cancer|Small Cell Lung Cancer
|
March 19, 2015 | Phase 1 |
| NCT05203913 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Muscle-Invasive Bladder Carcinoma
|
February 1, 2022 | Phase 2 |
| NCT04766827 | Tianjin Medical University Cancer Institute and Hospital |
Squamous Cell Carcinoma of Head and Neck
|
December 12, 2020 | Phase 4 |
| NCT05446870 | Merck Sharp & Dohme LLC |
High-grade Serous Ovarian Carcinoma|Ovarian Carcinoma
|
July 25, 2022 | Phase 2 |
| NCT02038621 | The Second People´s Hospital of Sichuan |
Advanced Gastric Cancer
|
January 2014 | Phase 2 |
| NCT00002854 | City of Hope Medical Center|National Cancer Institute (NCI) |
Cancer
|
December 1994 | Phase 1 |
| NCT00002894 | Medical Research Council|National Cancer Institute (NCI) |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
March 1996 | Phase 3 |
| NCT05017012 | Merck Sharp & Dohme LLC |
Advanced or Metastatic Solid Tumors
|
September 21, 2021 | Phase 1 |
| NCT05251766 | Xuli Meng|Zhejiang Provincial People´s Hospital |
Breast Cancer|Chemotherapy Effect
|
April 20, 2022 | Phase 1 |
| NCT00004057 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific
|
December 1998 | Phase 1 |
| NCT01281852 | National Cancer Institute (NCI)|NRG Oncology |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer AJCC v6 and v7
|
March 14, 2011 | Phase 1 |
| NCT02048020 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Human Papilloma Virus Infection|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Verrucous Carcinoma of the Larynx
|
December 26, 2013 | Phase 2 |
| NCT04188860 | Lei Li|Peking Union Medical College Hospital |
Recurrent Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Chemotherapy|Anti-PD-1 Antibody|Immunotherapy
|
December 6, 2019 | Phase 2 |
| NCT05449483 | Tianjin Medical University Cancer Institute and Hospital |
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage|Unresectable
|
May 11, 2022 | Phase 2 |
| NCT00002937 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
June 1996 | Phase 2 |
| NCT05012254 | Fundación GECP |
Non Small Cell Lung Cancer|Brain Metastases, Adult|Lung Cancer
|
November 18, 2021 | Phase 2 |
| NCT00003088 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
September 1997 | Phase 3 |
| NCT03464734 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Metastatic Urothelial Carcinoma
|
January 16, 2019 | Phase 2 |
| NCT00005059 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
January 2000 | Phase 2 |
| NCT00022139 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
January 2002 | Phase 2 |
| NCT00180479 | Abbott Medical Devices |
Stents|Coronary Artery Disease|Total Coronary Occlusion|Coronary Artery Restenosis|Stent Thrombosis|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis
|
June 2005 | Phase 3 |
| NCT00929162 | AstraZeneca|ISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALI |
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
|
June 2009 | Phase 2 |
| NCT05116189 | Merck Sharp & Dohme LLC |
Ovarian Cancer|Carcinoma, Ovarian Epithelial|Fallopian Tube Neoplasms
|
December 13, 2021 | Phase 3 |
| NCT03085004 | Milton S. Hershey Medical Center|National Cancer Institute (NCI) |
Pancreatic Cyst|EUS-FNA
|
April 12, 2019 | Phase 3 |
| NCT01506609 | AbbVie |
Metastatic Breast Cancer
|
January 23, 2012 | Phase 2 |
| NCT04669197 | HonorHealth Research Institute |
Untreated Resectable Pancreatic Adenocarcinoma|Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma
|
December 1, 2020 | Phase 2 |
| NCT00003334 | NYU Langone Health|National Cancer Institute (NCI) |
Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Sarcoma
|
March 1997 | Phase 2 |
| NCT04929392 | City of Hope Medical Center|National Cancer Institute (NCI) |
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
|
January 25, 2022 | Phase 2 |
| NCT01097746 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Carcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|FIGO Stage III Ovarian Cancer|FIGO Stage IIIA Ovarian Cancer|FIGO Stage IIIA1 Ovarian Cancer|FIGO Stage IIIA1(i) Ovarian Cancer|FIGO Stage IIIA1(ii) Ovarian Cancer|FIGO Stage IIIA2 Ovarian Cancer|FIGO Stage IIIB Ovarian Cancer|FIGO Stage IIIC Ovarian Cancer|FIGO Stage IVA Ovarian Cancer|FIGO Stage IVB Ovarian Cancer|Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Carcinoma|Primary Peritoneal Serous Adenocarcinoma
|
April 14, 2010 | Phase 2 |
| NCT04674956 | RenJi Hospital |
Pancreatic Cancer Stage IV|Pancreatic Cancer Metastatic
|
January 1, 2021 | Phase 3 |
| NCT03085914 | Incyte Corporation |
Solid Tumor
|
May 2, 2017 | Phase 1|Phase 2 |
| NCT01110603 | Tesaro, Inc. |
Cancer: Solid Tumors
|
July 2010 | Phase 1 |
| NCT01608009 | Imperial College London|GlaxoSmithKline |
Ovarian Neoplasm
|
July 2012 | Phase 1 |
| NCT02182245 | Boehringer Ingelheim |
Genital Neoplasms, Female
|
October 2005 | Phase 1 |
| NCT00513383 | Massachusetts General Hospital|Brigham and Women´s Hospital|Amgen |
Squamous Cell Carcinoma of the Head and Neck
|
April 2006 | Phase 1 |
| NCT00004159 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Lung Cancer
|
February 2000 | Phase 1|Phase 2 |
| NCT03668730 | Sun Yat-sen University |
Nasopharyngeal Carcinoma
|
October 19, 2018 | Phase 2 |
| NCT00003008 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|AIDS Associated Malignancies Clinical Trials Consortium |
Sarcoma
|
June 1997 | Phase 2 |
| NCT04205812 | Incyte Corporation|Zai Lab (Shanghai) Co., Ltd. |
Metastatic Squamous Non-Small Cell Lung Cancer|Metastatic Nonsquamous Non-Small Cell Lung Cancer
|
September 27, 2020 | Phase 3 |
| NCT00002627 | St. Louis University|National Cancer Institute (NCI) |
Breast Cancer
|
November 1994 | Phase 1|Phase 2 |
| NCT04983407 | Aravive, Inc. |
Pancreatic Adenocarcinoma
|
July 28, 2021 | Phase 1|Phase 2 |
| NCT00930930 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
June 2009 | Phase 2 |
| NCT00289835 | Laval University|Boston Scientific Corporation |
Coronary Artery Bypass Grafting
|
February 2006 | Phase 4 |
| NCT01331941 | Amgen |
Advanced Solid Tumors|Kidney Disease|Renal Impairment
|
September 19, 2011 | Phase 1 |
| NCT00019812 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 2 |
| NCT01120184 | Hoffmann-La Roche|Genentech, Inc. |
Breast Cancer
|
July 31, 2010 | Phase 3 |
| NCT04644250 | Wei Ren|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Esophageal Squamous Cell Carcinoma
|
September 1, 2020 | Phase 2 |
| NCT00511992 | University of Oklahoma|Genentech, Inc. |
Advanced Ovarian Carcinoma|Primary Peritoneal Carcinoma|Ovarian Carcinosarcoma
|
July 2007 | Phase 2 |
| NCT02996214 | Nanjing Luye Sike Pharmaceutical Co., Ltd. |
Squamous Non-small-cell Lung Cancer
|
November 2016 | Phase 4 |
| NCT01121406 | Boehringer Ingelheim |
Ovarian Neoplasms
|
April 2010 | Phase 2 |
| NCT00004202 | Spectrum Pharmaceuticals, Inc |
Lung Cancer
|
October 1998 | Phase 2 |
| NCT00062010 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
February 2004 | Phase 2 |
| NCT01421472 | Merrimack Pharmaceuticals|Sanofi |
ER Positive, Her2 Negative Breast Cancer Patients|Triple Negative Breast Cancer Patients
|
August 2011 | Phase 2 |
| NCT05190445 | Pieris Pharmaceuticals, Inc. |
HER2-positive Gastric Cancer
|
November 1, 2021 | Phase 2 |
| NCT03117933 | University of Oxford|AstraZeneca |
Ovarian Cancer
|
March 9, 2017 | Phase 2 |
| NCT05035147 | Tianjin Medical University Cancer Institute and Hospital |
Pancreatic Cancer
|
March 25, 2021 | Phase 4 |
| NCT04762953 | University of California, Irvine |
Gastric Cancer|Peritoneal Carcinomatosis|Gastroesophageal Junction Adenocarcinoma
|
February 18, 2021 | Phase 2 |
| NCT00610714 | AstraZeneca |
Ovarian Neoplasms|Ovarian Cancer
|
April 2008 | Phase 2 |
| NCT00003930 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer
|
September 1999 | Phase 1|Phase 2 |
| NCT00226746 | New York Presbyterian Brooklyn Methodist Hospital |
Carcinoma, Pancreatic Ductal
|
March 2003 | Phase 2 |
| NCT04374630 | Laekna Limited |
Platinum-resistant Ovarian Cancer
|
June 9, 2020 | Phase 2 |
| NCT03871036 | The Netherlands Cancer Institute|AstraZeneca |
Urothelial Carcinoma
|
May 1, 2019 | Phase 1|Phase 2 |
| NCT00823186 | Chang Gung Memorial Hospital|Sinphar Pharmaceutical Co., Ltd |
Cervical Cancer
|
February 2009 | Phase 1 |
| NCT03735082 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Cancer
|
November 1, 2018 | Phase 2 |
| NCT01599078 | Midwest Cardiovascular Research Foundation|Spectranetics Corporation |
Restenosis|Peripheral Arterial Disease
|
January 2012 | Not Applicable |
| NCT01244789 | Danish Gynecological Cancer Group|European Organisation for Research and Treatment of Cancer - EORTC|Arbeitsgemeinschaft Gynaekologische Onkologie Austria|North Eastern German Society of Gynaecological Oncology|Nordic Society of Gynaecological Oncology - Clinical Trials Unit|Belgian Gynaecological Oncology Group|Mario Negri Gynecologic Oncology group (MaNGO)|Israeli Society of Gynecologic Oncology|Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITTO)|Central and Eastern European Oncology Group |
Endometrial Cancer
|
December 2011 | Phase 2 |
| NCT04572100 | University of Chicago |
Oropharyngeal Squamous Cell Carcinoma
|
October 1, 2020 | Phase 1 |
| NCT00580333 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Genentech, Inc. |
Breast Cancer
|
September 2007 | Phase 2 |
| NCT00565851 | National Cancer Institute (NCI)|NRG Oncology |
Clear Cell Adenocarcinoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Mucinous Adenocarcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinofibroma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Clear Cell Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Primary Peritoneal Transitional Cell Carcinoma|Primary Peritoneal Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Carcinoma
|
December 6, 2007 | Phase 3 |
| NCT02488967 | NRG Oncology|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
July 2015 | Phase 3 |
| NCT00662129 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
November 2008 | Phase 2 |
| NCT02934464 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Stomach Neoplasms
|
December 2016 | Phase 3 |
| NCT05177796 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
|
March 11, 2022 | Phase 2 |
| NCT00006276 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Psoriasis
|
September 2000 | Phase 2 |
| NCT00546156 | Ian E. Krop, MD, PhD|Genentech, Inc.|Massachusetts General Hospital|Brigham and Women´s Hospital|New Hampshire Oncology-Hematology PA|Dana-Farber Cancer Institute |
Breast Cancer
|
October 2007 | Phase 2 |
| NCT01525706 | Lawson Health Research Institute|University of Western Ontario, Canada |
Mucinous Cystic Tumor With Moderate Dysplasia|Mucinous Cystadenoma of Pancreas|Mucinous Cystadenocarcinoma of Pancreas|Benign Neoplasm of Pancreas
|
September 2012 | Phase 1 |
| NCT00295893 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 14, 2005 | Phase 2 |
| NCT01763645 | Biocad |
Non-small Cell Lung Cancer
|
October 2012 | Phase 3 |
| NCT05535569 | Yonsei University |
Recurrent+Metastatic Gastric Cancer
|
July 17, 2017 | Phase 1|Phase 2 |
| NCT02593708 | Michelle Melisko|University of California, San Francisco |
Solid Tumor
|
November 3, 2015 | Phase 1 |
| NCT00021060 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
August 2002 | Phase 2|Phase 3 |
| NCT03286244 | AnewPharma |
Advanced Gastric Cancer
|
March 15, 2018 | Phase 1 |
| NCT04054531 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
Non-small Cell Lung Cancer
|
September 4, 2019 | Phase 2 |
| NCT00228319 | Jeanne Drisko, MD, CNS, FACN|Cancer Treatment Research Foundation|University of Kansas Medical Center |
Ovarian Cancer
|
October 2002 | Phase 1|Phase 2 |
| NCT01517997 | University of Patras |
Arterial Occlusive Disease
|
August 2011 | Phase 2|Phase 3 |
| NCT04177108 | Hoffmann-La Roche |
Triple-Negative Breast Cancer
|
November 25, 2019 | Phase 3 |
| NCT00793897 | Bristol-Myers Squibb |
Advanced Solid Tumors|Metastatic Solid Tumors
|
April 2009 | Phase 1 |
| NCT01982448 | Dana-Farber Cancer Institute|Myriad Genetics, Inc.|Translational Breast Cancer Research Consortium |
Triple Negative Breast Cancer
|
April 2014 | Phase 2 |
| NCT00252798 | AstraZeneca |
Non Small Cell Lung Carcinoma
|
July 2002 | Phase 1 |
| NCT00951665 | Genentech, Inc. |
Metastatic Breast Cancer
|
August 2009 | Phase 1|Phase 2 |
| NCT03138720 | HonorHealth Research Institute |
Resectable Pancreatic Cancer|Unresectable Pancreatic Cancer|Pancreatic Adenocarcinoma|Neoadjuvant Pancreatic Cancer
|
May 23, 2017 | Phase 2 |
| NCT00005048 | NYU Langone Health|National Cancer Institute (NCI) |
Prostate Cancer
|
April 1997 | Phase 1 |
| NCT05275777 | National University Hospital, Singapore|Adagene Inc |
HER2-negative Breast Cancer|Advanced Solid Tumor
|
May 19, 2022 | Phase 1|Phase 2 |
| NCT01333085 | GERCOR - Multidisciplinary Oncology Cooperative Group |
Head and Neck Cancer
|
October 2009 | Phase 1|Phase 2 |
| NCT04224922 | AZ-VUB|Universitaire Ziekenhuizen KU Leuven|Universitair Ziekenhuis Brussel |
Breast Cancer
|
May 2015 | Phase 2 |
| NCT05188313 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Esophageal Cancer|Esophageal Adenocarcinoma
|
March 9, 2022 | Phase 3 |
| NCT00005612 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Ovarian Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT04956692 | Merck Sharp & Dohme LLC |
Non-Small Cell Lung Cancer
|
August 5, 2021 | Phase 3 |
| NCT01224652 | Korean Cancer Study Group|Boryung Pharmaceutical Co., Ltd |
Gastric Cancer
|
Phase 3 | |
| NCT00807859 | Amgen |
Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors
|
March 9, 2009 | Phase 1 |
| NCT00513695 | University of Washington|National Cancer Institute (NCI) |
Inflammatory Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
June 2007 | Phase 2 |
| NCT02957968 | Virginia Commonwealth University|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor- Negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2+Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive Tumor|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Triple-negative Breast Carcinoma
|
January 24, 2017 | Phase 2 |
| NCT00091039 | National Cancer Institute (NCI) |
Lung Cancer
|
August 2004 | Not Applicable |
| NCT02406170 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Esophageal Neoplasms|Stomach Neoplasms|Neoplasm Metastasis
|
April 2015 | Phase 1|Phase 2 |
| NCT04069273 | Harry H Yoon|Merck Sharp & Dohme LLC|Mayo Clinic|Hoosier Cancer Research Network |
Gastric Cancer|GastroEsophageal Cancer|Adenocarcinoma
|
December 1, 2020 | Phase 2 |
| NCT05007106 | Merck Sharp & Dohme LLC |
Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma|Urinary Bladder Neoplasms|Ovarian Neoplasms|Stomach Neoplasms
|
September 16, 2021 | Phase 2 |
| NCT02230319 | Medical Oncology & Hematology Associates of Northern Virginia|Inova Health Care Services |
Breast Cancer
|
October 2014 | Phase 2 |
| NCT00001499 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Carcinoma, Non-Small-Cell Lung|Lung Neoplasms
|
March 1996 | Phase 2 |
| NCT04579224 | National Cancer Institute (NCI) |
Metastatic Bladder Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Ureter Urothelial Carcinoma|Metastatic Urethral Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Refractory Bladder Urothelial Carcinoma|Refractory Renal Pelvis Urothelial Carcinoma|Refractory Ureter Urothelial Carcinoma|Refractory Urethral Urothelial Carcinoma|Refractory Urothelial Carcinoma|Stage IV Bladder Cancer AJCC v8|Stage IV Renal Pelvis and Ureter Cancer AJCC v8|Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Stage IVA Bladder Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8
|
February 16, 2021 | Phase 3 |
| NCT01959490 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
September 24, 2013 | Phase 2 |
| NCT01297452 | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|Sai Life Sciences |
Solid Tumors
|
February 15, 2011 | Phase 1 |
| NCT03498716 | Hoffmann-La Roche|Breast International Group|Alliance Foundation Trials (AFT)|Institut Jules Bordet+Clinical Trials Support Unit (IJB+CTSU)|Frontier Science & Technology Research Foundation, Inc. |
Triple Negative Breast Cancer
|
August 2, 2018 | Phase 3 |
| NCT05624918 | Ashish Manne|NovoCure GmbH|Ohio State University|Big Ten Cancer Research Consortium |
Pancreatic Adenocarcinoma|Resectable Pancreatic Cancer
|
November 2022 | Phase 2 |
| NCT03474107 | Astellas Pharma Global Development, Inc.|Seagen Inc.|Astellas Pharma Inc |
Ureteral Cancer|Urothelial Cancer|Bladder Cancer
|
June 27, 2018 | Phase 3 |
| NCT01847677 | Grupo Español de Investigación en Cáncer de Ovario|Roche Pharma AG |
Cancer, Ovarian
|
May 6, 2013 | Phase 2 |
| NCT02789657 | Brown University|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital |
Breast Cancer
|
November 21, 2016 | Phase 2 |
| NCT04159155 | University Health Network, Toronto |
Endometrial Cancer|Serous Tumor|P53 Mutation
|
November 17, 2020 | Phase 2|Phase 3 |
| NCT00814086 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Chemotherapeutic Agent Toxicity|Endometrial Adenocarcinoma|Fallopian Tube Carcinoma|Gastrointestinal Complication|Malignant Ovarian Mixed Epithelial Tumor|Neurotoxicity Syndrome|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage II Ovarian Cancer|Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Undifferentiated Ovarian Carcinoma
|
February 2009 | Phase 1 |
| NCT03894540 | Ipsen |
Solid Tumor
|
March 22, 2019 | Phase 1 |
| NCT00487669 | Dartmouth-Hitchcock Medical Center|CTI BioPharma |
Advanced Non-small Cell Lung Cancer
|
October 2006 | Phase 2 |
| NCT05429463 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Squamous Cell Non-small Cell Lung Cancer
|
November 11, 2022 | Phase 3 |
| NCT00068757 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
August 2003 | Phase 1 |
| NCT00433511 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group |
Breast Adenocarcinoma
|
November 2, 2007 | Phase 3 |
| NCT05044728 | Sichuan Cancer Hospital and Research Institute |
Non-small Cell Lung Cancer|Esophageal Squamous Cell Carcinoma
|
April 1, 2021 | Phase 2 |
| NCT05427383 | Shanghai JMT-Bio Inc. |
Stomach Cancer
|
April 7, 2022 | Phase 2|Phase 3 |
| NCT02574078 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
November 23, 2015 | Phase 1|Phase 2 |
| NCT02909751 | Vejle Hospital |
Breast Cancer
|
September 14, 2016 | Phase 2 |
| NCT02436993 | University of California, Irvine |
Breast Carcinoma
|
April 2015 | Phase 2 |
| NCT00795678 | Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
September 2008 | |
| NCT03556358 | Tanvex BioPharma USA, Inc. |
Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
June 28, 2018 | Phase 3 |
| NCT00003624 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Neurotoxicity|Ovarian Cancer|Primary Peritoneal Cavity Cancer|Sarcoma
|
December 1998 | Phase 2 |
| NCT01159236 | M.D. Anderson Cancer Center |
Breast Cancer
|
September 2010 | Not Applicable |
| NCT00779714 | University of Wuerzburg|Hiege-Stiftung gegen Hautkrebs|medac GmbH|DCS Innovative Diagnostik Systeme |
Melanoma
|
October 2008 | Phase 3 |
| NCT05420454 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer
|
July 10, 2022 | Phase 4 |
| NCT02037048 | Case Comprehensive Cancer Center |
Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Adenocarcinoma of the Gastric Cardia|Stage IIIA Esophageal Cancer|Stage IIIB Esophageal Cancer|Stage IIIC Esophageal Cancer
|
February 10, 2014 | Phase 2 |
| NCT01146795 | Jason D. Wright|Genentech, Inc.|Columbia University |
Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer
|
May 17, 2010 | Phase 2 |
| NCT00524303 | GlaxoSmithKline |
Neoplasms, Breast
|
August 2007 | Phase 2 |
| NCT05325632 | H. Lee Moffitt Cancer Center and Research Institute|ImmunoRestoration |
HER2-positive Breast Cancer
|
November 1, 2021 | Phase 2 |
| NCT00360360 | SCRI Development Innovations, LLC|Genentech, Inc. |
Neoplasm, Unknown Primary
|
July 2006 | Phase 2 |
| NCT03834571 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Stellenbosch|University of Arkansas |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|FIGO Stage IIB Cervix Carcinoma|FIGO Stage III Cervix Carcinoma|FIGO Stage IVA Cervix Carcinoma|HIV Infection
|
May 31, 2022 | Phase 2 |
| NCT00084214 | Synta Pharmaceuticals Corp. |
Melanoma
|
May 2004 | Phase 1|Phase 2 |
| NCT05033769 | Institut fuer Frauengesundheit|Eisai GmbH |
Breast Cancer Female|Neoplasm, Breast|Breast Cancer Metastatic
|
March 11, 2021 | Phase 4 |
| NCT02603679 | Thomas Hatschek|Karolinska University Hospital |
Early-Stage Breast Carcinoma|Estrogen Receptor Positive Tumor
|
February 2015 | Phase 2 |
| NCT01253525 | Eli Lilly and Company |
Adenocarcinoma
|
November 2010 | Phase 1 |
| NCT03168880 | Tata Memorial Hospital |
Triple Negative Breast Cancer
|
April 2010 | Phase 3 |
| NCT04794699 | IDEAYA Biosciences |
Solid Tumor
|
April 14, 2021 | Phase 1 |
| NCT01756183 | Zhejiang Cancer Hospital |
Surgically-Created Resection Cavity|Drug Safety
|
September 2011 | Phase 2 |
| NCT04083963 | University of Illinois at Chicago |
Triple Negative Breast Cancer
|
August 9, 2019 | Phase 2 |
| NCT01918254 | Hoffmann-La Roche |
Breast Cancer
|
August 6, 2013 | Phase 1 |
| NCT00687817 | Peregrine Pharmaceuticals |
Non-small Cell Lung Cancer
|
June 2008 | Phase 2 |
| NCT03957590 | BeiGene |
Esophageal Squamous Cell Carcinoma (ESCC)
|
June 12, 2019 | Phase 3 |
| NCT04193059 | Fudan University |
Breast Cancer
|
August 1, 2018 | Phase 3 |
| NCT03309150 | Merck KGaA, Darmstadt, Germany |
Advanced Stage Solid Tumors
|
January 10, 2018 | Phase 1 |
| NCT00005028 | University of Maryland, Baltimore|National Cancer Institute (NCI) |
Prostate Cancer
|
May 2000 | Phase 2 |
| NCT04428151 | Merck Sharp & Dohme LLC|Eisai Inc. |
Squamous Cell Carcinoma of Head and Neck
|
August 6, 2020 | Phase 2 |
| NCT00898417 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lung Cancer
|
March 14, 2008 | |
| NCT00191256 | Eli Lilly and Company |
Carcinoma, Non Small Cell Lung
|
June 2001 | Phase 2 |
| NCT00128856 | Spanish Breast Cancer Research Group|Eli Lilly and Company|Bristol-Myers Squibb |
Breast Cancer
|
March 2003 | Phase 2 |
| NCT03840915 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Carcinoma, Non-Small-Cell Lung
|
April 2, 2019 | Phase 1|Phase 2 |
| NCT00820690 | Barretos Cancer Hospital|University of Sao Paulo |
Breast Cancer
|
July 2008 | |
| NCT05256225 | National Cancer Institute (NCI)|NRG Oncology |
Endometrial Serous Adenocarcinoma|Uterine Corpus Carcinosarcoma
|
August 12, 2022 | Phase 2|Phase 3 |
| NCT05322720 | Taizhou EOC Pharma Co., Ltd. |
Solid Tumor, Adult
|
April 2022 | Phase 2 |
| NCT01579578 | AstraZeneca |
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
|
April 2012 | Phase 2 |
| NCT00022633 | Southwest Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer
|
July 2001 | Phase 2 |
| NCT02622074 | Merck Sharp & Dohme LLC |
Triple Negative Breast Neoplasms
|
January 27, 2016 | Phase 1 |
| NCT01240655 | Novartis Pharmaceuticals|Novartis |
Solid Tumors
|
April 2011 | Phase 1 |
| NCT00618826 | Barbara Ann Karmanos Cancer Institute|Eli Lilly and Company|Genentech, Inc. |
Metastatic Breast Cancer
|
November 2006 | Phase 2 |
| NCT04133155 | Asan Medical Center|Bundang CHA Hospital|Ulsan University Hospital |
Pancreatic Cancer|Metastatic Pancreatic Cancer
|
September 16, 2019 | |
| NCT05382299 | Gilead Sciences |
Triple Negative Breast Cancer|PD-L1 Negative
|
July 20, 2022 | Phase 3 |
| NCT02004093 | Hoffmann-La Roche |
Ovarian Cancer
|
December 2005 | Phase 2 |
| NCT01215136 | Matthew Galsky|Hoosier Cancer Research Network|Novartis Pharmaceuticals |
Transitional Cell Carcinoma|Bladder Carcinoma|Urothelial Carcinoma
|
December 2010 | Phase 2 |
| NCT02658214 | AstraZeneca |
Small Cell Lung Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Stomach Neoplasms|Triple Negative Breast Neoplasms|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms|Esophagogastric Junction Neoplasms|Carcinoma, Pancreatic Ductal|Esophageal Squamous Cell Carcinoma
|
April 28, 2016 | Phase 1 |
| NCT02472964 | Mylan Inc.|Mylan GmbH|Viatris Inc. |
Breast Cancer
|
July 2012 | Phase 3 |
| NCT03048942 | University Hospitals Bristol and Weston NHS Foundation Trust |
HER2 Negative Metastatic Breast Cancer
|
November 2014 | Phase 2 |
| NCT00002972 | European Organisation for Research and Treatment of Cancer - EORTC |
Lung Cancer
|
January 1997 | Phase 2 |
| NCT00028743 | NCIC Clinical Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Grupo Español de Investigación en Cáncer de Ovario|Canadian Cancer Trials Group |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
August 31, 2001 | Phase 3 |
| NCT02413320 | Priyanka Sharma|University of Kansas Medical Center |
Triple-negative Breast Cancer
|
July 2015 | Phase 2 |
| NCT00589238 | National Cancer Centre, Singapore |
Breast Cancer
|
January 2008 | Phase 2 |
| NCT00028535 | National Cancer Institute (NCI) |
Male Breast Cancer|Recurrent Breast Cancer|Recurrent Endometrial Carcinoma|Recurrent Gastric Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Small Cell Lung Cancer
|
November 2001 | Phase 1 |
| NCT04982549 | Shandong Cancer Hospital and Institute |
Unresectable Stage III NSCLC
|
January 21, 2021 | Phase 2 |
| NCT00493025 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Esophageal Cancer
|
April 2005 | Phase 2 |
| NCT01850628 | NSABP Foundation Inc|Breast Cancer Research Foundation|Washington University School of Medicine |
Breast Cancer
|
July 2013 | |
| NCT03328234 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
|
September 1, 2017 | Phase 3 |
| NCT04475016 | Sun Yat-sen University |
Penile Cancer
|
August 12, 2020 | Phase 2 |
| NCT00618917 | Joel Greenberger|University of Pittsburgh |
Esophageal|Toxicity
|
November 11, 2005 | Phase 1|Phase 2 |
| NCT01716715 | National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
November 6, 2012 | Phase 2 |
| NCT02370498 | Merck Sharp & Dohme LLC |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
May 11, 2015 | Phase 3 |
| NCT00034346 | Amgen |
Non-Small Cell Lung Cancer|Neoplasm Metastasis|Lung Cancer
|
January 2002 | Phase 2 |
| NCT00707707 | AstraZeneca |
Breast Cancer|Triple Negative Breast Cancer|Metastatic Breast Cancer
|
September 15, 2008 | Phase 1 |
| NCT01620190 | University of Washington|National Cancer Institute (NCI)|Celgene Corporation |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer
|
December 2, 2012 | Phase 2 |
| NCT03330028 | M.D. Anderson Cancer Center |
Diseases of Oesophagus Stomach and Duodenum
|
October 27, 2017 | Phase 1 |
| NCT00003717 | St. Barnabas Medical Center|National Cancer Institute (NCI) |
Prostate Cancer
|
October 1998 | Phase 2 |
| NCT05189535 | Ain Shams University |
Breast Cancer Female|Peripheral Neuropathy
|
October 3, 2021 | Phase 2|Phase 3 |
| NCT00084565 | Fox Chase Cancer Center |
Prostate Cancer
|
November 2003 | Phase 2 |
| NCT00063999 | GOG Foundation|National Cancer Institute (NCI) |
Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
August 25, 2003 | Phase 3 |
| NCT05307705 | Eli Lilly and Company|Loxo Oncology, Inc. |
Breast Cancer
|
May 11, 2022 | Phase 1 |
| NCT01160601 | Peregrine Pharmaceuticals |
Non-Squamous Non-Small Cell Lung Cancer
|
June 2010 | Phase 2 |
| NCT02033551 | AbbVie |
Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors
|
December 2013 | Phase 1 |
| NCT01898117 | The Netherlands Cancer Institute|Borstkanker Onderzoek Groep|Roche Pharma AG |
Breast Cancer
|
July 2013 | Phase 2 |
| NCT01281150 | National Cancer Institute (NCI) |
Adult Solid Neoplasm|Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
|
January 2011 | Phase 1 |
| NCT00508326 | M.D. Anderson Cancer Center |
Advanced Cancer
|
October 2005 | Phase 1 |
| NCT01374620 | Centre Oscar Lambret |
Cancer
|
June 2011 | Phase 1 |
| NCT02423603 | Queen Mary University of London|AstraZeneca|Cancer Research UK |
Metastatic Breast Cancer
|
May 2014 | Phase 2 |
| NCT02163694 | AbbVie |
Metastatic Breast Cancer
|
July 17, 2014 | Phase 3 |
| NCT02929576 | Pfizer|Astellas Pharma Inc|Medivation, Inc. |
Breast Cancer
|
September 2016 | Phase 3 |
| NCT04872985 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer|Hormone-receptor Positive Breast Cancer
|
April 20, 2021 | Phase 2 |
| NCT01697293 | Prescient Therapeutics, Ltd.|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Estrogen Receptor Positive|HER2+Neu Negative|Recurrent Breast Carcinoma|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
January 2012 | Phase 1|Phase 2 |
| NCT00352690 | Washington University School of Medicine|CTI BioPharma |
Carcinoma, Non-Small-Cell Lung
|
April 2006 | Phase 2 |
| NCT01840579 | Merck Sharp & Dohme LLC |
Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer
|
April 26, 2013 | Phase 1 |
| NCT00680940 | Cadila Pharnmaceuticals |
Non Small Cell Lung Cancer
|
June 2008 | Phase 2 |
| NCT04943653 | Seoul St. Mary´s Hospital |
Stomach Neoplasms|Paclitaxel|Peritoneal Metastases
|
June 8, 2021 | Phase 1|Phase 2 |
| NCT00971867 | Bristol-Myers Squibb |
Head and Neck Cancer
|
August 4, 2006 | Phase 2 |
| NCT00343083 | University of Maryland, Baltimore|Bristol-Myers Squibb |
Cancer of Head and Neck
|
December 2004 | Phase 2 |
| NCT04426955 | Jiangsu HengRui Medicine Co., Ltd. |
Esophageal Cancer
|
June 30, 2020 | Phase 3 |
| NCT00570531 | University of Michigan Rogel Cancer Center|Genentech, Inc. |
Loco-regional Esophageal Cancer
|
June 2007 | Phase 2 |
| NCT00085358 | National Cancer Institute (NCI)|Gynecologic Oncology Group |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Carcinosarcoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Stage II Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer
|
May 2004 | Phase 1 |
| NCT03410030 | HonorHealth Research Institute|Stand Up To Cancer|Cancer Research UK|Lustgarten Foundation|Translational Genomics Research Institute|Princeton University|Salk Institute for Biological Studies|Cold Spring Harbor Laboratory|Barts Cancer Institute|University of Arizona|Imaging Endpoints |
Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreas Metastases
|
December 15, 2017 | Phase 1|Phase 2 |
| NCT02661815 | Dana-Farber Cancer Institute|Celgene Corporation |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma
|
June 15, 2016 | Phase 1 |
| NCT00113516 | Pfizer |
Non-small Cell Lung Cancer
|
September 2005 | Phase 2 |
| NCT01182610 | Accelerated Community Oncology Research Network|Amgen |
Gastroesophageal Adenocarcinoma|Adenocarcinoma of the Distal Esophagus|Adenocarcinomas of the Gastroesophageal Junction|Adenocarcinoma of the Proximal Stomach
|
April 2011 | Phase 2 |
| NCT05515315 | Fuzhou General Hospital |
Immunotherapy Esophagus Cancer
|
October 9, 2022 | Phase 2 |
| NCT04848753 | Shanghai Junshi Bioscience Co., Ltd. |
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
|
June 18, 2021 | Phase 3 |
| NCT01057563 | Catholic University of the Sacred Heart |
Coronary Artery Disease
|
November 2009 | Phase 4 |
| NCT00011921 | EBMT Solid Tumors Working Party|National Cancer Institute (NCI) |
Lung Cancer
|
September 1997 | Phase 3 |
| NCT00404235 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Melanoma (Skin)
|
October 2006 | Phase 2 |
| NCT02112552 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Endometrial Serous Adenocarcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC1 Uterine Corpus Cancer|Stage IIIC2 Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer
|
April 2014 | Phase 2 |
| NCT00486668 | NSABP Foundation Inc|GlaxoSmithKline |
Invasive Breast Cancer
|
July 2007 | Phase 3 |
| NCT01219777 | Ritu Salani|Genentech, Inc.|Ohio State University Comprehensive Cancer Center |
Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer
|
September 2010 | Phase 1 |
| NCT02903004 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Ovarian Neoplasms
|
April 11, 2016 | Phase 3 |
| NCT04743180 | iVascular S.L.U. |
Angioplasty|Peripheral Arterial Disease|Drug-eluting Balloon|Femoral Artery|Paclitaxel
|
January 18, 2021 | |
| NCT00276796 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer
|
Phase 2 | |
| NCT04266249 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8
|
February 11, 2020 | Phase 2 |
| NCT04964960 | John L. Villano, MD, PhD|University of Kentucky |
Lung Cancer|Lung Cancer Metastatic|Brain Cancer|Cancer
|
December 7, 2021 | Phase 2 |
| NCT00753909 | Hellenic Oncology Research Group |
Non Small Cell Lung Cancer
|
November 2008 | Phase 2 |
| NCT03056833 | Ronald Buckanovich|University of Pittsburgh |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma
|
June 10, 2017 | Phase 1 |
| NCT03839823 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
February 25, 2019 | Phase 2 |
| NCT02562716 | Southwest Oncology Group|National Cancer Institute (NCI) |
Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma
|
January 6, 2016 | Phase 2 |
| NCT02734524 | Southwest Hospital, China |
Non-small Cell Lung Cancer
|
March 2016 | Phase 2 |
| NCT03141359 | Wake Forest University Health Sciences |
Lung
|
May 11, 2017 | Phase 2 |
| NCT02368197 | Shaare Zedek Medical Center |
Dialysis Access Dysfunction
|
July 2015 | Phase 2|Phase 3 |
| NCT02962141 | ZhuHai Cardionovum Medical Device Co., Ltd. |
Peripheral Arterial Disease|Fistula
|
October 2016 | Not Applicable |
| NCT05205200 | Fudan University |
Breast Cancer|Metastatic Cancer
|
February 1, 2022 | Phase 2 |
| NCT00014573 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
August 1998 | Phase 2 |
| NCT02684227 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
August 24, 2016 | Phase 2 |
| NCT05485766 | Okayama University|Merck Sharp & Dohme LLC |
Triple Negative Breast Neoplasms|Triple Negative Breast Cancer|Breast Neoplasms|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|BRCA Mutation|BRCA-Associated Breast Carcinoma
|
October 1, 2022 | Phase 2 |
| NCT00936702 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Carcinoma of Unknown Primary Origin
|
September 2009 | Phase 2 |
| NCT02826161 | Sumitomo Pharma Oncology, Inc. |
Carcinoma, Non-Small-Cell Lung
|
November 2016 | Phase 3 |
| NCT03047265 | Sun Yat-sen University |
Nasopharyngeal Carcinoma
|
February 4, 2017 | Phase 2 |
| NCT04660760 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Unresectable Gastric Adenocarcinoma|Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
|
June 16, 2021 | Phase 2 |
| NCT00002922 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
January 1997 | Phase 2 |
| NCT01967199 | Seung-Jung Park|CardioVascular Research Foundation, Korea|Asan Medical Center |
Coronary Restenosis
|
April 18, 2013 | Phase 4 |
| NCT03189446 | University of Oklahoma |
Endometrial Cancer|Papillary Serous|Clear Cell Endometrial Cancer
|
October 2, 2017 | Phase 2 |
| NCT03914612 | National Cancer Institute (NCI)|Canadian Cancer Trials Group|NRG Oncology |
Endometrial Clear Cell Adenocarcinoma|Endometrial Dedifferentiated Carcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Mixed Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Endometrial Adenocarcinoma|Recurrent Endometrial Carcinoma|Recurrent Endometrial Clear Cell Adenocarcinoma|Recurrent Endometrial Dedifferentiated Carcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Recurrent Endometrial Mixed Cell Adenocarcinoma|Recurrent Endometrial Serous Adenocarcinoma|Recurrent Endometrial Undifferentiated Carcinoma|Stage III Uterine Corpus Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8
|
July 16, 2019 | Phase 3 |
| NCT00113399 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
April 2005 | Phase 3 |
| NCT04623775 | Bristol-Myers Squibb |
Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer
|
February 17, 2021 | Phase 2 |
| NCT02344095 | Seoul National University Hospital |
Epithelial Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma
|
December 2014 | Phase 1 |
| NCT00891072 | National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia
|
July 2009 | Phase 1 |
| NCT01952249 | OncoMed Pharmaceuticals, Inc.|Mereo BioPharma |
Primary Peritoneal Carcinoma
|
August 5, 2013 | Phase 1 |
| NCT04808687 | Tianjin Medical University Cancer Institute and Hospital |
Pancreatic Neoplasms
|
March 2021 | Phase 2 |
| NCT02560038 | The University of Texas Health Science Center, Houston |
Urinary Bladder Neoplasms
|
October 2015 | Phase 2 |
| NCT05233696 | University of Colorado, Denver|Cancer League of Colorado |
Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Unresectable Breast Carcinoma|Metastatic Breast Cancer|PD-L1 Gene Mutation
|
January 4, 2022 | Phase 2 |
| NCT00803062 | National Cancer Institute (NCI)|NRG Oncology |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer
|
April 2009 | Phase 3 |
| NCT00683059 | Sunnybrook Health Sciences Centre|Celgene Corporation |
Transitional Cell Carcinoma
|
March 2008 | Phase 2 |
| NCT01154920 | M.D. Anderson Cancer Center|Dana-Farber Cancer Institute |
Head and Neck Squamous Cell Carcinoma
|
July 2010 | Phase 2 |
| NCT00662597 | Novartis Pharmaceuticals|Novartis |
Non-Small Cell Lung Cancer
|
April 2008 | Phase 3 |
| NCT04731467 | Famewave Ltd.|Bristol-Myers Squibb|Purple Biotech Ltd. |
Solid Tumor|Non Small Cell Lung Cancer|Pancreatic Cancer|Ovarian Cancer|Papillary Thyroid Cancer|Melanoma|Colorectal Adenocarcinoma
|
March 19, 2021 | Phase 1|Phase 2 |
| NCT04554771 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Noordwest Ziekenhuisgroep |
Esophageal Adenocarcinoma|Oesophageal Adenocarcinoma|Resectable Carcinoma
|
January 27, 2021 | Phase 2 |
| NCT04058990 | Boston Scientific Corporation |
Coronary Artery Disease
|
December 12, 2019 | Not Applicable |
| NCT00401674 | National Cancer Institute, Naples |
Ovarian Cancer
|
June 2003 | Phase 2 |
| NCT04267848 | National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Lung Non-Small Cell Squamous Carcinoma|Lung Non-Squamous Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8
|
June 3, 2020 | Phase 3 |
| NCT02023710 | Peking University Cancer Hospital & Institute |
Melanoma
|
December 2013 | Phase 2 |
| NCT02489903 | EpicentRx, Inc. |
Small Cell Carcinoma|Carcinoma, Non-Small-Cell Lung|Neuroendocrine Tumors|Ovarian Epithelial Cancer
|
June 2015 | Phase 2 |
| NCT03237507 | Harbin Medical University |
Stage IV Gastric Cancer With Metastasis
|
July 1, 2017 | |
| NCT04729387 | Novartis Pharmaceuticals|Novartis |
Ovarian Cancer
|
July 2, 2021 | Phase 3 |
| NCT00002984 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer
|
March 1997 | Phase 1|Phase 2 |
| NCT00003004 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 1997 | Phase 1 |
| NCT03794778 | Women´s Hospital School Of Medicine Zhejiang University |
Efficacy and Safety
|
March 19, 2019 | Phase 4 |
| NCT01827163 | Memorial Sloan Kettering Cancer Center|GlaxoSmithKline |
HER2-Positive Early Stage Breast Cancer
|
April 2013 | Phase 2 |
| NCT02015676 | Hoffmann-La Roche |
Breast Cancer
|
July 2001 | Phase 1|Phase 2 |
| NCT00989651 | National Cancer Institute (NCI)|NRG Oncology |
Fallopian Tube Carcinoma|Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Neoplasm|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Carcinoma|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Tumor|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
October 28, 2009 | Phase 1 |
| NCT00016276 | National Cancer Institute (NCI) |
Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer
|
May 2001 | Phase 3 |
| NCT01347424 | Sun Yat-sen University |
Non Small Cell Lung Cancer|Nasopharyngeal Cancer|Liver Metastasis
|
January 2011 | Phase 2 |
| NCT00397761 | Medstar Health Research Institute |
Breast Cancer
|
July 2006 | Phase 2|Phase 3 |
| NCT04892953 | M.D. Anderson Cancer Center |
Stage III Lung Cancer AJCC v8|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IIIC Lung Cancer AJCC v8
|
July 31, 2021 | Phase 2 |
| NCT04025879 | Bristol-Myers Squibb |
Carcinoma, Non-Small-Cell Lung
|
November 5, 2019 | Phase 3 |
| NCT01822613 | Novartis Pharmaceuticals|Novartis |
Esophageal Squamous Cell Carcinoma
|
July 26, 2013 | Phase 1 |
| NCT02698891 | Dana-Farber Cancer Institute |
Early Stage Breast Cancer
|
April 7, 2016 | Phase 2 |
| NCT00089297 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
December 2004 | Phase 2 |
| NCT03096418 | University of Wisconsin, Madison |
Breast Neoplasm Female
|
March 13, 2017 | Not Applicable |
| NCT01407562 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|GlaxoSmithKline |
Unspecified Adult Solid Tumor - Protocol Specific|Breast Cancer - Female
|
September 17, 2010 | Phase 1 |
| NCT00670436 | University of Ulm|B. Braun Melsungen AG |
Coronary Artery Disease|Chronic Total Occlusion|Native Coronary Artery
|
February 2008 | Phase 2 |
| NCT00660218 | State University of New York - Upstate Medical University|CTI BioPharma |
Carcinoma, Squamous Cell
|
March 2008 | Phase 1|Phase 2 |
| NCT03929094 | Fudan University|CSPC Ouyi Pharmaceutical Co., Ltd. |
Metastatic Pancreatic Cancer
|
March 1, 2019 | Phase 2 |
| NCT02667743 | Shanghai Yizhong Biotechnology Co., Ltd. |
Non-Small Cell Lung Cancer(NSCLC)
|
May 2015 | Phase 3 |
| NCT01260870 | Bayer |
PAD
|
August 2011 | Phase 2 |
| NCT03766607 | Korean South West Oncology Group |
Gastric Cancer
|
September 30, 2019 | Phase 2 |
| NCT00004859 | National Cancer Institute (NCI) |
Lung Cancer
|
January 2000 | Phase 3 |
| NCT00547443 | University of Texas Southwestern Medical Center |
Lung Cancer
|
July 2007 | Phase 1|Phase 2 |
| NCT00421889 | Onxeo |
Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Bladder Cancer
|
August 2005 | Phase 1|Phase 2 |
| NCT02252796 | West Virginia University |
Non-small Cell Lung Cancer
|
July 2014 | Phase 1 |
| NCT00846027 | Hoffmann-La Roche |
Breast Cancer
|
January 2009 | Phase 2 |
| NCT00495170 | M.D. Anderson Cancer Center |
Lung Cancer
|
April 14, 2006 | Phase 2 |
| NCT03503604 | SuZhou Stainwei Biotech Inc. |
Solid Tumors
|
May 1, 2018 | Phase 1 |
| NCT03026881 | Jiangsu HengRui Medicine Co., Ltd.|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
Recurrent and Metastatic Gastric Cancer
|
January 2017 | Phase 1 |
| NCT01649947 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey |
Non-small Cell Lung Cancer|Advanced Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer
|
December 23, 2011 | Phase 2 |
| NCT00008021 | University of California, Davis|National Cancer Institute (NCI) |
Lymphoma
|
February 2001 | Phase 1 |
| NCT03762564 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Eli Lilly and Company|Trium Analysis Online GmbH |
Squamous Cell Carcinoma of the Esophagus
|
March 8, 2019 | Phase 2 |
| NCT00828009 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lung Cancer
|
December 22, 2010 | Phase 2 |
| NCT03668418 | University of Pisa|Azienda Ospedaliero, Universitaria Pisana |
Liver Cancer|Pancreatic Cancer|Gastric Cancer|Esophageal Cancer|Colo-rectal Cancer|Gall Bladder Cancer|Biliary Tract Cancer
|
June 1, 2018 | |
| NCT02530437 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Adenocarcinoma AJCC v7|Stage II Esophageal Adenocarcinoma AJCC v7|Stage IIA Esophageal Adenocarcinoma AJCC v7|Stage IIB Esophageal Adenocarcinoma AJCC v7|Stage IIIA Esophageal Adenocarcinoma AJCC v7|Stage IIIB Esophageal Adenocarcinoma AJCC v7
|
March 7, 2017 | Phase 1|Phase 2 |
| NCT02858206 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Hebei Medical University Fourth Hospital|Affiliated Hospital of Hebei University|Beijing Army General Hospital|Beijing Hospital|Peking University First Hospital|Tianjin Medical University Cancer Institute and Hospital|Henan Cancer Hospital|The Affiliated Hospital of Inner Mongolia Medical University|The First Affiliated Hospital with Nanjing Medical University|Fujian Cancer Hospital |
Esophageal Neoplasms
|
June 2016 | Phase 2 |
| NCT00003130 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
November 1997 | Phase 2 |
| NCT00434356 | Genentech, Inc. |
Metastatic Breast Cancer
|
March 2007 | Phase 2 |
| NCT01223443 | Centre de Recherche de l´Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Boston Scientific Corporation|Canadian Institutes of Health Research (CIHR)|Institut universitaire de cardiologie et de pneumologie de Québec, University Laval |
Coronary Artery Bypass Grafting
|
April 2010 | Phase 4 |
| NCT03751761 | Asan Medical Center|Hallym University Medical Center|Seoul National University Bundang Hospital |
Metastatic Gastric Cancer
|
June 11, 2018 | Phase 1|Phase 2 |
| NCT01063517 | AstraZeneca |
Gastric Cancer
|
February 2, 2010 | Phase 2 |
| NCT03887130 | Pierre Fabre Medicament |
Breast Cancer
|
March 2006 | Phase 2 |
| NCT02383212 | Regeneron Pharmaceuticals|Sanofi |
Advanced Cancer|Advanced Malignancies
|
February 2, 2015 | Phase 1 |
| NCT03977194 | Intergroupe Francophone de Cancerologie Thoracique |
Non Small Cell Lung Cancer Metastatic
|
July 23, 2019 | Phase 3 |
| NCT01960647 | Eurocor GmbH |
Peripheral Artery Disease
|
May 2011 | Phase 3 |
| NCT05065021 | University Health Network, Toronto|GlaxoSmithKline |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|High Grade Serous Cancer|High Grade Endometrioid Cancer
|
June 6, 2022 | Phase 2 |
| NCT03742986 | NYU Langone Health |
Breast Cancer
|
May 2, 2019 | Phase 2 |
| NCT04647344 | Akeso |
Lung Cancer Non-Small Cell Stage IIIB+IIIC+IV
|
November 24, 2020 | Phase 1|Phase 2 |
| NCT02672475 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
|
March 2016 | Phase 1 |
| NCT02305654 | Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)|ECOG-ACRIN Cancer Research Group|Canadian Cancer Trials Group |
Squamous Cell Carcinoma of the Penis, Usual Type
|
May 12, 2017 | Phase 3 |
| NCT00003880 | Merck Sharp & Dohme LLC |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
February 1999 | Phase 2|Phase 3 |
| NCT03845543 | ID3 Medical |
Peripheral Arterial Disease
|
November 28, 2018 | Not Applicable |
| NCT04054362 | Barts & The London NHS Trust |
Pancreatic Cancer
|
November 29, 2018 | Phase 2 |
| NCT02145065 | Balton Sp.zo.o.|American Heart of Poland |
Peripheral Artery Disease|Femoropopliteal Artery Disease
|
September 2014 | Not Applicable |
| NCT01196741 | University College, London|AstraZeneca|Cancer Research UK |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
March 2011 | Phase 2|Phase 3 |
| NCT01487226 | Korean Gynecologic Oncology Group |
Cervical Cancer
|
January 2008 | Phase 2 |
| NCT05383482 | Laekna Limited |
Solid Tumor|NSCLC|Cervical Cancer|Endometrial Cancer|Esophageal Cancer|Gastric and Gastroesophageal Junction Adenocarcinoma
|
June 30, 2022 | Phase 1|Phase 2 |
| NCT02229045 | Sun Yat-sen University |
Gastric Caner
|
November 2010 | Phase 2 |
| NCT00028860 | Tulane University Health Sciences Center|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter
|
October 2001 | Phase 2 |
| NCT02073487 | The Methodist Hospital Research Institute|Celgene Corporation|Novartis |
Breast Cancer
|
February 2014 | Phase 2 |
| NCT04528680 | Northwestern University|CarThera|Bristol-Myers Squibb|Lantheus Medical Imaging |
Glioblastoma|Gliosarcoma|GBM|Glioblastoma Multiforme|Glioblastoma, IDH-wildtype|Recurrent Glioblastoma
|
October 29, 2020 | Phase 1|Phase 2 |
| NCT01100931 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
NSCLC|Solid Tumors
|
February 2010 | Phase 1|Phase 2 |
| NCT01688791 | Endocyte |
Advanced Cancer
|
December 2012 | Phase 1 |
| NCT00951496 | National Cancer Institute (NCI)|NRG Oncology |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Clear Cell Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Primary Peritoneal Transitional Cell Carcinoma|Primary Peritoneal Undifferentiated Carcinoma|Stage II Fallopian Tube Cancer AJCC v6 and v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
August 11, 2009 | Phase 3 |
| NCT00095914 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 2004 | Phase 1 |
| NCT01366144 | National Cancer Institute (NCI)|Abbott |
Breast Carcinoma|Carcinoma of Unknown Primary|Endometrial Carcinoma|Esophageal Carcinoma|Liver Failure|Lung Carcinoma|Malignant Head and Neck Neoplasm|Malignant Testicular Neoplasm|Melanoma|Metastatic Malignant Neoplasm|Ovarian Carcinoma|Renal Failure|Unresectable Malignant Neoplasm|Urothelial Carcinoma
|
June 20, 2011 | Phase 1 |
| NCT03462251 | iOMEDICO AG|Novartis Pharmaceuticals |
Breast Cancer|Hormone Receptor Positive Tumor|HER 2 Negative Breast Cancer
|
May 24, 2018 | Phase 3 |
| NCT05291910 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Cancer
|
March 12, 2022 | Phase 4 |
| NCT05183126 | University of Michigan Rogel Cancer Center |
Breast Cancer
|
March 28, 2022 | Phase 4 |
| NCT03699033 | Stephanie Smiddy|University of Toledo |
Non Small Cell Lung Cancer
|
October 1, 2018 | Phase 2 |
| NCT00193141 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Esophagus Cancer
|
October 1999 | Phase 2 |
| NCT00054184 | CTI BioPharma |
Lung Cancer
|
January 2003 | Phase 3 |
| NCT01167712 | National Cancer Institute (NCI)|NRG Oncology |
Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinofibroma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
September 27, 2010 | Phase 3 |
| NCT00553462 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
March 2008 | Phase 2 |
| NCT00003413 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Ovarian Cancer
|
September 1998 | Phase 2 |
| NCT02551432 | Seoul National University Hospital |
Small Cell Lung Cancer
|
September 2015 | Phase 2 |
| NCT01081262 | National Cancer Institute (NCI)|NRG Oncology |
Borderline Ovarian Mucinous Tumor|Ovarian Mucinous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IA Ovarian Cancer AJCC v6 and v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IB Ovarian Cancer AJCC v6 and v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage IC Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7
|
October 12, 2010 | Phase 3 |
| NCT01276769 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Triple Negative Breast Cancer
|
January 2008 | Phase 2 |
| NCT02193633 | Royal Marsden NHS Foundation Trust|Institute of Cancer Research, United Kingdom|AstraZeneca |
Advanced Cancer
|
April 26, 2013 | Phase 1 |
| NCT00110084 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Cancer
|
August 2005 | Phase 2 |
| NCT00004126 | University of Chicago|National Cancer Institute (NCI) |
Lung Cancer
|
November 1999 | Phase 2 |
| NCT00786552 | University Hospital Schleswig-Holstein |
Thyroid Cancer
|
November 2008 | Phase 2 |
| NCT00050960 | Eisai Inc. |
Non-small Cell Lung Cancer
|
May 2002 | Phase 3 |
| NCT01026116 | Fudan University |
Breast Neoplasms
|
December 2009 | Phase 3 |
| NCT04035473 | Athenex, Inc.|PharmaEssentia|Zenith Technology Corporation Limited |
Solid Tumor
|
August 1, 2015 | Phase 1 |
| NCT02938442 | University of Arkansas |
Triple Negative Breast Cancer|Breast Neoplasms
|
January 25, 2019 | Phase 1|Phase 2 |
| NCT01820858 | Ding Ma|Shandong University|Huazhong University of Science and Technology|Zhejiang University |
Endometrial Neoplasms
|
November 2012 | Phase 3 |
| NCT00002662 | Aventis Pharmaceuticals|National Cancer Institute (NCI) |
Breast Cancer
|
August 1994 | Phase 3 |
| NCT01835236 | Swiss Group for Clinical Cancer Research |
Metastatic Breast Cancer
|
March 3, 2013 | Phase 2 |
| NCT00281788 | Duke University|National Cancer Institute (NCI) |
Esophageal Cancer
|
September 2003 | Phase 1 |
| NCT01366131 | Genentech, Inc. |
Non-Squamous Non-Small Cell Lung Cancer
|
June 2011 | Phase 2 |
| NCT00151060 | University of Michigan Rogel Cancer Center |
Prostate Cancer
|
December 1998 | Phase 2 |
| NCT01366183 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Stage I Ovarian Cancer AJCC v6 and v7|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
August 15, 2011 | |
| NCT01548924 | Centro Nacional de Investigaciones Oncologicas CARLOS III|Hospital Universitario de Fuenlabrada|M.D. Anderson Cancer Center|Hospital Universitari de Bellvitge |
Solid Tumors
|
April 2012 | Phase 1 |
| NCT04355858 | Fudan University |
Breast Cancer|Metastatic Cancer
|
May 1, 2020 | Phase 2 |
| NCT02756013 | Case Comprehensive Cancer Center |
Gynecologic Malignancies
|
April 20, 2016 | Phase 2 |
| NCT00005026 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
February 2000 | Phase 1 |
| NCT00280787 | UNC Lineberger Comprehensive Cancer Center|AstraZeneca|Amgen |
Non Small Cell Lung Cancer
|
November 2003 | Phase 2 |
| NCT04472429 | Incyte Corporation |
Squamous Cell Carcinoma of the Anal Canal
|
January 12, 2021 | Phase 3 |
| NCT00960960 | Genentech, Inc. |
Breast Cancer
|
August 2009 | Phase 1 |
| NCT00006256 | Case Comprehensive Cancer Center |
Breast Cancer
|
June 8, 2000 | Phase 2 |
| NCT01320592 | Abramson Cancer Center of the University of Pennsylvania |
Breast Cancer
|
March 2011 | Phase 1 |
| NCT00897026 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
July 2008 | |
| NCT01229930 | University of Glasgow|National Cancer Institute (NCI) |
Cervical Cancer
|
June 2010 | Phase 2 |
| NCT00915018 | Puma Biotechnology, Inc. |
Breast Cancer
|
August 21, 2009 | Phase 2 |
| NCT00584909 | University of Alabama at Birmingham |
Uterine Cancer
|
March 2006 | Phase 2 |
| NCT02390427 | Otto Metzger|Genentech, Inc.|Dana-Farber Cancer Institute |
Metastatic Breast Cancer|Recurrent Breast Cancer
|
April 20, 2015 | Phase 1 |
| NCT00323583 | Seattle Cancer Treatment and Wellness Center |
Adenocarincoma of Pancreas|Stage III Pancreatic Cancer|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer
|
May 2006 | Phase 2 |
| NCT03125902 | Hoffmann-La Roche |
Triple-Negative Breast Cancer
|
August 25, 2017 | Phase 3 |
| NCT01617928 | AbbVie (prior sponsor, Abbott)|AbbVie |
Solid Tumors
|
May 2012 | Phase 1 |
| NCT02835586 | Hospices Civils de Lyon |
Critical Ischemia
|
May 2013 | Phase 3 |
| NCT04895358 | Merck Sharp & Dohme LLC |
Breast Neoplasms
|
June 18, 2021 | Phase 3 |
| NCT00170664 | North Eastern German Society of Gynaecological Oncology |
Ovarian Cancer
|
January 1999 | Phase 2 |
| NCT00003386 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer
|
July 1999 | Phase 2 |
| NCT00052351 | National Cancer Institute (NCI) |
Breast Cancer
|
September 2002 | Phase 2 |
| NCT03181100 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma
|
July 27, 2017 | Phase 2 |
| NCT00001272 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Ovarian Neoplasms
|
September 1991 | Phase 1 |
| NCT03126708 | Peking University |
Esophageal Cancer, Squamous Cell|Cetuximab Effect|Chemotherapy Effect
|
April 10, 2017 | Phase 2 |
| NCT04516616 | Huazhong University of Science and Technology|Women´s Hospital School Of Medicine Zhejiang University|Qilu Hospital of Shandong University|Obstetrics & Gynecology Hospital of Fudan University|First Affiliated Hospital of Chongqing Medical University|Army Medical University|Peking University People´s Hospital|Tianjin Medical University General Hospital|Harbin Medical University|Chongqing University Cancer Hospital |
Uterine Cervical Neoplasm|Uterine Cervical Cancer|Cervical Cancer
|
December 1, 2020 | Phase 2 |
| NCT00637897 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Breast Cancer
|
March 2008 | Phase 1 |
| NCT04643405 | Ascentage Pharma Group Inc. |
Advanced Pancreatic Cancer
|
March 17, 2021 | Phase 1|Phase 2 |
| NCT00003084 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Prostate Cancer
|
December 1997 | Phase 2 |
| NCT00979212 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
February 2011 | Phase 2 |
| NCT03162510 | National Health Research Institutes, Taiwan|National Cheng-Kung University Hospital|National Taiwan University Hospital |
Gastric Cancer in Situ|Pancreatic Cancers|Biliary Cancers
|
June 26, 2018 | Phase 1 |
| NCT01015118 | Boehringer Ingelheim |
Ovarian Neoplasms|Peritoneal Neoplasms
|
November 17, 2009 | Phase 3 |
| NCT01534585 | Taizhou Hospital |
Nasopharyngeal Carcinoma
|
February 2012 | Phase 1|Phase 2 |
| NCT04072263 | Leiden University Medical Center |
Ovarian Cancer Recurrent
|
August 1, 2018 | Phase 1|Phase 2 |
| NCT01816412 | C. R. Bard|Medicon, Inc. |
Femoral Arterial Stenosis|Stenosis of Popliteal Arteries|Femoral Artery Occlusion|Occlusion of Popliteal Arteries
|
March 2013 | Phase 2 |
| NCT00006027 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Gynecologic Oncology Group |
Endometrial Cancer
|
August 2000 | Phase 3 |
| NCT00003313 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Drug+Agent Toxicity by Tissue+Organ|Lung Cancer|Oral Complications|Radiation Toxicity
|
September 1998 | Phase 3 |
| NCT01333033 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer
|
July 2011 | Phase 2 |
| NCT00005847 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Prostate Cancer
|
January 2001 | Phase 2 |
| NCT03279237 | Massachusetts General Hospital|National Cancer Institute (NCI) |
GastroEsophageal Cancer
|
October 24, 2017 | Phase 1 |
| NCT05601700 | Ente Ospedaliero Ospedali Galliera|Istituto Di Ricerche Farmacologiche Mario Negri|Humanitas Hospital, Italy |
Carcinoma, Ovarian Epithelial|Low Grade Serous Adenocarcinoma of Ovary
|
September 22, 2022 | Phase 3 |
| NCT02274012 | Columbia University|Boehringer Ingelheim |
HER-2 Positive Gastric Cancer|Gastrooesophageal Cancer|Esophageal Cancer
|
May 29, 2014 | Phase 2 |
| NCT00003518 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Ovarian Cancer|Testicular Germ Cell Tumor
|
January 1999 | Phase 2 |
| NCT00107341 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Esophageal Cancer
|
August 2005 | Phase 2 |
| NCT01199263 | National Cancer Institute (NCI)|NRG Oncology |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 6, 2010 | Phase 2 |
| NCT01317615 | Novartis Pharmaceuticals|Novartis |
Carcinoma, Large Cell|Neuroendocrine Tumors
|
April 2011 | Phase 4 |
| NCT00146549 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital|North Shore Medical Center|GlaxoSmithKline |
Breast Cancer|Stage IV Breast Cancer
|
August 2001 | Phase 3 |
| NCT01816594 | Novartis Pharmaceuticals|Breast International Group|German Breast Group|SOLTI Breast Cancer Research Group|Novartis |
HER2-positive Newly Diagnosed, Primary Breast Cancer
|
September 3, 2013 | Phase 2 |
| NCT02032277 | AbbVie|German Breast Group|NSABP Foundation Inc|Grupo Español de Investigación del Cáncer de Mama|US Oncology Research |
Triple Negative Breast Cancer
|
April 2, 2014 | Phase 3 |
| NCT00002931 | City of Hope Medical Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor
|
February 1997 | Phase 2 |
| NCT00003587 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
October 1998 | Phase 2 |
| NCT01704287 | Merck Sharp & Dohme LLC |
Malignant Melanoma
|
November 20, 2012 | Phase 2 |
| NCT01779479 | German Breast Group |
Primary Breast Cancer
|
February 2013 | Phase 2 |
| NCT03193853 | Baylor Research Institute|Takeda |
Triple Negative Breast Cancer
|
July 18, 2017 | Phase 2 |
| NCT02978495 | Barretos Cancer Hospital |
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
|
May 17, 2017 | Phase 2 |
| NCT05298423 | Merck Sharp & Dohme LLC |
Carcinoma, Non-Small-Cell Lung
|
May 3, 2022 | Phase 3 |
| NCT02050009 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Ovarian Papillary Serous Carcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Cavity Cancer
|
Phase 1 | |
| NCT04632992 | Genentech, Inc. |
Advanced Unresectable or Metastatic Solid Malignancy
|
January 13, 2021 | Phase 2 |
| NCT03987867 | Tianjin Medical University Cancer Institute and Hospital |
Non-small Cell Lung Cancer|First-line Treatment
|
June 1, 2019 | Phase 1 |
| NCT04143711 | Dragonfly Therapeutics |
Solid Tumor, Adult
|
November 11, 2019 | Phase 1|Phase 2 |
| NCT04267549 | Tianjin Medical University Cancer Institute and Hospital |
Gastric Cancer Stage
|
December 1, 2019 | Phase 2 |
| NCT03925233 | Xijing Hospital |
Breast Cancer Organoids
|
January 2, 2019 | |
| NCT00003614 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Prostate Cancer
|
December 1998 | Phase 2 |
| NCT05131893 | National Institute of Oncology, Hungary |
Breast Cancer
|
March 2022 | |
| NCT02866370 | NHS Greater Glasgow and Clyde|Boehringer Ingelheim|Cancer Research UK|European Organisation for Research and Treatment of Cancer - EORTC|Nordic Society of Gynaecological Oncology - Clinical Trials Unit|ARCAGY+ GINECO GROUP |
Ovarian Clear Cell Carcinoma|Endometrial Clear Cell Carcinoma
|
April 2015 | Phase 2 |
| NCT00088556 | Telik |
Carcinoma, Non-Small-Cell Lung
|
August 2004 | Phase 1|Phase 2 |
| NCT00178256 | University of Rochester |
Carcinoma, Non-Small-Cell Lung
|
June 1998 | Phase 1|Phase 2 |
| NCT05429684 | First Affiliated Hospital Xi´an Jiaotong University |
HER2&addition; Breast Cancer
|
January 1, 2021 | Phase 3 |
| NCT02965677 | ZhuHai Cardionovum Medical Device Co., Ltd. |
Peripheral Arterial Disease
|
December 2016 | Not Applicable |
| NCT00079287 | Japan Multinational Trial Organization|National Cancer Institute (NCI) |
Lung Cancer
|
March 2001 | Phase 3 |
| NCT03038100 | Hoffmann-La Roche|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms
|
March 8, 2017 | Phase 3 |
| NCT02564263 | Merck Sharp & Dohme LLC |
Esophageal Carcinoma|Esophagogastric Junction Carcinoma
|
December 1, 2015 | Phase 3 |
| NCT04723875 | Huazhong University of Science and Technology|Women´s Hospital School Of Medicine Zhejiang University|Qilu Hospital of Shandong University|Obstetrics & Gynecology Hospital of Fudan University|First Affiliated Hospital of Chongqing Medical University|Hunan Cancer Hospital|The Third Xiangya Hospital of Central South University |
Uterine Cervical Neoplasms|Cervical Cancer
|
February 1, 2021 | Phase 3 |
| NCT03044613 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb |
Gastric Cancer|Esophageal Cancer|GastroEsophageal Cancer
|
July 11, 2017 | Phase 1 |
| NCT03348904 | Incyte Corporation|Bristol-Myers Squibb |
Lung Cancer
|
December 27, 2017 | Phase 3 |
| NCT01218516 | Morphotek |
Adenocarcinoma of the Lung
|
June 27, 2011 | Phase 2 |
| NCT01024712 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|National Cancer Institute (NCI) |
Lung Cancer
|
May 2009 | Phase 2 |
| NCT02366949 | Bayer |
Medical Oncology
|
February 27, 2015 | Phase 1 |
| NCT02597036 | Eli Lilly and Company |
Solid Tumors
|
November 6, 2015 | Phase 1 |
| NCT03579004 | Mona Frolova|Russian Academy of Medical Sciences |
Esophageal Neoplasms|Squamous Cell Carcinoma|Concurrent Chemoradiotherapy
|
July 10, 2017 | Phase 2 |
| NCT00462397 | University College London Hospitals|National Cancer Institute (NCI) |
Cervical Cancer
|
June 2005 | Phase 2 |
| NCT04556773 | AstraZeneca|Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Company, Limited |
Metastatic Breast Cancer
|
December 17, 2020 | Phase 1 |
| NCT00003127 | Southwest Oncology Group|National Cancer Institute (NCI) |
Endometrial Cancer
|
February 1998 | Phase 2 |
| NCT04555304 | Chengdu Kanghong Biotech Co., Ltd. |
Gastric Cancer|Gastroesophageal Cancer
|
September 15, 2020 | Phase 2 |
| NCT05524974 | Fujian Medical University |
Locally Advanced Gastric Cancer
|
September 1, 2022 | Phase 2 |
| NCT01006252 | Eli Lilly and Company |
Melanoma
|
December 2009 | Phase 3 |
| NCT04766359 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Nasopharyngeal Carcinoma
|
March 1, 2021 | Phase 3 |
| NCT01042379 | QuantumLeap Healthcare Collaborative |
Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
|
March 1, 2010 | Phase 2 |
| NCT02389985 | NewLink Genetics Corporation|Lumos Pharma |
Ovarian Cancer
|
July 2015 | Phase 1|Phase 2 |
| NCT01209520 | University of Miami |
Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation
|
July 2009 | Not Applicable |
| NCT03635489 | Hoffmann-La Roche |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
August 15, 2018 | Phase 3 |
| NCT00407888 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
May 2006 | Phase 2 |
| NCT04832854 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer (NSCLC)
|
April 23, 2021 | Phase 2 |
| NCT04858009 | Mayo Clinic|National Cancer Institute (NCI) |
Metastatic Pancreatic Carcinoma|Stage IV Pancreatic Cancer AJCC v8
|
October 15, 2022 | Phase 2 |
| NCT04034251 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Gastric Adenocarcinoma|Gastric Cancer|Esophagogastric Junction|Peritoneal Carcinomatosis
|
June 9, 2020 | Phase 2 |
| NCT05420948 | University of Chicago |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Head and Neck Neoplasms|Head Cancer|Throat Carcinoma
|
September 1, 2022 | Phase 2 |
| NCT02855788 | Huashan Hospital|Seattle Integrative Cancer Center |
Metastatic Gastric Cancer|Locally Advanced Gastric Cancer
|
May 2015 | Phase 2 |
| NCT01199055 | Daiichi Sankyo Co., Ltd.|ICON Clinical Research|Daiichi Sankyo, Inc. |
Carcinoma, Non-Small-Cell Lung
|
March 2010 | Phase 1 |
| NCT03315364 | Daehwa Pharmaceutical Co., Ltd. |
Recurrent or Metastatic Breast Cancer
|
December 18, 2017 | Phase 2|Phase 3 |
| NCT00997009 | National Cancer Institute, Naples |
Cervical Cancer
|
October 2009 | Phase 2 |
| NCT04081389 | Roswell Park Cancer Institute |
Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2+Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma
|
December 6, 2019 | Phase 1 |
| NCT00309959 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma
|
November 2006 | Phase 2 |
| NCT03707028 | Elevar Therapeutics |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
October 1, 2018 | Phase 1|Phase 2 |
| NCT01700010 | University of Michigan Rogel Cancer Center|GlaxoSmithKline |
Urothelial Cancer|Bladder Cancer
|
November 2012 | Phase 2 |
| NCT01015339 | Peking University|Roche Pharma AG |
Advanced Gastric Cancer
|
November 2009 | Phase 3 |
| NCT01946074 | AbbVie |
Advanced Solid Tumors
|
August 8, 2013 | Phase 1 |
| NCT00954174 | GOG Foundation|National Cancer Institute (NCI) |
Mixed Mesodermal (Mullerian) Tumor|Ovarian Carcinosarcoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage I Ovarian Cancer AJCC v6 and v7|Stage IA Fallopian Tube Cancer AJCC v6 and v7|Stage IA Ovarian Cancer AJCC v6 and v7|Stage IA Uterine Sarcoma AJCC v7|Stage IB Fallopian Tube Cancer AJCC v6 and v7|Stage IB Ovarian Cancer AJCC v6 and v7|Stage IB Uterine Sarcoma AJCC v7|Stage IC Fallopian Tube Cancer AJCC v6 and v7|Stage IC Ovarian Cancer AJCC v6 and v7|Stage IC Uterine Sarcoma AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage IIA Fallopian Tube Cancer AJCC v6 and v7|Stage IIA Ovarian Cancer AJCC V6 and v7|Stage IIA Uterine Sarcoma AJCC v7|Stage IIB Fallopian Tube Cancer AJCC v6 and v7|Stage IIB Ovarian Cancer AJCC v6 and v7|Stage IIB Uterine Sarcoma AJCC v7|Stage IIC Fallopian Tube Cancer AJCC v6 and v7|Stage IIC Ovarian Cancer AJCC v6 and v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIA Uterine Sarcoma AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIB Uterine Sarcoma AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IIIC Uterine Sarcoma AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7|Stage IVA Uterine Sarcoma AJCC v7|Stage IVB Uterine Sarcoma AJCC v7|Uterine Carcinosarcoma
|
August 17, 2009 | Phase 3 |
| NCT04055649 | Ira Winer|Barbara Ann Karmanos Cancer Institute |
Malignant Ovarian Epithelial Tumor|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma
|
January 21, 2020 | Phase 2 |
| NCT00084448 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
April 2004 | Phase 2 |
| NCT00798252 | Bristol-Myers Squibb |
Advanced Cancer
|
March 2009 | Phase 1 |
| NCT01454102 | Bristol-Myers Squibb |
Non-small Cell Lung Cancer
|
December 16, 2011 | Phase 1 |
| NCT02013271 | C. R. Bard |
Femoral Artery Occlusion|Femoral Arterial Stenosis
|
December 2013 | |
| NCT01802749 | National Cancer Institute, Naples|Mario Negri Institute for Pharmacological Research |
Recurrent Ovarian Cancer
|
November 2013 | Phase 3 |
| NCT01644825 | National Cancer Institute, Naples |
Ovarian Cancer
|
December 2010 | Phase 2 |
| NCT00054392 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
September 2001 | Phase 3 |
| NCT00038545 | M.D. Anderson Cancer Center |
Non-Hodgkin´s Lymphoma
|
May 18, 2001 | Phase 2 |
| NCT00110695 | NSABP Foundation Inc|Celgene Corporation |
Breast Neoplasms
|
April 2005 | Phase 2 |
| NCT03013218 | ALX Oncology Inc. |
Metastatic Cancer|Solid Tumor|Advanced Cancer|NonHodgkin Lymphoma
|
February 3, 2017 | Phase 1 |
| NCT00028990 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|NCIC Clinical Trials Group|NSABP Foundation Inc |
Breast Cancer
|
December 2001 | Phase 3 |
| NCT00077129 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Kidney Cancer
|
September 2004 | Phase 2 |
| NCT03092986 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
Carcinoma, Non-Small-Cell Lung
|
January 1, 2017 | Phase 4 |
| NCT03165994 | Apexigen, Inc. |
Esophageal Cancer|GastroEsophageal Cancer
|
October 6, 2017 | Phase 2 |
| NCT01014351 | SCRI Development Innovations, LLC|Novartis |
Metastatic Melanoma
|
February 2010 | Phase 2 |
| NCT02824575 | Montefiore Medical Center|Deciphera Pharmaceuticals LLC|Albert Einstein College of Medicine |
Breast Cancer|Breast Adenocarcinoma|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Recurrent Breast Carcinoma|Stage IV Breast Cancer
|
July 2016 | Phase 1 |
| NCT01704690 | Peking University |
Esophageal Cancer
|
August 2012 | Phase 2|Phase 3 |
| NCT01969578 | European Organisation for Research and Treatment of Cancer - EORTC |
Salivary Gland Cancer
|
February 2015 | Phase 2 |
| NCT00006049 | AstraZeneca|National Cancer Institute (NCI) |
Lung Cancer
|
May 2000 | Phase 3 |
| NCT00818090 | Korean Cancer Study Group |
Thymoma|Thymic Carcinoma
|
September 2008 | Phase 2 |
| NCT01255956 | Medical University of Warsaw|KCRI |
In-Stent Restenosis
|
December 2010 | Phase 3 |
| NCT00971945 | Bristol-Myers Squibb |
Breast Cancer
|
June 30, 2005 | Phase 2 |
| NCT01998347 | Shantou University Medical College |
Esophageal Cancer
|
November 2013 | Phase 3 |
| NCT01423123 | NSABP Foundation Inc|Pfizer |
Breast Cancer
|
May 2011 | Phase 1 |
| NCT00807768 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Fatigue|Neurotoxicity Syndrome|Obesity|Stage I Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7
|
March 23, 2009 | Phase 3 |
| NCT05585580 | Qilu Hospital of Shandong University |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
|
November 1, 2022 | Phase 2 |
| NCT02422563 | Charite University, Berlin, Germany |
Cervical Cancer
|
October 2015 | Phase 3 |
| NCT01254526 | Genentech, Inc. |
Breast Cancer
|
December 2010 | Phase 1 |
| NCT04815408 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Ovarian Cancer|Neoadjuvant Chemotherapy|Anti-PD-1|Neoadjuvant Immunotherapy
|
April 1, 2021 | Phase 2 |
| NCT00768469 | Puma Biotechnology, Inc. |
Advanced Malignant Solid Tumors
|
October 2008 | Phase 1 |
| NCT00434135 | Southern Italy Cooperative Oncology Group |
Non-Small Cell Lung Cancer|Stage IIIB or IV
|
May 2006 | Phase 2 |
| NCT03982485 | RenJi Hospital |
Breast Cancer
|
October 16, 2018 | Phase 2 |
| NCT00003896 | Southwest Oncology Group|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
September 1999 | Phase 2 |
| NCT00003862 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Gastric Cancer
|
November 1999 | Phase 2 |
| NCT01227408 | University of Southern California|CTI BioPharma |
Breast Cancer
|
February 2009 | Phase 2 |
| NCT01954355 | Swiss Group for Clinical Cancer Research |
Solid Tumor|Ovarian Cancer
|
September 2013 | Phase 1 |
| NCT01523678 | Belgian Gynaecological Oncology Group |
Ovarian Cancer|Endometrial Cancer|Uterine Cervical Cancer
|
February 2012 | Phase 2 |
| NCT01505569 | Masonic Cancer Center, University of Minnesota |
Ewing´s Family Tumors|Renal Tumors|Hepatoblastoma|Rhabdomyosarcoma|Soft Tissue Sarcoma|Primary Malignant Brain Neoplasms|Retinoblastoma|Medulloblastoma|Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)|Atypical Teratoid+Rhabdoid Tumor (AT+RT)|CNS Tumors|Germ Cell Tumors
|
October 20, 2011 | Not Applicable |
| NCT03631784 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
October 19, 2018 | Phase 2 |
| NCT05540145 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Gastric Cancer
|
May 1, 2022 | |
| NCT00919880 | Tao OUYANG|Peking University |
Breast Cancer
|
July 2009 | Phase 2 |
| NCT03535701 | Ohio State University Comprehensive Cancer Center |
Stage IV Breast Cancer AJCC v6 and v7
|
October 20, 2017 | Not Applicable |
| NCT03631199 | Novartis Pharmaceuticals|Novartis |
Non-small Cell Lung Cancer
|
December 21, 2018 | Phase 3 |
| NCT03366480 | Ability Pharmaceuticals SL|Hospital Vall d´Hebron|Institut Català d´Oncologia|Hospital Clínico Universitario de Valencia|Hospitales Universitarios Virgen del Rocío|Centre Leon Berard|Institut Paoli-Calmettes|Gustave Roussy, Cancer Campus, Grand Paris |
Endometrial Cancer|Squamous Non-Small Cell Lung Cancer
|
December 1, 2016 | Phase 1|Phase 2 |
| NCT01764087 | Hanmi Pharmaceutical Company Limited |
Unspecified Adult Solid Tumor, Protocol Specific|Gastric Cancer|Breast Cancer
|
December 2012 | Phase 1|Phase 2 |
| NCT02996318 | InnoRa GmbH |
DES In-stent Stenosis
|
December 1, 2015 | Not Applicable |
| NCT00059787 | National Cancer Institute (NCI) |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer
|
April 2003 | Phase 2 |
| NCT02138812 | Bayer |
Medical Oncology
|
May 9, 2014 | Phase 1 |
| NCT00003377 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer
|
November 1999 | Phase 1 |
| NCT02122770 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Tumors
|
April 1, 2014 | Phase 1 |
| NCT00008138 | Southwest Oncology Group|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
March 2001 | Phase 2 |
| NCT00004137 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
October 1999 | Phase 2 |
| NCT00245154 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lung Cancer
|
September 7, 2005 | Phase 2|Phase 3 |
| NCT01831089 | PharmaMar |
Breast Cancer|Ovarian Cancer|Gynecological Cancer|Head and Neck Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Non-squamous Cell Lung Cancer
|
September 2013 | Phase 1 |
| NCT03517449 | Eisai Inc.|Merck Sharp & Dohme LLC |
Endometrial Neoplasms
|
June 11, 2018 | Phase 3 |
| NCT04342910 | Jiangsu HengRui Medicine Co., Ltd. |
Gastric Cancer
|
September 21, 2020 | Phase 3 |
| NCT04418154 | Fudan University |
Triple Negative Breast Cancer
|
June 9, 2020 | Phase 2 |
| NCT00795340 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lung Cancer
|
November 6, 2008 | Phase 3 |
| NCT00472472 | University Hospital, Saarland |
Peripheral Arterial Disease
|
April 2004 | Phase 1|Phase 2 |
| NCT01653912 | Accenture |
Recurrent Platinum-resistant Ovarian Cancer
|
November 2012 | Phase 1|Phase 2 |
| NCT04615013 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Cervical Esophagus Adenocarcinoma|Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Gastroesophageal Junction Adenocarcinoma|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Thoracic Esophagus Adenocarcinoma
|
November 23, 2020 | Phase 1 |
| NCT04768075 | Guangdong Association of Clinical Trials |
Non-Small-Cell Lung Cancer
|
March 5, 2021 | Phase 3 |
| NCT03829722 | University of Michigan Rogel Cancer Center|Bristol-Myers Squibb |
Oropharynx Squamous Cell Carcinoma
|
September 5, 2019 | Phase 2 |
| NCT01604863 | Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline |
Cancer
|
June 2012 | Phase 1 |
| NCT05449366 | Erasmus Medical Center |
Peritoneal Malignant Mesothelioma
|
February 1, 2022 | Phase 1|Phase 2 |
| NCT00483782 | Medical Research Council|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
April 2006 | Phase 3 |
| NCT04884906 | Tianjin Medical University Cancer Institute and Hospital |
Locally Advanced Cervical Cancer
|
November 1, 2020 | Phase 2 |
| NCT01752205 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
Esophageal Squamous Carcinoma
|
November 2012 | Phase 3 |
| NCT02467907 | Hoffmann-La Roche |
Cervical Cancer
|
July 28, 2015 | Phase 2 |
| NCT00004105 | NYU Langone Health|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific
|
September 1998 | Phase 1|Phase 2 |
| NCT02599324 | Pharmacyclics LLC. |
Metastatic Renal Cell Carcinoma|Advanced Urothelial Carcinoma|Advanced Gastric Adenocarcinoma|Metastatic Colorectal Adenocarcinoma
|
December 1, 2015 | Phase 1|Phase 2 |
| NCT01756170 | xie congying|Wenzhou Medical University |
Cervical Cancer
|
January 2011 | Phase 3 |
| NCT04858269 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Head Neck Cancer|Metastatic Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharynx Squamous Cell Carcinoma|Hypopharynx Squamous Cell Carcinoma|Larynx Squamous Cell Carcinoma
|
May 27, 2021 | Phase 2 |
| NCT01867086 | Gradalis, Inc. |
Stage III Ovarian Cancer|Stage IV Ovarian Cancer
|
June 2013 | Phase 2 |
| NCT00003193 | Massachusetts General Hospital |
Head and Neck Cancer|Oral Complications
|
January 1998 | Phase 1|Phase 2 |
| NCT00964626 | Russian Academy of Medical Sciences|National Cancer Institute (NCI) |
Ovarian Cancer
|
April 2009 | Phase 2 |
| NCT00230451 | University of Michigan Rogel Cancer Center |
Esophageal Cancer
|
November 1997 | Phase 2 |
| NCT01174238 | Adil Daud|University of California, San Francisco |
Melanoma
|
July 2010 | Phase 2 |
| NCT04568200 | Peking Union Medical College Hospital |
Esophageal Squamous Cell Carcinoma
|
June 19, 2020 | Phase 2 |
| NCT00003111 | Yale University|National Cancer Institute (NCI) |
Lung Cancer
|
April 1997 | Phase 2 |
| NCT01868984 | Englewood Hospital and Medical Center|Spectranetics Corporation |
Fistula Stenosis
|
May 2013 | Phase 2 |
| NCT01566435 | Washington University School of Medicine|Celgene |
Head and Neck Neoplasms
|
August 9, 2012 | Phase 2 |
| NCT00003972 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 1998 | Phase 3 |
| NCT01930292 | Debiopharm International SA |
Solid Tumors
|
April 2013 | Phase 1 |
| NCT00656669 | Indiana University|Pfizer |
Breast Cancer
|
April 2008 | Not Applicable |
| NCT00551122 | University of Southampton|University Hospital Southampton NHS Foundation Trust |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor
|
November 2006 | Phase 1|Phase 2 |
| NCT02013453 | University of Michigan Rogel Cancer Center |
Cancer of Head and Neck
|
December 2013 | Phase 2 |
| NCT02570893 | Zhejiang Cancer Hospital |
Esophageal Cancer
|
May 2015 | Phase 3 |
| NCT01591135 | Fudan University|Jiangsu Cancer Institute & Hospital|First Affiliated Hospital of Zhejiang University|The First Affiliated Hospital of Xiamen University|Fujian Cancer Hospital|Affiliated Hospital of Jiangnan University |
Esophageal Squamous Cell Carcinoma
|
April 2012 | Phase 3 |
| NCT04771871 | University College Hospital, Ibadan|Lagos State University|Obafemi Awolowo University Teaching Hospital|University of Chicago|University of Lagos, Nigeria|University of Ibadan |
Triple Negative Breast Cancer
|
November 29, 2021 | Phase 2 |
| NCT05610332 | Fujian Medical University |
Locally Advanced Gastric Cancer
|
November 1, 2022 | Phase 3 |
| NCT02891005 | Shandong Branden Med.Device Co.,Ltd |
Small Vessel Lesion
|
December 2015 | Phase 3 |
| NCT02539225 | Eli Lilly and Company |
Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
October 5, 2015 | Phase 2 |
| NCT01966003 | Amgen|Actavis Inc. |
Non-small Cell Lung Cancer Metastatic
|
November 11, 2013 | Phase 3 |
| NCT02327169 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Nonhematologic Malignancies
|
January 14, 2015 | Phase 1 |
| NCT03949634 | Fudan University |
Early Breast Cancer
|
September 1, 2017 | Phase 3 |
| NCT00209612 | Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital |
Gastric Cancer
|
April 2004 | Phase 1|Phase 2 |
| NCT00270790 | Mohan Suntharalingam|MedImmune LLC|University of Maryland, Baltimore |
Head and Neck Cancer
|
May 2002 | Phase 2 |
| NCT01333852 | Lucas Vieira dos Santos|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas, Brazil|Barretos Cancer Hospital |
Head and Neck Neoplasms|Squamous Cell Carcinoma
|
February 2011 | Phase 2 |
| NCT00006377 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Endometrial Cancer
|
June 2000 | Phase 2 |
| NCT00626405 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Melanoma (Skin)
|
August 2008 | Phase 2 |
| NCT00318136 | Genentech, Inc. |
Non-small Cell Lung Cancer
|
September 2005 | Phase 2 |
| NCT03020329 | Sun Yat-sen University |
Nasopharyngeal Carcinoma|Children
|
November 14, 2016 | Phase 2 |
| NCT00388076 | GlaxoSmithKline |
Neoplasms, Breast
|
April 28, 2006 | Phase 1 |
| NCT00368875 | National Cancer Institute (NCI) |
Male Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
July 2006 | Phase 1|Phase 2 |
| NCT00193193 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Prostate Cancer
|
August 2000 | Phase 2 |
| NCT04158362 | UNICANCER |
Cancer Metastatic
|
June 11, 2020 | Phase 3 |
| NCT05189483 | Henan Cancer Hospital |
Soft Tissue Sarcoma
|
January 1, 2022 | Phase 2 |
| NCT00075270 | GlaxoSmithKline |
Neoplasms, Breast
|
January 2004 | Phase 3 |
| NCT00087217 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
May 2004 | Phase 1 |
| NCT05047991 | CSPC Ouyi Pharmaceutical Co., Ltd. |
Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic
|
October 2021 | Phase 2 |
| NCT00563784 | M.D. Anderson Cancer Center|Genentech, Inc.|United States Department of Defense |
Non-Small Cell Lung Cancer|Lung Cancer
|
November 2007 | Phase 2 |
| NCT01264328 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Amgen|Trial Form Support S.L. |
Head and Neck Cancer
|
March 9, 2011 | Phase 2 |
| NCT00002519 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
January 1997 | Phase 1 |
| NCT01558492 | Weill Medical College of Cornell University |
Prostate Cancer
|
March 2011 | Phase 2 |
| NCT02562898 | Margaret Tempero|Stand Up To Cancer|Lustgarten Foundation|University of California, San Francisco |
Metastatic Pancreatic Adenocarcinoma
|
October 12, 2015 | Phase 1|Phase 2 |
| NCT03412643 | NSABP Foundation Inc|Celcuity, LLC|Genentech, Inc. |
HER2-negative Breast Cancer
|
May 14, 2018 | Phase 2 |
| NCT01612351 | UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck
|
June 2012 | Phase 2 |
| NCT04416035 | Zhejiang Teruisi Pharmaceutical Inc. |
Advanced Non-squamous Non-small-cell Lung Cancer
|
August 17, 2020 | Phase 3 |
| NCT02204345 | Hoffmann-La Roche |
Squamous Non-Small Cell Lung Cancer
|
October 2014 | Phase 1|Phase 2 |
| NCT04449549 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Neoplasms
|
August 24, 2020 | Phase 2 |
| NCT00607438 | Veeda Oncology|Bayer|Celgene Corporation |
Breast Cancer
|
September 2007 | Phase 2 |
| NCT02861690 | Sun Yat-sen University |
Esophageal Carcinoma
|
January 2010 | Phase 2 |
| NCT05318443 | Shanghai Institute Of Biological Products|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Non-squamous Non-small-cell Lung Cancer
|
April 17, 2020 | Phase 3 |
| NCT03745911 | Associació per a la Recerca Oncologica, Spain|Takeda|Pivotal S.L. |
Metastatic Urothelial Cancer
|
May 4, 2018 | Phase 2 |
| NCT01962948 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer
|
October 9, 2013 | Phase 1|Phase 2 |
| NCT00730925 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
June 2008 | Phase 2 |
| NCT02879513 | RenJi Hospital |
Invasive Ductal Breast Cancer|Tubular Breast Cancer|Mucinous Breast Cancer|Inflammatory Breast Cancer
|
January 2014 | Phase 3 |
| NCT02998268 | Weill Medical College of Cornell University|Merck Sharp & Dohme LLC |
Esophageal Adenocarcinoma
|
March 7, 2017 | Phase 2 |
| NCT00820170 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb |
Breast Cancer
|
January 2009 | Phase 1|Phase 2 |
| NCT02549209 | Daniela Matei, MD|Merck Sharp & Dohme LLC|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium |
Endometrial Cancer|Endometrial Adenocarcinoma
|
August 22, 2017 | Phase 2 |
| NCT01830270 | Centre Hospitalier Universitaire de Besancon |
Stomach Neoplasms|Oesophageal Junction Cancer|Lower Oesophagus Cancer
|
May 2011 | Phase 2 |
| NCT00004067 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
February 2000 | Phase 3 |
| NCT00112294 | Eli Lilly and Company |
Non-Small-Cell Lung Carcinoma
|
December 2004 | Phase 3 |
| NCT00534729 | King Faisal Specialist Hospital & Research Center |
Laryngeal Neoplasms|Hypopharyngeal Neoplasms
|
September 2007 | Not Applicable |
| NCT01256762 | Geron Corporation |
Locally Recurrent or Metastatic Breast Cancer
|
November 2010 | Phase 2 |
| NCT04443348 | Alice Ho|Merck Sharp & Dohme LLC|Breast Cancer Research Foundation|Translational Breast Cancer Research Consortium|Massachusetts General Hospital |
Triple Negative Breast Cancer|Hormone Receptor Positive (HR&addition;), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s)
|
December 16, 2020 | Phase 2 |
| NCT00119262 | National Cancer Institute (NCI) |
Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer
|
October 2005 | Phase 2 |
| NCT02784288 | University of Michigan Rogel Cancer Center |
Oropharyngeal Squamous Cell Cancer
|
October 31, 2016 | Phase 2 |
| NCT00815308 | Shandong Cancer Hospital and Institute|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Peking University Cancer Hospital & Institute|Hebei Fourth Hospital|Jiangsu Cancer Institute & Hospital|RenJi Hospital|The Affiliated Cancer Hospital of Zhengzhou University|West China Hospital |
Esophageal Cancer
|
January 2009 | Phase 2 |
| NCT00003582 | University of Miami |
Carcinoma of Unknown Primary|Head and Neck Cancer
|
May 1988 | Phase 1|Phase 2 |
| NCT00002917 | Mary Babb Randolph Cancer Center at West Virginia University Hospitals|National Cancer Institute (NCI) |
Bladder Cancer
|
November 1996 | Phase 1|Phase 2 |
| NCT00716534 | AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie |
Advanced or Metastatic Non-Small Cell Lung Cancer
|
June 2008 | Phase 2 |
| NCT03976362 | Merck Sharp & Dohme LLC |
Carcinoma, Squamous Cell, Non-small-cell Lung
|
June 28, 2019 | Phase 3 |
| NCT01491217 | Hanmi Pharmaceutical Company Limited |
Advanced Metastatic Gastric Cancer|Recurrent Gastric Cancer
|
May 2009 | Phase 1|Phase 2 |
| NCT00193206 | SCRI Development Innovations, LLC|Eli Lilly and Company|Celgene Corporation |
Breast Cancer
|
September 2005 | Phase 2 |
| NCT00251095 | Achieve Life Sciences |
Breast Neoplasm
|
September 2005 | Phase 3 |
| NCT00334802 | Eli Lilly and Company |
Metastatic Breast Cancer
|
June 2006 | Phase 2 |
| NCT05020860 | Baylor Breast Care Center |
Breast Cancer|Breast Neoplasm|Breast Cancer Female|Breast Cancer Invasive|Breast Cancer Stage II|Breast Cancer Stage III|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Neoplasms|Estrogen Receptor-positive Breast Cancer
|
June 15, 2022 | Phase 2 |
| NCT04780347 | Fudan University |
Breast Cancer
|
December 15, 2020 | Phase 2 |
| NCT00055601 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NRG Oncology |
Bladder Cancer
|
December 2002 | Phase 2 |
| NCT02862457 | Merck Sharp & Dohme LLC |
Neoplasms|Carcinoma, Non-Small-Cell Lung
|
August 23, 2016 | Phase 1 |
| NCT01547741 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
April 2012 | Phase 3 |
| NCT05295589 | National Cancer Institute (NCI)|NRG Oncology |
Platinum-Refractory Fallopian Tube Carcinoma|Platinum-Refractory Ovarian Carcinoma|Platinum-Refractory Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian High Grade Serous Adenocarcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
|
June 30, 2022 | Phase 2 |
| NCT04842838 | Peking University Third Hospital |
Coronary Artery Disease
|
June 30, 2021 | Not Applicable |
| NCT03834948 | Arch Oncology|Merck Sharp & Dohme LLC |
Solid Tumor
|
February 4, 2019 | Phase 1|Phase 2 |
| NCT02495896 | University of Southern California|National Cancer Institute (NCI)|Vasgene Therapeutics, Inc |
Head and Neck Squamous Cell Carcinoma|Metastatic Pancreatic Adenocarcinoma|Non-Resectable Cholangiocarcinoma|Pancreatic Adenocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Gallbladder Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pancreatic Cancer|Unresectable Gallbladder Carcinoma|Unresectable Pancreatic Cancer
|
September 3, 2015 | Phase 1 |
| NCT00003235 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
April 1998 | Phase 3 |
| NCT00933426 | M.D. Anderson Cancer Center|Celgene Corporation |
Prostate Cancer
|
August 2009 | Phase 1 |
| NCT00048893 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Neoplasms|Metastases, Neoplasm
|
November 2002 | Phase 1|Phase 2 |
| NCT02301988 | Genentech, Inc.|SOLTI Breast Cancer Research Group |
Breast Cancer
|
February 17, 2015 | Phase 2 |
| NCT01694576 | Jiangsu Cancer Institute & Hospital |
Nasopharyngeal Carcinoma
|
September 2012 | Phase 2 |
| NCT03571633 | Centre Leon Berard|Amgen |
HER2-positive Breast Cancer|Operable Breast Cancer
|
August 6, 2018 | Phase 2 |
| NCT00480831 | Genentech, Inc. |
Non-Small Cell Lung Cancer
|
June 2007 | Phase 2 |
| NCT00002826 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
June 1997 | Phase 2 |
| NCT03367871 | University of Miami|Merck Sharp & Dohme LLC |
Cervical Cancer
|
September 6, 2018 | Phase 2 |
| NCT04519905 | Fudan University|Huadong Hospital|Jiangsu Cancer Institute & Hospital|Gansu Cancer Hospital|The First Affiliated Hospital of Xiamen University|Fujian Cancer Hospital|Taihe Hospital|Wuxi No. 4 People´s Hospital|Ningbo No.2 Hospital |
Esophageal Squamous Cell Carcinoma|Chemoradiotherapy|Survival
|
January 6, 2020 | Not Applicable |
| NCT04031703 | Fudan University |
Breast Cancer
|
January 1, 2011 | Phase 3 |
| NCT04906382 | Floor Backes|Ohio State University Comprehensive Cancer Center |
Lynch Syndrome|Recurrent Endometrial Carcinoma|Recurrent Endometrial Clear Cell Adenocarcinoma|Recurrent Uterine Corpus Carcinosarcoma|Mismatch Repair Deficiency|Recurrent Endometrial Cancer|Metastatic Endometrial Cancer
|
July 1, 2021 | Early Phase 1 |
| NCT00298415 | Intergroupe Francophone de Cancerologie Thoracique |
NSCLC
|
March 2006 | Phase 3 |
| NCT00002189 | Baker Norton Pharmaceuticals|NIH AIDS Clinical Trials Information Service |
Sarcoma, Kaposi|HIV Infections
|
Phase 2 | |
| NCT00750386 | Hellenic Oncology Research Group|University Hospital of Crete |
Ovarian Cancer
|
January 2008 | Phase 1|Phase 2 |
| NCT04385550 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
|
May 20, 2020 | Phase 3 |
| NCT02501954 | Women´s Cancer Care Associates, LLC |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer
|
March 2015 | Phase 3 |
| NCT04153734 | Kobe Minimally Invasive Cancer Center|Merck Sharp & Dohme LLC |
Locally Advanced Non-small Cell Lung Cancer
|
December 1, 2019 | Phase 2 |
| NCT00807573 | Memorial Sloan Kettering Cancer Center |
Lung Cancer
|
December 2008 | Phase 2 |
| NCT04393389 | Acotec Scientific Co., Ltd |
Peripheral Artery Disease
|
June 4, 2020 | |
| NCT00006472 | Medstar Health Research Institute |
Esophageal Cancer
|
January 2000 | Phase 2 |
| NCT04617821 | Fudan University |
Borderline Resectable Pancreatic Cancer|Locally Advanced Pancreatic Adenocarcinoma
|
September 1, 2021 | Phase 3 |
| NCT00467012 | Chugai Pharmaceutical |
Metastatic Breast Cancer
|
April 2007 | Phase 2 |
| NCT04821778 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophagus Cancer|Esophagogastric Junction Cancer|Chemoradiation|Targeted Therapy|Immunotherapy|Chemotherapy Effect
|
January 1, 2002 | Phase 3 |
| NCT02412722 | Millennium Pharmaceuticals, Inc.|Takeda |
Non-hematologic Malignancy
|
March 26, 2015 | Phase 1 |
| NCT02924909 | Instituto Nacional de Cancer, Brazil |
Esophageal Cancer|Induction Chemotherapy
|
February 1, 2017 | Phase 2 |
| NCT02221999 | RenJi Hospital |
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer
|
January 2014 | Phase 2|Phase 3 |
| NCT03083613 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
May 2015 | Phase 2 |
| NCT04425018 | Dana-Farber Cancer Institute|MacroGenics|Translational Breast Cancer Research Consortium |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer
|
July 13, 2020 | Phase 2 |
| NCT00043108 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
July 2002 | Phase 2 |
| NCT00231075 | ARCAGY+ GINECO GROUP |
Ovarian Cancer
|
January 2001 | Phase 2 |
| NCT00499252 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma
|
June 2007 | Phase 2 |
| NCT04826016 | MedSIR |
Advanced Breast Cancer
|
July 2021 | Phase 1|Phase 2 |
| NCT02470585 | AbbVie|Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology Group |
Ovarian Cancer|Ovarian Neoplasm
|
June 29, 2015 | Phase 3 |
| NCT00255762 | National Cancer Institute (NCI) |
Recurrent Melanoma|Stage IV Melanoma
|
December 2005 | Phase 2 |
| NCT00394251 | Celgene |
Breast Cancer
|
August 1, 2006 | Phase 2 |
| NCT01236547 | National Cancer Institute (NCI)|NRG Oncology |
Thyroid Gland Anaplastic Carcinoma
|
October 28, 2010 | Phase 2 |
| NCT00016874 | Vion Pharmaceuticals|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
December 2000 | Phase 1 |
| NCT01938872 | Ospedale San Donato |
Critical Limb Ischemia
|
September 2013 | |
| NCT03195569 | Qilu Pharmaceutical Co., Ltd.|Tianjin Medical University Cancer Institute and Hospital |
Non Small Cell Lung Cancer
|
March 1, 2017 | |
| NCT02124317 | Chinese PLA General Hospital |
Advanced Pancreatic Cancer
|
April 2014 | Phase 2 |
| NCT01848197 | Taizhou Hospital |
Breast Cancer|Paclitaxel|Epirubicin|Cyclophosphamide
|
May 2013 | Not Applicable |
| NCT00217607 | UNICANCER |
Sarcoma
|
February 2005 | Phase 2 |
| NCT00533585 | M.D. Anderson Cancer Center|Bayer |
Lung Cancer
|
May 2006 | Phase 1 |
| NCT02754882 | Samsung Bioepis Co., Ltd. |
Lung Cancer|Non-small Cell Lung Cancer
|
July 5, 2016 | Phase 3 |
| NCT00003612 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
April 1999 | Phase 2 |
| NCT00849472 | GlaxoSmithKline|NSABP Foundation Inc |
Neoplasms, Breast
|
July 2009 | Phase 2 |
| NCT03493854 | Hoffmann-La Roche |
Early Breast Cancer
|
June 14, 2018 | Phase 3 |
| NCT03801668 | Huazhong University of Science and Technology|CSPC Ouyi Pharmaceutical Co., Ltd. |
Gastric Cancer
|
March 8, 2019 | Phase 3 |
| NCT00527735 | Bristol-Myers Squibb |
Lung Cancer|Small Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung
|
February 2008 | Phase 2 |
| NCT03770299 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA
|
January 15, 2021 | Phase 2 |
| NCT03064126 | Boston Scientific Corporation |
Peripheral Artery Disease|Atherosclerosis|Artery Diseases, Peripheral|Plaque, Atherosclerotic|Occlusive Arterial Disease
|
March 2, 2017 | Phase 3 |
| NCT02322281 | Clovis Oncology, Inc. |
Non-small Cell Lung Cancer
|
February 2015 | Phase 3 |
| NCT04047953 | Peking University Cancer Hospital & Institute |
Gastric Adenocarcinoma
|
September 10, 2019 | Not Applicable |
| NCT05204173 | Ruijin Hospital |
Gastric Cancer Stage IV|Peritoneal Metastases
|
May 20, 2021 | Phase 2 |
| NCT04864782 | Qilu Pharmaceutical Co., Ltd. |
Cervical Cancer
|
September 23, 2020 | Phase 2|Phase 3 |
| NCT00887575 | SCRI Development Innovations, LLC|Pfizer |
Breast Cancer
|
June 2009 | Phase 1|Phase 2 |
| NCT00611962 | Sanofi |
Neoplasms, Germ Cell and Embryonal
|
December 2000 | Phase 2 |
| NCT04506138 | Zhejiang Cancer Hospital |
Esophageal Squamous Cell Carcinoma
|
August 11, 2020 | Phase 1|Phase 2 |
| NCT05019690 | Fujian Cancer Hospital |
Advanced Triple Negative Breast Cancer
|
October 1, 2021 | Phase 1|Phase 2 |
| NCT05145569 | Haider Mahdi|University of Pittsburgh |
Ovarian Cancer
|
September 2022 | Phase 1 |
| NCT04753177 | Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary |
The Neoadjuvant Therapy
|
January 28, 2021 | Phase 2|Phase 3 |
| NCT04459611 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Non-small Cell Lung Cancer
|
July 1, 2020 | Phase 2 |
| NCT00021372 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 1996 | Phase 2 |
| NCT01016041 | Maasstad Hospital |
Stable Angina|Unstable Angina|Acute Coronary Syndrome
|
February 2007 | Phase 3 |
| NCT04380636 | Merck Sharp & Dohme LLC |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung
|
July 6, 2020 | Phase 3 |
| NCT04499924 | Seagen Inc. |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma
|
March 22, 2021 | Phase 2|Phase 3 |
| NCT00254891 | Pfizer |
Carcinoma, Non-Small-Cell Lung
|
November 2005 | Phase 3 |
| NCT01512199 | Daiichi Sankyo, Inc. |
Metastatic Breast Cancer
|
November 2011 | Phase 1|Phase 2 |
| NCT03149913 | Prof. Dr. med. Gunnar Tepe|InnoRa GmbH|Klinikum Rosenheim |
Stenosis|Occlusion|Restenosis
|
December 15, 2016 | Not Applicable |
| NCT00004924 | Yale University|National Cancer Institute (NCI) |
Lung Cancer
|
March 1999 | Phase 2 |
| NCT02269293 | Memorial Sloan Kettering Cancer Center |
Ovarian Cancer|Endometrial Cancer
|
October 13, 2014 | Phase 1 |
| NCT01650376 | Swedish Medical Center|AstraZeneca |
Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Uterine Cancer
|
August 2012 | Phase 1|Phase 2 |
| NCT02429687 | Beihua Kong|Huazhong University of Science and Technology|Zhejiang University|Sun Yat-sen University|Shandong University |
Ovarian Germ Cell Cancer|Ovarian Neoplasms|Ovarian Cancer
|
April 2015 | Phase 3 |
| NCT02614833 | Immutep S.A.S. |
Adenocarcinoma Breast Stage IV
|
December 2015 | Phase 2 |
| NCT00322452 | AstraZeneca |
Non-Small Cell Lung Cancer
|
March 2006 | Phase 3 |
| NCT00522834 | Synta Pharmaceuticals Corp. |
Melanoma
|
August 2007 | Phase 3 |
| NCT01494688 | Hoffmann-La Roche |
Advanced Solid Tumors
|
December 20, 2011 | Phase 1 |
| NCT00004979 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
Phase 1|Phase 2 | |
| NCT00458315 | Rigshospitalet, Denmark |
Unknown Primary Tumors
|
May 2007 | Phase 2 |
| NCT00408460 | University of Washington|National Cancer Institute (NCI) |
Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
February 2006 | Phase 2 |
| NCT05502237 | Gilead Sciences|Arcus Biosciences, Inc. |
Non-small Cell Lung Cancer
|
October 12, 2022 | Phase 3 |
| NCT00316199 | Eli Lilly and Company |
Metastatic Breast Cancer
|
April 2006 | Phase 2 |
| NCT00423852 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor
|
August 2006 | Phase 1|Phase 2 |
| NCT02718417 | Pfizer |
Ovarian Cancer
|
May 19, 2016 | Phase 3 |
| NCT01084083 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer|Precancerous Condition
|
March 2010 | Phase 2 |
| NCT01862081 | Genentech, Inc. |
Breast Cancer, Non-small Lung Cancer
|
July 16, 2013 | Phase 1 |
| NCT00502203 | M.D. Anderson Cancer Center |
Mixed Tumor, Mullerian
|
August 2001 | Phase 2 |
| NCT05067530 | Medical University of Gdansk |
Triple Negative Breast Neoplasms
|
January 1, 2022 | Phase 2 |
| NCT03747120 | University of Texas Southwestern Medical Center|Merck Sharp & Dohme LLC |
HER2-positive Breast Cancer|Breast Cancer
|
January 25, 2019 | Phase 2 |
| NCT01316757 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary
|
February 16, 2011 | Phase 2 |
| NCT00531011 | Abbott Medical Devices |
Coronary Disease|Coronary Artery Disease|Coronary Artery Stenosis|Coronary Artery Restenosis
|
September 2007 | Phase 4 |
| NCT03912415 | Biocad |
Cervical Cancer
|
October 1, 2019 | Phase 3 |
| NCT02358161 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Novartis|Celgene Corporation |
Pancreatic Cancer
|
September 2015 | Phase 1|Phase 2 |
| NCT01702714 | Hoffmann-La Roche |
Non-Squamous Non-Small Cell Lung Cancer
|
July 2014 | Phase 1 |
| NCT00226590 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Lung Cancer
|
April 2003 | Phase 2 |
| NCT00006110 | UNC Lineberger Comprehensive Cancer Center |
Breast Cancer
|
December 1998 | Phase 2 |
| NCT00768131 | Eli Lilly and Company |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung
|
October 2008 | Phase 2 |
| NCT05580887 | Moscow Clinical Scientific Center |
Breast Cancer|Pancreas Cancer
|
May 12, 2022 | |
| NCT00517621 | ARCAGY+ GINECO GROUP |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms
|
February 2006 | Phase 2 |
| NCT04949256 | Merck Sharp & Dohme LLC|Eisai Inc. |
Metastatic Esophageal Squamous Cell Carcinoma
|
July 28, 2021 | Phase 3 |
| NCT01248403 | Krankenhaus Nordwest |
Advanced Gastric Cancer|Esophagogastric Junction Cancer
|
October 2011 | Phase 3 |
| NCT00268970 | Agennix |
Non-small Cell Lung Cancer
|
December 2005 | Phase 2 |
| NCT01447706 | Merrimack Pharmaceuticals|Sanofi |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
|
October 2011 | Phase 2 |
| NCT01332656 | Sanofi |
Ovarian Cancer Recurrent
|
May 2011 | Phase 2 |
| NCT02256436 | Merck Sharp & Dohme LLC |
Urothelial Cancer
|
October 22, 2014 | Phase 3 |
| NCT03348098 | Tianjin Medical University Cancer Institute and Hospital |
Triple Negative Breast Cancer
|
September 6, 2017 | Phase 2 |
| NCT01525966 | City of Hope Medical Center|National Cancer Institute (NCI) |
Inflammatory Breast Cancer|Stage IIA Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer|Stage IIB Breast Cancer|Estrogen Receptor Negative|Progesterone Receptor Negative|HER2+Neu Negative
|
February 15, 2012 | Phase 2 |
| NCT01051934 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Non-Small Cell Lung Cancer|Adenocarcinoma
|
December 29, 2009 | Phase 1 |
| NCT02059876 | Guangdong Provincial People´s Hospital |
Breast Cancer
|
November 2013 | Phase 2 |
| NCT04299880 | Sumitomo Pharma Oncology, Inc. |
Oncology
|
February 24, 2020 | Phase 1 |
| NCT02312804 | The University of Texas Health Science Center at San Antonio |
Cancer of Cervix|Tumors
|
January 2015 | Phase 1 |
| NCT00004055 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
November 1999 | Phase 2 |
| NCT00404404 | Premiere Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
October 2006 | Phase 2 |
| NCT00003899 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
January 1999 | Phase 1 |
| NCT00598247 | University of Southern California|CTI BioPharma|ASCEND Therapeutics |
Advanced Colorectal Cancer
|
January 2008 | Phase 1 |
| NCT02912715 | Biotronik (Beijing) Medical Device Ltd. |
Peripheral Arterial Disease
|
October 2016 | Not Applicable |
| NCT03872505 | Cedars-Sinai Medical Center|AstraZeneca |
Breast Cancer|Triple Negative Breast Cancer
|
July 2022 | Phase 2 |
| NCT00032032 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
May 2002 | Phase 1 |
| NCT03763123 | Jiangsu Simcere Pharmaceutical Co., Ltd. |
Ovarian Cancer
|
April 24, 2018 | Phase 1 |
| NCT03800836 | Hoffmann-La Roche |
Breast Cancer
|
February 13, 2018 | Phase 1 |
| NCT02476955 | ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) |
Solid Tumors|Ovarian Cancer|Endometrial Cancer
|
June 9, 2015 | Phase 1 |
| NCT03838159 | Fundación GECP |
Non Small Cell Lung Cancer
|
May 15, 2019 | Phase 2 |
| NCT03825328 | Yanqiao Zhang|Harbin Medical University |
Pancreatic Cancer
|
January 30, 2019 | Phase 2 |
| NCT00016341 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Cancer
|
May 2001 | Phase 3 |
| NCT03296163 | mAbxience Research S.L. |
Non-small Cell Lung Cancer
|
February 6, 2018 | Phase 3 |
| NCT02520154 | M.D. Anderson Cancer Center |
Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
July 5, 2016 | Phase 2 |
| NCT03138889 | Nektar Therapeutics |
Non-Small Cell Lung Cancer
|
June 9, 2017 | Phase 1|Phase 2 |
| NCT01372202 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Esophageal Cancer
|
June 2011 | Phase 2 |
| NCT00038246 | M.D. Anderson Cancer Center|Celgene |
Prostate Cancer
|
October 2000 | Phase 1|Phase 2 |
| NCT00689715 | Asan Medical Center |
Cystic Tumors of the Pancreas
|
June 2006 | Phase 2|Phase 3 |
| NCT04625543 | Qilu Hospital of Shandong University |
Esophagus SCC
|
December 2020 | Phase 2 |
| NCT00140101 | Abbott Medical Devices |
Coronary Disease|Coronary Artery Disease|Coronary Restenosis
|
May 2005 | Phase 2 |
| NCT00828841 | Accelerated Community Oncology Research Network |
Non-Small Cell Lung Cancer
|
December 2008 | Phase 2 |
| NCT04888403 | The First Affiliated Hospital of Zhengzhou University |
Locally Advanced Esophageal Squamous Cell Carcinoma
|
December 31, 2021 | Phase 2 |
| NCT02608216 | University of Pennsylvania |
Breast Neoplasm|Metastatic Breast Cancer|Rb&addition; Breast Cancer
|
November 2015 | Phase 1 |
| NCT05244213 | Guangdong Provincial People´s Hospital |
Non-small Cell Lung Cancer|EGFR Activating Mutation
|
June 4, 2022 | Phase 2 |
| NCT01209195 | Merrimack Pharmaceuticals|Sanofi |
Locally Advanced+Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,|Primary Peritoneal Cancer or Endometrial Cancer|Locally Advanced+Metastatic Her2 Non Overexpressing Breast Cancer
|
October 2010 | Phase 1 |
| NCT04576143 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Women´s Hospital School Of Medicine Zhejiang University|Changxing People´s Hospital|Zhejiang Provincial People´s Hospital|Hangzhou First People´s Hospital, School of Medicine, Zhejiang Universiry|Huizhou Municipal Central Hospital |
HER2-negative Breast Cancer|Neoadjuvant Chemotherapy
|
September 20, 2020 | Phase 2|Phase 3 |
| NCT00470301 | National Cancer Institute (NCI) |
Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
April 2007 | Phase 1|Phase 2 |
| NCT04222972 | Hoffmann-La Roche |
RET-fusion Non Small Cell Lung Cancer|Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms by Site|Neoplasms|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Diseases|Head and Neck Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Germ Cell and Embryonal|Neoplasms, Nerve Tissue
|
July 24, 2020 | Phase 3 |
| NCT05112536 | G1 Therapeutics, Inc. |
Triple Negative Breast Cancer|Breast Cancer
|
November 19, 2021 | Phase 2 |
| NCT00785291 | National Cancer Institute (NCI) |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|HER2+Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIC Breast Cancer AJCC v6|Stage IV Breast Cancer AJCC v6 and v7
|
October 13, 2008 | Phase 3 |
| NCT00006229 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lung Cancer
|
April 4, 2000 | Phase 2|Phase 3 |
| NCT01034189 | National Taiwan University Hospital |
Esophageal Cancer
|
October 2008 | Phase 2 |
| NCT03081143 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Advanced Gastric or EGJ Cancer
|
May 10, 2017 | Phase 2|Phase 3 |
| NCT04253964 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Nonsmall Cell Lung Cancer|Performance Status
|
July 1, 2020 | Phase 2 |
| NCT01745367 | AVEO Pharmaceuticals, Inc.|Astellas Pharma Inc |
Triple Negative Breast Cancer
|
November 2012 | Phase 2 |
| NCT00531687 | Rigshospitalet, Denmark |
Testicular Cancer
|
September 2007 | Phase 2 |
| NCT02597946 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
March 18, 2016 | Phase 2 |
| NCT00003696 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lung Cancer
|
October 1998 | Phase 3 |
| NCT00891605 | AbbVie|Genentech, Inc. |
Solid Tumors
|
July 2009 | Phase 1 |
| NCT01684878 | Hoffmann-La Roche |
Ovarian Cancer
|
October 22, 2012 | Phase 3 |
| NCT02379585 | Western Regional Medical Center |
HER2-positive Breast Cancer
|
January 2013 | Phase 1|Phase 2 |
| NCT05251038 | Devalingam Mahalingam|Amgen|Hoosier Cancer Research Network |
Pancreatic Cancer|Unresectable Pancreatic Cancer|Metastatic Pancreatic Cancer|KRAS P.G12C
|
September 13, 2022 | Phase 1|Phase 2 |
| NCT03721744 | 1Globe Health Institute LLC|1Globe Biomedical Co., Ltd. |
Metastatic Pancreatic Cancer
|
October 25, 2018 | Phase 3 |
| NCT04213378 | Second Affiliated Hospital, School of Medicine, Zhejiang University|West China Hospital|First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|The Third Xiangya Hospital of Central South University|Hebei Medical University Third Hospital|TEDA International Cardiovascular Hospital|Tianjin People´s Hospital|The Second Hospital of Shandong University|Hainan People´s Hospital|The First Affiliated Hospital of Xiamen University|Shanghai Chest Hospital|Renmin Hospital of Wuhan University|Taizhou Hospital |
Coronary In-stent Restenosis
|
January 1, 2017 | Phase 2|Phase 3 |
| NCT00984464 | Oncolytics Biotech|University of Texas |
Metastatic Melanoma
|
September 2009 | Phase 2 |
| NCT00003742 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
October 1998 | Phase 1 |
| NCT05111444 | Fudan University |
Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma
|
December 31, 2021 | Phase 2 |
| NCT00189644 | Association Européenne de Recherche en Oncologie|Bristol-Myers Squibb |
Breast Cancer
|
Phase 3 | |
| NCT01186991 | Genentech, Inc.|Hoffmann-La Roche |
Breast Cancer
|
March 2011 | Phase 2 |
| NCT03490292 | University of Wisconsin, Madison |
Resectable Esophageal Cancer|GastroEsophageal Cancer
|
May 29, 2018 | Phase 1|Phase 2 |
| NCT04000906 | University Hospital, Geneva |
Peritoneal Carcinomatosis
|
November 11, 2020 | Phase 1 |
| NCT02142738 | Merck Sharp & Dohme LLC |
Non-Small Cell Lung Carcinoma
|
August 25, 2014 | Phase 3 |
| NCT03601897 | Deciphera Pharmaceuticals LLC |
Locally Advanced or Metastatic Solid Tumor
|
September 19, 2018 | Phase 1|Phase 2 |
| NCT02735239 | Ludwig Institute for Cancer Research|AstraZeneca |
Esophageal Cancer
|
June 24, 2016 | Phase 1|Phase 2 |
| NCT02754726 | HonorHealth Research Institute|Translational Genomics Research Institute|Bristol-Myers Squibb|Lustgarten Foundation |
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
|
April 2016 | Phase 2 |
| NCT00728845 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey |
Lung Cancer
|
June 16, 2008 | Phase 1|Phase 2 |
| NCT02514681 | Japan Breast Cancer Research Group|Chugai Pharmaceutical |
HER2-positive Locally Advanced or Metastatic Breast Cancer
|
August 1, 2015 | Phase 3 |
| NCT01566240 | University College, London|Cancer Research UK |
Cervical Cancer
|
September 2012 | Phase 3 |
| NCT00326456 | National Cancer Institute, Naples |
Ovarian Cancer
|
January 2003 | Phase 3 |
| NCT02389751 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Gastroesophageal Junction Adenocarcinoma|Malignant Neoplasm of the Cervical Esophagus|Malignant Neoplasm of the Thoracic Esophagus|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer AJCC v7
|
April 10, 2015 | Phase 1 |
| NCT03057600 | Calithera Biosciences, Inc |
Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer
|
May 1, 2017 | Phase 2 |
| NCT01501487 | Agendia|University of South Florida|University of Miami|Morton Plant Mease Health Care|AdventHealth|Plano Cancer Center|Ohio State University Comprehensive Cancer Center|University of Oklahoma|University of South Alabama |
Breast Cancer
|
October 2011 | Phase 4 |
| NCT03486314 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Neoplasm
|
August 13, 2018 | Phase 1 |
| NCT00367471 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
December 7, 2006 | Phase 1 |
| NCT01763710 | Fundacion Oncosur |
Breast Cancer
|
December 2012 | Phase 2 |
| NCT01989780 | Japan Breast Cancer Research Group|Chugai Pharmaceutical |
Metastatic Breast Cancer
|
January 2014 | Phase 2 |
| NCT03125928 | Fox Chase Cancer Center|Genentech, Inc. |
HER2-positive Breast Cancer
|
June 13, 2017 | Phase 2 |
| NCT01750073 | University of Nebraska|National Cancer Institute (NCI) |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|HER2+Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
December 2012 | Phase 2 |
| NCT04520035 | Fudan University |
PFS
|
August 1, 2020 | Phase 2 |
| NCT03275818 | Grupo Espanol de Investigacion en Sarcomas |
Tumor, Desmoplastic Small Round Cell, Adult|Tumor, Desmoplastic Small Round Cell, Childhood|Sarcoma, Ewing|Sarcoma|Desmoid
|
May 9, 2017 | Phase 2 |
| NCT00618657 | University of California, Irvine|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Breast Cancer|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
February 2008 | Phase 2 |
| NCT00034164 | Achieve Life Sciences |
Carcinoma, Non-Small-Cell Lung
|
April 2002 | Phase 2 |
| NCT03072992 | National Center of Oncology, Armenia|BRIU GmbH |
Advanced Breast Cancer|Metastatic Breast Cancer
|
March 20, 2017 | Phase 2 |
| NCT01196390 | National Cancer Institute (NCI)|NRG Oncology |
Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Cancer AJCC v7|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7
|
December 30, 2010 | Phase 3 |
| NCT03179904 | Mayo Clinic|National Cancer Institute (NCI) |
Advanced Breast Carcinoma|HER2 Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
September 25, 2017 | Phase 2 |
| NCT04274426 | AGO Research GmbH |
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
|
October 13, 2021 | Phase 2 |
| NCT01526369 | Cancer Trials Ireland |
Metastatic Breast Cancer
|
January 2012 | Phase 3 |
| NCT02220894 | Merck Sharp & Dohme LLC |
Non-small Cell Lung Cancer
|
October 30, 2014 | Phase 3 |
| NCT01712919 | Jiangsu Cancer Institute & Hospital |
Nasopharyngeal Carcinoma
|
May 2010 | Phase 1|Phase 2 |
| NCT01220154 | David O´Malley|Genentech, Inc.|Ohio State University Comprehensive Cancer Center |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|No Prior Chemotherapy
|
October 2010 | Phase 1 |
| NCT00900172 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lung Cancer
|
March 15, 2008 | |
| NCT05367206 | Sun Yat-sen University |
Cervical Cancer|Neoadjuvant Chemotherapy|Bulky Neoplasm
|
March 14, 2022 | Phase 3 |
| NCT00629499 | SCRI Development Innovations, LLC|Celgene Corporation |
Breast Cancer
|
April 2008 | Phase 2 |
| NCT04492033 | Handok Inc.|Compass Therapeutics|ABL Bio, Inc. |
P1b: Advanced Solid Tumors|P2: Biliary Tract Cancer
|
June 22, 2020 | Phase 1|Phase 2 |
| NCT00005051 | NYU Langone Health|National Cancer Institute (NCI) |
Ovarian Cancer
|
August 1999 | Phase 2 |
| NCT00028769 | Southwest Oncology Group|National Cancer Institute (NCI) |
Prostate Cancer
|
December 2001 | Phase 2 |
| NCT02129127 | TriReme Medical, LLC |
Peripheral Vascular Disease
|
March 2014 | Not Applicable |
| NCT03273595 | Xijing Hospital |
Neoplasms, Breast
|
July 2016 | Phase 2 |
| NCT00002632 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
March 1995 | Phase 2 |
| NCT03534713 | University Hospital, Toulouse|Institut Claudius Regaud |
Cervical Cancer TNM Staging Regional Lymph Nodes (N)
|
July 1, 2020 | Phase 3 |
| NCT00003294 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific
|
May 1997 | Phase 1 |
| NCT04016389 | University Health Network, Toronto|Hotel Dieu Hospital|The Netherlands Cancer Institute |
Cervical Cancer
|
February 11, 2020 | Not Applicable |
| NCT00004547 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm
|
January 2000 | Phase 2 |
| NCT03308552 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Hebei Medical University Fourth Hospital|Tianjin Medical University Cancer Institute and Hospital|Anyang Tumor Hospital|The First Affiliated Hospital with Nanjing Medical University|Affiliated Hospital of Hebei University|Fujian Cancer Hospital|Sichuan Cancer Hospital and Research Institute |
Esophageal Neoplasms
|
December 1, 2017 | Phase 3 |
| NCT04681911 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
September 9, 2020 | Phase 2 |
| NCT03748134 | Innovent Biologics (Suzhou) Co. Ltd. |
Esophageal Squamous Cell Carcinoma
|
December 24, 2018 | Phase 3 |
| NCT01301729 | Hoffmann-La Roche |
Breast Cancer
|
March 2011 | Phase 4 |
| NCT05310331 | Lei Li|Peking Union Medical College Hospital |
Targeted Therapy|Chemotherapy|Recurrent Cervical Carcinoma|Metastatic Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Survival Outcomes|Adverse Effect
|
March 27, 2022 | Phase 2 |
| NCT00006012 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Lung Cancer|Radiation Toxicity
|
February 2001 | Phase 1|Phase 2 |
| NCT00003342 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter
|
December 1997 | Phase 1 |
| NCT01994031 | Nanjing Luye Sike Pharmaceutical Co., Ltd. |
Solid Tumors
|
August 2014 | Phase 4 |
| NCT03731442 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|The First Affiliated Hospital with Nanjing Medical University|Tianjin Medical University Cancer Institute and Hospital|Anyang Tumor Hospital|Fujian Cancer Hospital|Peking University Cancer Hospital & Institute|Hebei Medical University Fourth Hospital |
Esophageal Cancer
|
November 1, 2018 | Phase 3 |
| NCT04896177 | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
Coronary Bifurcation Lesions
|
March 18, 2021 | Not Applicable |
| NCT02637375 | University of Chicago |
Breast Cancer
|
May 2016 | Not Applicable |
| NCT02396108 | National University Hospital, Singapore |
Breast Cancer
|
March 2015 | Phase 1|Phase 2 |
| NCT04846452 | The First Affiliated Hospital with Nanjing Medical University |
Metastatic NSCLC|Recurrent NSCLC|Advanced Non-Small Cell Squamous Lung Cancer
|
June 1, 2021 | Phase 2 |
| NCT00544167 | SCRI Development Innovations, LLC|Bayer |
Breast Cancer
|
May 2007 | Not Applicable |
| NCT01301716 | Genentech, Inc. |
Solid Cancers
|
September 2011 | Phase 1 |
| NCT02551055 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
|
October 15, 2015 | Phase 1 |
| NCT01852292 | Novartis Pharmaceuticals|Novartis |
Head and Neck Squamous Cell Carcinoma
|
October 1, 2013 | Phase 2 |
| NCT00003013 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI) |
Breast Cancer
|
October 1996 | Phase 3 |
| NCT00117442 | Amgen |
Breast Cancer|Lung Cancer|Ovarian Cancer
|
August 2002 | Phase 2 |
| NCT00946712 | Southwest Oncology Group|National Cancer Institute (NCI) |
Recurrent Large Cell Lung Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Squamous Cell Lung Carcinoma|Stage IV Large Cell Lung Carcinoma|Stage IV Lung Adenocarcinoma|Stage IV Squamous Cell Lung Carcinoma
|
July 15, 2009 | Phase 3 |
| NCT00085839 | OSI Pharmaceuticals|Astellas Pharma Inc |
Non-Small Cell Lung Cancer
|
February 2004 | Phase 2 |
| NCT04294784 | Huazhong University of Science and Technology |
Gastric Cancer|GastroEsophageal Cancer
|
April 3, 2020 | Phase 2 |
| NCT00005021 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
July 1996 | Phase 1 |
| NCT01367301 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Stage IA Uterine Sarcoma|Stage IB Uterine Sarcoma|Stage IC Uterine Sarcoma|Stage IIA Uterine Sarcoma|Stage IIB Uterine Sarcoma|Stage IIIA Uterine Sarcoma|Stage IIIB Uterine Sarcoma|Stage IIIC Uterine Sarcoma|Stage IVA Uterine Sarcoma|Stage IVB Uterine Sarcoma|Uterine Carcinosarcoma
|
May 2011 | Not Applicable |
| NCT02629848 | Takeda |
Carcinoma, Non-Small-Cell Lung
|
July 2012 | Phase 3 |
| NCT00617409 | H. Lee Moffitt Cancer Center and Research Institute |
Small Cell Lung Cancer
|
October 2, 2007 | Phase 2 |
| NCT01160185 | GlaxoSmithKline |
Cervical Intraepithelial Neoplasia
|
June 2009 | |
| NCT01705691 | NSABP Foundation Inc|Eisai Inc. |
Breast Cancer|HER2-negative Breast Cancer
|
September 2012 | Phase 2 |
| NCT00937560 | Hoffmann-La Roche |
Ovarian Cancer
|
June 25, 2009 | Phase 2 |
| NCT00855764 | Bristol-Myers Squibb |
Head and Neck Cancer
|
October 2005 | Phase 2 |
| NCT02125513 | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
Ovarian Cancer|Fallopian Tube Carcinoma|Peritoneal Carcinoma
|
January 2014 | Phase 2 |
| NCT01847001 | Columbia University |
Locally Advanced Malignant Neoplasm|Breast Cancer
|
October 2012 | Phase 2 |
| NCT05418309 | Tianjin Medical University Second Hospital |
High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
|
December 27, 2021 | Phase 2 |
| NCT00003998 | University of Glasgow|National Cancer Institute (NCI) |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
October 1998 | Phase 3 |
| NCT01711697 | Emory University|Washington University Siteman Cancer Center |
Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
September 4, 2012 | Phase 1 |
| NCT00003569 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Head and Neck Cancer|Lung Cancer|Neurotoxicity|Ovarian Cancer
|
March 1998 | |
| NCT00954512 | Merck Sharp & Dohme LLC |
Neoplasms
|
September 25, 2009 | Phase 1|Phase 2 |
| NCT01587482 | Nantes University Hospital |
Peripheral Arterial Disease
|
December 2011 | |
| NCT03866993 | Akeso|Akeso Tiancheng, Inc |
Lung Cancer Non-small Cell Stage IV|Squamous Cell Lung Cancer
|
December 20, 2018 | Phase 3 |
| NCT01031446 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
October 2009 | Phase 1|Phase 2 |
| NCT00199758 | University Hospital, Limoges|Groupe Français de Pneumologie Cancérologie (GFPC) |
Non Small Cell Lung Carcinoma
|
September 2003 | Phase 2 |
| NCT00003732 | Rigshospitalet, Denmark|National Cancer Institute (NCI) |
Ovarian Cancer
|
September 1998 | Phase 2 |
| NCT00034541 | Eli Lilly and Company|University of Colorado, Denver|Greenwich Hospital|Indiana University |
Carcinoma, Non-Small-Cell Lung
|
December 2000 | Phase 1|Phase 2 |
| NCT03429972 | National Cancer Centre, Singapore|Terry Fox Foundation|Duke-NUS Academic Medicine Research Institute|Singapore General Hospital |
Breast Cancer
|
September 2016 | Phase 2 |
| NCT05157542 | Juan LI, MD|Sichuan Cancer Hospital and Research Institute |
Stage III Non-small Cell Lung Cancer
|
June 10, 2021 | Phase 1 |
| NCT01778803 | Verastem, Inc. |
Ovarian Cancer
|
February 26, 2013 | Phase 1 |
| NCT02073968 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
July 2013 | Phase 2 |
| NCT00020007 | National Cancer Institute (NCI) |
Lung Cancer|Metastatic Cancer
|
December 1999 | Phase 1 |
| NCT01711541 | National Cancer Institute (NCI) |
Head and Neck Squamous Cell Carcinoma|Stage IVA Oropharyngeal Carcinoma AJCC v7|Stage IVB Oropharyngeal Carcinoma AJCC v7
|
October 22, 2012 | Phase 1|Phase 2 |
| NCT02502266 | National Cancer Institute (NCI)|Canadian Cancer Trials Group|NRG Oncology |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
February 5, 2016 | Phase 2|Phase 3 |
| NCT00181701 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital |
Ovarian Carcinoma
|
October 2004 | Phase 2 |
| NCT05451043 | AHS Cancer Control Alberta |
Pancreatic Cancer|Hepatocellular Cancer|Biliary Tract Cancer|Cholangiocarcinoma
|
October 1, 2022 | Phase 2 |
| NCT01970722 | City of Hope Medical Center|National Cancer Institute (NCI) |
FIGO Stage IVA Ovarian Cancer|FIGO Stage IVB Ovarian Cancer|Platinum-Resistant Ovarian Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
May 19, 2014 | Phase 1 |
| NCT01966471 | Hoffmann-La Roche |
Breast Cancer
|
January 31, 2014 | Phase 3 |
| NCT03965689 | National Cancer Institute (NCI) |
Metastatic Lung Non-Small Cell Squamous Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
|
September 3, 2019 | Phase 2 |
| NCT04060472 | Dong Wang|Third Military Medical University |
Advanced Hepatobiliary and Malignant Tumors
|
August 20, 2019 | Phase 2|Phase 3 |
| NCT02607982 | Hangzhou Cancer Hospital |
Esophageal Cancer|Concurrent Chemoradiotherapy|Oxaliplatin|Paclitaxel
|
January 2005 | Phase 2 |
| NCT04278287 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Cancer|Chemoradiotherapy|Albumin-bound Paxlitaxel|Unresectable Malignant Neoplasm
|
October 1, 2019 | Phase 1|Phase 2 |
| NCT02446600 | National Cancer Institute (NCI)|AstraZeneca|NRG Oncology |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Tumor|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal Carcinoma
|
February 4, 2016 | Phase 3 |
| NCT02630264 | Guangzhou Double Bioproducts Co., Ltd |
Head and Neck Neoplasms
|
June 2013 | Phase 3 |
| NCT01294293 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma
|
March 2011 | Phase 1 |
| NCT04679064 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS|GlaxoSmithKline |
Ovarian Cancer
|
December 1, 2020 | Phase 3 |
| NCT04261218 | Translational Research in Oncology|Effector Therapeutics|Stand Up To Cancer |
Breast Cancer
|
August 25, 2020 | Phase 1 |
| NCT00431080 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
August 2004 | Phase 3 |
| NCT00196872 | German Breast Group |
Breast Cancer
|
July 2004 | Phase 3 |
| NCT02366143 | Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
March 31, 2015 | Phase 3 |
| NCT00005647 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Head and Neck Cancer
|
May 2000 | Phase 1 |
| NCT00453323 | National Cancer Center, Korea |
Esophageal Cancer
|
June 2006 | Phase 2 |
| NCT03603756 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Squamous Cell Carcinoma
|
July 31, 2018 | Phase 2 |
| NCT03616886 | Jules Bordet Institute|AstraZeneca |
Triple Negative Breast Cancer
|
December 28, 2018 | Phase 1|Phase 2 |
| NCT04150575 | Shanghai Henlius Biotech |
Cervical Cancer
|
March 10, 2020 | Phase 2 |
| NCT05125055 | Shanghai Jiao Tong University School of Medicine |
Oral Squamous Cell Carcinoma|Neoadjvant Therapy|Anti-PD-1|Chemotherapy
|
October 1, 2021 | Phase 2|Phase 3 |
| NCT00009932 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
January 2001 | Phase 1 |
| NCT04603846 | Lee´s Pharmaceutical Limited |
Advanced Urothelial Carcinoma
|
September 10, 2020 | Phase 1 |
| NCT00667251 | Novartis Pharmaceuticals|NCIC Clinical Trials Group|Novartis |
Breast Cancer
|
October 7, 2008 | Phase 3 |
| NCT04856176 | Tufts Medical Center|Partner Therapeutics, Inc. |
Advanced Lung Non-Small Cell Carcinoma|Non-Small Cell Carcinoma of Lung, TNM Stage 4
|
January 3, 2022 | Phase 2 |
| NCT00344552 | Bristol-Myers Squibb |
Esophageal Cancer
|
June 2006 | Phase 2 |
| NCT02576574 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
First Line Non-Small Cell Lung Cancer
|
October 29, 2015 | Phase 3 |
| NCT02581982 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Transitional Cell Carcinoma
|
April 6, 2016 | Phase 2 |
| NCT02881125 | University of Washington|National Cancer Institute (NCI) |
Small Cell Carcinoma
|
November 3, 2016 | Phase 1 |
| NCT05522894 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Akeso Pharmaceuticals, Inc. |
Unresectable Esophageal Squamous Cell Carcinoma|Locally Advanced Esophageal Squamous Cell Carcinoma|Metastatic Esophageal Squamous Cell Carcinoma
|
October 1, 2022 | Phase 2 |
| NCT02644863 | Shenzhen Hornetcorn Bio-technology Company, LTD|Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
Esophageal Neoplasms|Neoplasms|Digestive System Neoplasms|Esophageal Cancer
|
December 2015 | Phase 2 |
| NCT03921008 | Washington University School of Medicine |
Cutaneous Angiosarcoma
|
May 21, 2019 | Phase 1|Phase 2 |
| NCT02162719 | Genentech, Inc. |
Breast Neoplasms
|
August 19, 2014 | Phase 2 |
| NCT04856137 | National Health Research Institutes, Taiwan|Taipei Veterans General Hospital, Taiwan|Chang Gung Memorial Hospital|China Medical University Hospital|Shin Kong Wu Huo-Shih Memorial Hospital |
Refractory Diffuse Large B-cell Lymphoma
|
May 1, 2021 | Phase 1|Phase 2 |
| NCT01818063 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation|Thomas Jefferson University |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer
|
April 25, 2013 | Phase 2 |
| NCT00002814 | Dartmouth-Hitchcock Medical Center |
Brain and Central Nervous System Tumors
|
August 1996 | Phase 2 |
| NCT00055887 | Spectrum Pharmaceuticals, Inc |
Lung Cancer
|
November 2002 | Phase 3 |
| NCT01570582 | Korean Gynecologic Oncology Group |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer
|
March 2010 | Phase 2 |
| NCT00387374 | National Cancer Institute (NCI) |
Adenosquamous Cell Lung Cancer|Drug+Agent Toxicity by Tissue+Organ|Hemoptysis|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
October 2006 | Phase 2 |
| NCT02053597 | Jules Bordet Institute |
Breast Cancer
|
October 2014 | Phase 2 |
| NCT00003072 | University of California, San Francisco |
Lung Cancer|Neurotoxicity|Ovarian Cancer
|
May 1997 | Phase 2 |
| NCT03177291 | H. Lee Moffitt Cancer Center and Research Institute |
Lung Cancer|Non Small Cell Lung Cancer|Advanced Cancer|Metastatic Lung Cancer|Squamous Cell Lung Cancer|Non-Squamous Non-Small Cell Neoplasm of Lung
|
September 26, 2017 | Phase 1 |
| NCT01495247 | Novartis Pharmaceuticals|Novartis |
Inoperable Locally Advanced Breast Cancer|Metastatic Breast Cancer (MBC)
|
January 30, 2012 | Phase 1|Phase 2 |
| NCT02459457 | Fudan University|Huadong Hospital|Wuxi No. 4 People´s Hospital|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital of Xiamen University|Jiangxi Provincial Cancer Hospital|Shanxi Province Cancer Hospital|Gansu Cancer Hospital |
Stage III Esophageal Squamous Cell Carcinoma
|
July 1, 2015 | Phase 3 |
| NCT03085056 | Memorial Sloan Kettering Cancer Center|Novartis |
Anaplastic Thyroid Cancer
|
March 15, 2017 | Early Phase 1 |
| NCT03871153 | Greg Durm, MD|AstraZeneca|Indiana University School of Medicine|Hoosier Cancer Research Network |
Non Small Cell Lung Cancer|Stage III Non-small-cell Lung Cancer
|
August 2, 2019 | Phase 2 |
| NCT05025033 | Tianjin Medical University Cancer Institute and Hospital |
Gastric Cancer
|
May 30, 2019 | Phase 2 |
| NCT04033354 | Shanghai Henlius Biotech |
Squamous Non Small Cell Lung Cancer
|
August 14, 2019 | Phase 3 |
| NCT04540692 | Latin American Cooperative Oncology Group|Brazilian Breast Cancer Study Group (GBECAM) |
Breast Cancer
|
January 12, 2021 | Phase 3 |
| NCT00508625 | Amgen|Genentech, Inc. |
Non-Small Cell Lung Cancer
|
June 2006 | Phase 2 |
| NCT03554044 | University of California, San Francisco|Amgen |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2+Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma
|
February 5, 2020 | Phase 1 |
| NCT04282070 | Jiangsu HengRui Medicine Co., Ltd. |
Nasopharyngeal Carcinoma
|
March 27, 2020 | Phase 1 |
| NCT00533936 | Instituto Nacional de Cancerologia, Columbia|National Cancer Institute (NCI) |
Breast Cancer
|
September 2006 | Phase 2 |
| NCT04196257 | Bio-Path Holdings, Inc. |
Solid Tumor, Adult|Carcinoma, Ovarian Epithelial|Fallopian Tube Neoplasms|Endometrial Cancer|Peritoneal Cancer|Solid Tumor
|
August 19, 2022 | Phase 1 |
| NCT01855828 | Yale University|Genentech, Inc. |
Her2-Positive Breast Cancer
|
September 2013 | Phase 2 |
| NCT04711161 | Green3Bio, Inc. |
Ovarian Tumors
|
December 21, 2020 | Phase 1 |
| NCT03328494 | Boston Pharmaceuticals |
Advanced Nonhaematologic Malignancies
|
October 13, 2017 | Phase 1 |
| NCT04862650 | Marcelo Bonomi|Ohio State University Comprehensive Cancer Center |
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oropharyngeal Squamous Cell Carcinoma|Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Oral Cavity Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Unknown Primary|Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Laryngeal Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IVA Hypopharyngeal Carcinoma AJCC v8|Stage IVA Laryngeal Cancer AJCC v8|Stage IVA Lip and Oral Cavity Cancer AJCC v8|Stage IVB Hypopharyngeal Carcinoma AJCC v8|Stage IVB Laryngeal Cancer AJCC v8|Stage IVB Lip and Oral Cavity Cancer AJCC v8|Stage IVC Hypopharyngeal Carcinoma AJCC v8|Stage IVC Laryngeal Cancer AJCC v8|Stage IVC Lip and Oral Cavity Cancer AJCC v8
|
November 30, 2021 | Phase 2 |
| NCT01688609 | National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
July 2012 | Phase 2 |
| NCT04391049 | NRG Oncology|National Cancer Institute (NCI) |
Advanced Esophageal Adenocarcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Unresectable Gastroesophageal Junction Adenocarcinoma|Squamous Cell Carcinoma|Squamous Cell Cancer
|
June 29, 2020 | Phase 1 |
| NCT00002953 | Medical Research Council|National Cancer Institute (NCI) |
Breast Cancer
|
December 1996 | Phase 3 |
| NCT01656538 | Canadian Cancer Trials Group|Oncolytics Biotech |
Metastatic Breast Cancer
|
July 30, 2012 | Phase 2 |
| NCT03841747 | Queen Mary University of London|Merck Sharp & Dohme LLC|European Institute of Oncology |
Breast Cancer
|
May 2019 | Phase 2 |
| NCT04973904 | Peking Union Medical College Hospital |
Cervical Cancer
|
August 1, 2021 | Phase 2 |
| NCT01838538 | Chinese PLA General Hospital |
Ovarian Cancer With Malignant Ascites
|
June 2011 | Phase 2 |
| NCT00096226 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
September 2004 | Phase 2 |
| NCT01411410 | Bayer |
Neoplasms
|
August 24, 2011 | Phase 1 |
| NCT01722968 | Theodoros Foukakis|Karolinska University Hospital |
Breast Cancer
|
November 2012 | Phase 2 |
| NCT01405235 | Institut fuer Frauengesundheit|GlaxoSmithKline|Schantl Pharma Service, Germany |
Recurrent, Persistent or Metastasized Cervical Cancer
|
September 2006 | Phase 3 |
| NCT00491855 | M.D. Anderson Cancer Center |
Peritoneal Cancer
|
June 2007 | Phase 1 |
| NCT02134067 | Taiho Oncology, Inc. |
Advanced Solid Tumors
|
August 2014 | Phase 1 |
| NCT03530397 | MedImmune LLC |
Selected Advanced Solid Tumors
|
April 24, 2018 | Phase 1 |
| NCT01249443 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas |
HIV Infection|Recurrent Anal Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Anal Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Unspecified Adult Solid Tumor, Protocol Specific
|
November 2013 | Phase 1 |
| NCT05360394 | Singapore General Hospital |
Neointimal Hyperplasia|Dialysis Access Malfunction
|
April 20, 2022 | Not Applicable |
| NCT00861705 | National Cancer Institute (NCI) |
Male Breast Carcinoma|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
May 15, 2009 | Phase 2 |
| NCT03081689 | Spanish Lung Cancer Group |
Non Small Cell Lung Cancer
|
April 15, 2017 | Phase 2 |
| NCT03199885 | National Cancer Institute (NCI)|NRG Oncology |
Metastatic Breast Adenocarcinoma|Metastatic HER2-Positive Breast Carcinoma|Recurrent Breast Adenocarcinoma|Recurrent HER2-Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Breast Carcinoma|Unresectable HER2-Positive Breast Carcinoma
|
March 12, 2019 | Phase 3 |
| NCT04865289 | Merck Sharp & Dohme LLC|Eisai Inc. |
Endometrial Neoplasms
|
October 22, 2019 | Phase 3 |
| NCT00011986 | Gynecologic Oncology Group|Southwest Oncology Group|Medical Research Council|National Cancer Institute (NCI)|GOG Foundation |
Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer
|
January 2001 | Phase 3 |
| NCT00574587 | Albert Einstein College of Medicine|Merck Sharp & Dohme LLC |
Breast Cancer
|
December 2007 | Phase 1|Phase 2 |
| NCT02152137 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Daiichi Sankyo, Inc. |
Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer
|
September 2014 | Phase 2 |
| NCT04460352 | Karolinska University Hospital|University of Leipzig|The Swedish Research Council |
Esophageal Squamous Cell Carcinoma
|
November 27, 2020 | Phase 3 |
| NCT00081042 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Melanoma (Skin)
|
February 2004 | Phase 2 |
| NCT00454649 | Pfizer |
Neoplasms
|
December 2005 | Phase 1 |
| NCT00558636 | Bayer |
Carcinoma, Non-Small-Cell Lung
|
September 2007 | Phase 3 |
| NCT00307047 | Abbott Medical Devices |
Coronary Artery Disease
|
August 2006 | Phase 3 |
| NCT01362374 | Genentech, Inc. |
Neoplasms
|
July 11, 2011 | Phase 1 |
| NCT01065532 | University Hospital, Gasthuisberg |
Restenosis
|
May 2009 | Not Applicable |
| NCT00455533 | Bristol-Myers Squibb |
Breast Cancer
|
October 2007 | Phase 2 |
| NCT04339738 | National Cancer Institute (NCI) |
Skin Angiosarcoma|Skin Radiation-Related Angiosarcoma|Visceral Angiosarcoma
|
September 4, 2020 | Phase 2 |
| NCT00568451 | Mayo Clinic|National Cancer Institute (NCI) |
Melanoma (Skin)
|
June 2006 | Phase 2 |
| NCT00961181 | Biotronik AG |
In-stent Coronary Artery Restenosis
|
August 2009 | Not Applicable |
| NCT00550771 | Merck Sharp & Dohme LLC |
Breast Neoplasm
|
July 16, 2007 | Phase 2 |
| NCT00006459 | Eli Lilly and Company |
Breast Cancer
|
July 2000 | Phase 3 |
| NCT03233139 | Regeneron Pharmaceuticals |
Advanced Malignancies
|
June 21, 2017 | Phase 1 |
| NCT00516724 | AstraZeneca |
Triple Negative Metastatic Breast Cancer|Advanced Ovarian Cancer|Carboplatin|Paclitaxel
|
June 22, 2007 | Phase 1 |
| NCT02311907 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Chemotherapeutic Agent Toxicity|Neuropathy|Neurotoxicity Syndrome|Pain|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer
|
December 2009 | Phase 3 |
| NCT02905591 | Joseph J. Cullen, MD, FACS|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Holden Comprehensive Cancer Center|University of Iowa |
Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|NSCLC
|
November 16, 2018 | Phase 2 |
| NCT05175703 | Ajou University School of Medicine |
Angioplasty, Balloon|Disease, Peripheral Artery
|
March 5, 2018 | Not Applicable |
| NCT00679029 | University of Nebraska|National Cancer Institute (NCI) |
HER2-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
May 2008 | Phase 2 |
| NCT00039546 | Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI) |
Breast Cancer
|
August 2001 | Phase 3 |
| NCT03326102 | Daehwa Pharmaceutical Co., Ltd. |
Recurrent or Metastatic Breast Cancer
|
July 25, 2018 | Phase 2 |
| NCT00622466 | University of Texas Southwestern Medical Center |
Breast Cancer
|
April 23, 2008 | Phase 2 |
| NCT03393884 | Imunon |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
September 5, 2018 | Phase 1|Phase 2 |
| NCT03112590 | H. Lee Moffitt Cancer Center and Research Institute|Horizon Pharma Ireland, Ltd., Dublin Ireland |
Breast Cancer|Breast Cancer, Male|Breast Cancer Female|HER2-positive Breast Cancer
|
June 23, 2017 | Phase 1|Phase 2 |
| NCT01902875 | Jinling Hospital, China |
Non Small Cell Lung Cancer
|
June 2013 | |
| NCT00006929 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
September 2000 | Phase 2 |
| NCT00575952 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Mixed Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Squamous Cell Carcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer
|
January 17, 2008 | Phase 1 |
| NCT00002559 | Memorial Sloan Kettering Cancer Center |
Ovarian Cancer|Testicular Germ Cell Tumor
|
January 1994 | Phase 1|Phase 2 |
| NCT00193362 | SCRI Development Innovations, LLC|Eli Lilly and Company|GlaxoSmithKline |
Lung Cancer
|
June 2004 | Phase 3 |
| NCT00028587 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
December 2001 | Phase 1 |
| NCT00499603 | M.D. Anderson Cancer Center|Novartis|National Cancer Institute (NCI) |
Breast Cancer
|
July 2007 | Phase 2 |
| NCT03095209 | Fox Chase Cancer Center |
Lung Cancer|Esophageal Cancer
|
February 24, 2017 | |
| NCT00189553 | ARCAGY+ GINECO GROUP|Schering-Plough|Arbeitsgemeinschaft Gynaekologische Onkologie Austria|AGO Study Group|Australia New Zealand Gynaecological Oncology Group|European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group|NSGO |
Ovarian Cancer|Fallopian Tube Cancer
|
April 2005 | Phase 3 |
| NCT01293630 | Sanofi |
Advanced Solid Tumors
|
January 2011 | Phase 1 |
| NCT04252768 | Immutep S.A.S. |
Metastatic Breast Cancer
|
June 2023 | Phase 1 |
| NCT01763671 | Intergroupe Francophone de Cancerologie Thoracique |
Non-squamous Non-small Cell Lung Cancer
|
May 2013 | Phase 3 |
| NCT00054197 | CTI BioPharma |
Lung Cancer
|
January 2003 | Phase 3 |
| NCT05420324 | Eucure (Beijing) Biopharma Co., Ltd |
Mucosal Melanoma
|
June 13, 2022 | Phase 2 |
| NCT05290935 | Lei Li|Peking Union Medical College Hospital |
Recurrent Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Chemotherapy|Immune Checkpoint Inhibitors|Anti-PD-1 Antibody|Albumin-bound Paclitaxel
|
March 13, 2022 | Phase 2 |
| NCT00009776 | University of California, Davis|National Cancer Institute (NCI) |
Lymphoma
|
March 2001 | Phase 1 |
| NCT03287271 | Michael McHale|Verastem, Inc.|Nine Girls Ask|University of California, San Diego |
Ovarian Cancer
|
February 6, 2018 | Phase 1|Phase 2 |
| NCT00960297 | SCRI Development Innovations, LLC|Genentech, Inc. |
Non-Small Cell Lung Cancer
|
August 2009 | Phase 2 |
| NCT02450058 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
Breast Cancer|Chemotherapy, Adjuvant
|
November 1996 | Phase 3 |
| NCT02244502 | NovoCure Ltd. |
Ovarian Carcinoma
|
September 2014 | Phase 1|Phase 2 |
| NCT03101748 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Breast Inflammatory Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
January 29, 2018 | Phase 1|Phase 2 |
| NCT00724386 | University of Chicago|Amgen |
Breast Cancer
|
June 1999 | Phase 1 |
| NCT00426556 | Novartis Pharmaceuticals|Novartis |
Metastatic Breast Cancer
|
July 2007 | Phase 1 |
| NCT00236899 | Eli Lilly and Company |
Metastatic Breast Cancer (MBC)
|
September 2005 | Phase 3 |
| NCT04494425 | AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo |
Advanced or Metastatic Breast Cancer
|
July 24, 2020 | Phase 3 |
| NCT01440998 | National Cancer Institute (NCI) |
Endometrial Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Mucinous Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Squamous Cell Carcinoma|Endometrial Transitional Cell Carcinoma|Endometrial Undifferentiated Carcinoma|Endometrioid Adenocarcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
September 20, 2011 | Phase 1 |
| NCT01970579 | B. Braun Melsungen AG |
Stenosis|Restenosis
|
October 2013 | Phase 3 |
| NCT04325698 | Pfizer |
Advanced Non-squamous NSCLC
|
June 11, 2020 | Phase 3 |
| NCT03573947 | Jeffrey Clarke|Duke University |
Non-small Cell Lung Cancer
|
October 2, 2018 | Phase 2 |
| NCT02297217 | AHS Cancer Control Alberta |
Esophageal Cancer
|
November 21, 2019 | Phase 2 |
| NCT03610347 | Fundacion Investigacion Interhospitalaria Cardiovascular|Effice Servicios Para la Investigacion S.L. |
Acute Myocardial Infarction
|
June 29, 2016 | Not Applicable |
| NCT00025298 | European Organisation for Research and Treatment of Cancer - EORTC |
Drug+Agent Toxicity by Tissue+Organ|Head and Neck Cancer|Oral Complications|Radiation Toxicity
|
July 2001 | Phase 2 |
| NCT03918278 | Merck Sharp & Dohme LLC |
Neoplasms
|
June 19, 2019 | Phase 1 |
| NCT00238420 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group |
Bladder Urothelial Carcinoma|Stage I Bladder Cancer AJCC v6 and v7|Stage II Bladder Cancer AJCC v6 and v7|Stage III Bladder Cancer AJCC v6 and v7
|
July 26, 2005 | Phase 1|Phase 2 |
| NCT00936780 | Sahajanand Medical Technologies Pvt. Ltd. |
Coronary Artery Disease
|
July 2008 | Phase 4 |
| NCT00129922 | Spanish Breast Cancer Research Group|Bristol-Myers Squibb|Pfizer|Hoffmann-La Roche |
Breast Cancer
|
November 1999 | Phase 3 |
| NCT01386385 | National Cancer Institute (NCI) |
Lung Adenocarcinoma|Lung Adenocarcinoma, Mixed Subtype|Lung Large Cell Carcinoma|Lung Squamous Cell Carcinoma|Minimally Invasive Lung Adenocarcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7
|
June 20, 2011 | Phase 1|Phase 2 |
| NCT02741856 | Lisette Nixon|Cancer Research UK|Velindre NHS Trust |
Oesophageal Cancer
|
November 4, 2016 | Phase 2|Phase 3 |
| NCT00473889 | Merck Sharp & Dohme LLC |
Stage IIIB or IV Non-Small Cell Lung Cancer
|
May 2007 | Phase 2|Phase 3 |
| NCT04850235 | Sun Yat-sen University |
Nasopharyngeal Cancer
|
April 15, 2021 | Phase 1 |
| NCT00002562 | Gynecologic Oncology Group|National Cancer Institute (NCI) |
Cervical Cancer|Vaginal Cancer
|
March 1994 | Phase 2 |
| NCT02442063 | Bayer |
Neoplasms|Bone Diseases
|
August 2015 | Phase 1 |
| NCT00025389 | University of Chicago|National Cancer Institute (NCI) |
Lung Cancer
|
November 2001 | Phase 2 |
| NCT04543071 | Gulam Manji|Regeneron Pharmaceuticals|BioLine Rx|Columbia University |
Pancreatic Cancer|Adenocarcinoma of the Pancreas|Adenocarcinoma
|
November 9, 2020 | Phase 2 |
| NCT00193531 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Neuroendocrine Carcinoma
|
December 1998 | Phase 2 |
| NCT00031694 | National Cancer Institute (NCI) |
Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer
|
March 2002 | Phase 2 |
| NCT01234038 | Ionis Pharmaceuticals, Inc. |
Non-small Cell Lung Cancer
|
November 2010 | Phase 1|Phase 2 |
| NCT00331630 | Northwestern University|GlaxoSmithKline|Celgene Corporation |
Breast Cancer
|
May 4, 2006 | Early Phase 1 |
| NCT00003120 | Southwest Oncology Group|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
November 1997 | Phase 3 |
| NCT03197584 | ImmunityBio, Inc. |
Ovarian Cancer
|
December 2017 | Phase 1|Phase 2 |
| NCT01239732 | Hoffmann-La Roche |
Ovarian Cancer
|
December 2010 | Phase 3 |
| NCT03423979 | Urotronic Inc. |
Benign Prostatic Hyperplasia|Benign Prostatic Hypertrophy
|
December 19, 2017 | Phase 2 |
| NCT01746771 | Hanmi Pharmaceutical Company Limited|National OncoVenture |
HER-2 Positive Advanced Gastric Cancer
|
November 2012 | Phase 1|Phase 2 |
| NCT04038489 | University of Virginia |
Breast Cancer|Estrogen Receptor-positive Breast Cancer
|
October 18, 2019 | Phase 2 |
| NCT01817452 | West German Study Group|Roche Pharma AG |
Breast Cancer
|
March 2014 | Phase 2 |
| NCT03018080 | Wake Forest University Health Sciences|Merck Sharp & Dohme LLC |
Breast - Female|Male Breast Cancer
|
June 12, 2017 | Phase 2 |
| NCT03428425 | Hebei Medical University |
Gastric Cancer
|
February 2018 | Phase 2 |
| NCT00003539 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
April 1998 | Phase 2 |
| NCT03912402 | Biocad |
Cervical Cancer|Cervical Cancer Metastatic|Cervical Cancer Recurrent
|
December 25, 2018 | Phase 2 |
| NCT00966914 | BioNumerik Pharmaceuticals, Inc.|Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019. |
Non-small Cell Lung Cancer
|
April 2010 | Phase 3 |
| NCT01187199 | M.D. Anderson Cancer Center |
Advanced Cancer
|
August 2010 | Phase 1 |
| NCT02341456 | AstraZeneca |
Advanced Solid Tumours
|
January 16, 2015 | Phase 1 |
| NCT03932409 | University of Oklahoma|Merck Sharp & Dohme LLC |
Endometrial Cancer
|
February 19, 2020 | Phase 1 |
| NCT02258659 | University of Chicago|National Cancer Institute (NCI) |
Human Papilloma Virus Infection|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx
|
September 22, 2014 | Phase 2 |
| NCT00006011 | Gynecologic Oncology Group|Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer
|
July 2000 | Phase 3 |
| NCT02594371 | Athenex, Inc. |
Metastatic Breast Cancer
|
December 2, 2015 | Phase 3 |
| NCT02132949 | Hoffmann-La Roche |
Breast Cancer
|
July 14, 2014 | Phase 2 |
| NCT00002852 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IB Non-small Cell Lung Cancer
|
October 1996 | Phase 3 |
| NCT02279732 | Bristol-Myers Squibb |
Lung Cancer (NSCLC)
|
October 13, 2014 | Phase 3 |
| NCT00756847 | Sanofi |
Cancer|Non-Small Cell Lung Cancer|Endometrial Carcinoma|Ovarian Carcinoma
|
September 2008 | Phase 1 |
| NCT01287624 | Fudan University|307 Hospital of PLA|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Sun Yat-sen University|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Cancer Hospital|Changhai Hospital |
Breast Cancer
|
January 2011 | Phase 3 |
| NCT04714190 | RemeGen Co., Ltd. |
Gastric Cancer|HER2 Overexpressing Gastric Carcinoma
|
March 24, 2021 | Phase 3 |
| NCT00269828 | CTI BioPharma |
NSCLC
|
December 2005 | Phase 3 |
| NCT00384826 | Intergroupe Francophone de Cancerologie Thoracique |
Adenocarcinoma, Bronchiolo-Alveolar
|
September 2006 | Phase 2 |
| NCT01636622 | M.D. Anderson Cancer Center |
Advanced Cancers
|
July 9, 2012 | Phase 1 |
| NCT01314833 | Fudan University|Chinese Anti-Cancer Association |
Primary Breast Cancer
|
June 1, 2010 | Phase 3 |
| NCT00803556 | Bristol-Myers Squibb |
Solid Tumor|Breast Cancer
|
January 2006 | Phase 1 |
| NCT02038647 | Millennium Pharmaceuticals, Inc.|Takeda |
Small Cell Lung Cancer
|
May 12, 2014 | Phase 2 |
| NCT03760822 | Federation Francophone de Cancerologie Digestive|Eli Lilly and Company |
Stomach Cancer|Stomach Neoplasm|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
November 16, 2018 | Phase 2 |
| NCT00481078 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
May 2007 | Phase 2 |
| NCT02730416 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit|North Eastern German Society of Gynaecological Oncology|Belgian Gynaecological Oncology Group|ARCAGY+ GINECO GROUP |
Endometrial Cancer
|
November 15, 2016 | Phase 2 |
| NCT02513563 | H. Lee Moffitt Cancer Center and Research Institute |
Lung Cancer
|
October 30, 2015 | Phase 2 |
| NCT04209686 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme LLC |
Advanced Gastric Adenocarcinoma
|
July 31, 2020 | Phase 2 |
| NCT00998192 | Oncolytics Biotech|University of Texas |
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
|
October 2009 | Phase 2 |
| NCT04561817 | Icahn School of Medicine at Mount Sinai |
Ovarian Neoplasms
|
October 1, 2020 | Phase 2 |
| NCT04215146 | Oncolytics Biotech|PrECOG, LLC. |
Breast Cancer Metastatic
|
June 10, 2020 | Phase 2 |
| NCT01998906 | Hoffmann-La Roche |
Breast Cancer
|
May 2002 | Phase 3 |
| NCT00322881 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital |
Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Mixed Tumor, Mesodermal
|
April 2006 | Phase 2 |
| NCT00005838 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group|National Center for Complementary and Integrative Health (NCCIH) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
March 2000 | Phase 3 |
| NCT00002819 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|Cancer and Leukemia Group B|GOG Foundation |
Ovarian Cancer
|
November 1996 | Phase 3 |
| NCT01142388 | National Cancer Institute (NCI) |
Metastatic Esophageal Adenocarcinoma|Metastatic Esophageal Squamous Cell Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Recurrent Esophageal Adenocarcinoma|Recurrent Esophageal Carcinoma|Recurrent Esophageal Squamous Cell Carcinoma|Recurrent Gastroesophageal Junction Adenocarcinoma|Stage IV Esophageal Cancer AJCC v7
|
September 21, 2010 | Phase 2 |
| NCT00005831 | National Cancer Institute (NCI) |
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Squamous Cell Carcinoma of the Bladder|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder
|
March 2000 | Phase 2 |
| NCT02092363 | OncoMed Pharmaceuticals, Inc.|Mereo BioPharma |
Ovarian Cancer
|
January 2014 | Phase 1 |
| NCT01285609 | Bristol-Myers Squibb |
Lung Cancer - Non Small Cell Squamous
|
January 16, 2011 | Phase 3 |
| NCT00003622 | James Ahlgren|George Washington University |
Prostate Cancer
|
January 1999 | Phase 2 |
| NCT00850577 | Bristol-Myers Squibb |
Non-small Cell Lung Cancer (NSCLC)
|
June 2009 | Phase 2 |
| NCT00005032 | University of Chicago|National Cancer Institute (NCI) |
Lung Cancer
|
April 2000 | Phase 1|Phase 2 |
| NCT02954055 | ETOP IBCSG Partners Foundation |
Breast Cancer
|
September 13, 2017 | Phase 2 |
| NCT01165216 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
September 2010 | Phase 1 |
| NCT01485848 | Esperance Pharmaceuticals Inc |
Ovarian Cancer Recurrent
|
February 2012 | Phase 2 |
| NCT02613208 | Hoffmann-La Roche |
Breast Cancer
|
December 9, 2015 | |
| NCT03783949 | Universitaire Ziekenhuizen KU Leuven|European Commission |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma
|
November 30, 2018 | Phase 2 |
| NCT01369433 | AVEO Pharmaceuticals, Inc. |
Solid Tumors
|
June 2010 | Not Applicable |
| NCT03570437 | University of Manchester|AstraZeneca|Cardiff University |
Carcinosarcoma|Endometrial Neoplasms
|
May 17, 2018 | Phase 2 |
| NCT01593228 | Sanofi |
Solid Tumors
|
May 2012 | Phase 3 |
| NCT05276973 | National Cancer Institute (NCI)|NRG Oncology |
Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube High Grade Serous Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Unresectable Fallopian Tube Endometrioid Adenocarcinoma|Unresectable Fallopian Tube High Grade Serous Adenocarcinoma|Unresectable Ovarian Endometrioid Adenocarcinoma|Unresectable Ovarian High Grade Serous Adenocarcinoma|Unresectable Primary Peritoneal Endometrioid Adenocarcinoma|Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma
|
June 27, 2022 | Phase 1 |
| NCT04037241 | Sorrento Therapeutics, Inc. |
Malignant Tumor of Pancreas Metastatic to Liver
|
November 1, 2021 | Phase 2|Phase 3 |
| NCT01395537 | Case Comprehensive Cancer Center |
Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction
|
August 2011 | Phase 1|Phase 2 |
| NCT01739218 | Hoffmann-La Roche |
Ovarian Cancer
|
February 1, 2013 | Phase 2 |
| NCT04527900 | University of Maryland, Baltimore |
Endometrial Cancer
|
February 23, 2021 | Phase 2 |
| NCT04001569 | Seoul National University Bundang Hospital |
Solid Tumor|Stomach Cancer
|
May 14, 2019 | Phase 1|Phase 2 |
| NCT02883062 | National Cancer Institute (NCI) |
Invasive Breast Carcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
May 17, 2017 | Phase 2 |
| NCT03690739 | AGO Research GmbH |
Recurrent Ovarian Carcinoma
|
August 9, 2019 | Phase 3 |
| NCT00063401 | Eli Lilly and Company|Bristol-Myers Squibb |
Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms
|
September 2003 | Phase 2 |
| NCT02124707 | UNC Lineberger Comprehensive Cancer Center |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck
|
June 16, 2014 | Phase 2 |
| NCT00009750 | University of California, Davis|National Cancer Institute (NCI) |
Prostate Cancer
|
March 2001 | Phase 1 |
| NCT01839890 | Francisco Javier Goicolea|Effice Servicios Para la Investigacion S.L.|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular |
Acute Myocardial Infarction
|
April 2012 | Phase 3 |
| NCT01306942 | Spanish Breast Cancer Research Group|Bristol-Myers Squibb |
Metastatic Breast Cancer
|
July 2011 | Phase 1|Phase 2 |
| NCT01803282 | Gilead Sciences |
Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer
|
March 29, 2013 | Phase 1 |
| NCT00191672 | Eli Lilly and Company |
Breast Neoplasms
|
December 2003 | Phase 2 |
| NCT03853707 | City of Hope Medical Center|National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
|
March 4, 2019 | Phase 1|Phase 2 |
| NCT04608409 | Frederick R. Ueland, M.D.|University of Kentucky |
Ovarian Cancer
|
November 16, 2020 | Phase 1 |
| NCT04762901 | Wake Forest University Health Sciences|Tesaro, Inc. |
Breast Cancer
|
April 1, 2021 | Phase 1 |
| NCT01525602 | Daiichi Sankyo, Inc.|Plexxikon |
Solid Tumors
|
May 2012 | Phase 1 |
| NCT00106587 | University Hospital, Saarland |
Coronary Restenosis
|
December 2003 | Phase 1|Phase 2 |
| NCT02214381 | West German Study Group|Teva Pharmaceuticals USA |
Early Primary Breast Cancer
|
July 2014 | Phase 3 |
| NCT05192798 | First Affiliated Hospital Bengbu Medical College |
Triple-negative Breast Cancer
|
January 14, 2022 | Phase 2 |
| NCT00004863 | Montefiore Medical Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 1999 | Phase 1 |
| NCT04548440 | Sun Yat-sen University|Innovent Biologics (Suzhou) Co. Ltd.|CSPC Pharmaceutical Group Limited |
Esophageal Squamous Cell Carcinoma
|
August 31, 2020 | Phase 2 |
| NCT00300885 | Bayer |
Carcinoma, Non-Small Cell Lung
|
February 2006 | Phase 3 |
| NCT03544047 | Peking Union Medical College |
Organoid
|
January 1, 2019 | Not Applicable |
| NCT04213898 | Henan Cancer Hospital |
Triple-negative Breast Cancer
|
January 2020 | Phase 1|Phase 2 |
| NCT02013154 | Leap Therapeutics, Inc.|Merck Sharp & Dohme LLC |
Esophageal Neoplasms|Adenocarcinoma of the Gastroesophageal Junction|Gastroesophageal Cancer|Squamous Cell Carcinoma|Gastric Adenocarcinoma
|
May 5, 2014 | Phase 1 |
| NCT00809133 | Boehringer Ingelheim |
Neoplasms
|
May 2007 | Phase 1 |
| NCT00154882 | National Taiwan University Hospital |
Breast Cancer
|
September 2003 | Phase 2 |
| NCT00976573 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Melanoma (Skin)
|
April 2010 | Phase 2 |
| NCT02446574 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Neoplasms
|
July 2007 | Phase 1|Phase 2 |
| NCT00540514 | Celgene |
Non-Small Cell Lung Carcinoma
|
November 1, 2007 | Phase 3 |
| NCT04046575 | Washington University School of Medicine |
Esophagus Cancer|Esophageal Cancer|Cancer of the Esophagus
|
November 7, 2019 | Phase 1 |
| NCT05582499 | Fudan University |
Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
|
October 2022 | Phase 1|Phase 2 |
| NCT00003117 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
October 1997 | Phase 3 |
| NCT01698710 | Massachusetts General Hospital |
Pancreatic Cysts
|
November 2012 | Not Applicable |
| NCT00042835 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
May 2002 | Phase 1 |
| NCT01083537 | University Health Network, Toronto |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Bowel Obstruction
|
February 2010 | Phase 1|Phase 2 |
| NCT00014222 | NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group|Cancer and Leukemia Group B|Canadian Cancer Trials Group |
Breast Cancer
|
December 4, 2000 | Phase 3 |
| NCT00020449 | National Cancer Institute (NCI) |
Sarcoma
|
January 2001 | Phase 2 |
| NCT04828395 | Tianjin Medical University Cancer Institute and Hospital |
Non-small Cell Lung Cancer
|
March 1, 2021 | Phase 2 |
| NCT02474186 | NYU Langone Health |
Breast Cancer|Metastatic Breast Cancer|Solid Tumor
|
April 2003 | Phase 2 |
| NCT03019588 | Merck Sharp & Dohme LLC |
Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma
|
February 16, 2017 | Phase 3 |
| NCT04676997 | Shandong Cancer Hospital and Institute|Jiangsu HengRui Medicine Co., Ltd. |
Triple Negative Breast Cancer
|
May 20, 2020 | Phase 2 |
| NCT00004865 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Eli Lilly and Company |
Head and Neck Cancer
|
November 1999 | Phase 2 |
| NCT02375204 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|European Organisation for Research and Treatment of Cancer - EORTC|Movember Foundation|Institute of Cancer Research (ICR), United Kingdom|Cancer Research UK|UNICANCER|Irish Group CTI |
Germ Cell Tumor|Teratoma|Choriocarcinoma|Germinoma|Mixed Germ Cell Tumor|Yolk Sac Tumor|Childhood Teratoma|Malignant Germ Cell Neoplasm|Extragonadal Seminoma|Non-seminomatous Germ Cell Tumor|Seminoma
|
March 2015 | Phase 3 |
| NCT04922450 | Hunan Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd. |
Head and Neck Cancer|Squamous Cell Carcinoma
|
January 20, 2021 | Phase 2 |
| NCT00704145 | A.O. Ospedale Papa Giovanni XXIII|Case Western Reserve University|Boston Scientific Corporation |
Coronary Artery Disease
|
November 2007 | Phase 4 |
| NCT00104676 | UNICANCER |
Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor
|
November 26, 2003 | Phase 3 |
| NCT00151034 | University of Michigan Rogel Cancer Center|Genentech, Inc. |
Urologic Neoplasms
|
September 2000 | Phase 2 |
| NCT04092283 | National Cancer Institute (NCI) |
Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma
|
April 9, 2020 | Phase 3 |
| NCT00003379 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Cancer
|
November 1999 | Phase 1|Phase 2 |
| NCT02730546 | Mayo Clinic|National Cancer Institute (NCI) |
Gastric Cardia Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Gastric Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage IIA Gastric Cancer AJCC v7|Stage IIB Gastric Cancer AJCC v7|Stage IIIA Gastric Cancer AJCC v7|Stage IIIB Gastric Cancer AJCC v7
|
June 24, 2016 | Phase 1|Phase 2 |
| NCT05002127 | ALX Oncology Inc.|Eli Lilly and Company |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma
|
January 15, 2022 | Phase 2|Phase 3 |
| NCT00004093 | Northwestern University|National Cancer Institute (NCI) |
Lung Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT00578149 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital |
Non-Small Cell Lung Cancer
|
May 2006 | Phase 2 |
| NCT02545010 | National University Hospital, Singapore |
Ovarian Cancer
|
September 2015 | Phase 1 |
| NCT03411161 | Institut de Recherches Internationales Servier|ADIR, a Servier Group company|Servier |
Metastatic Breast Cancer|Metastatic Triple Negative Breast Cancer
|
January 4, 2018 | Phase 1|Phase 2 |
| NCT00986674 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
September 2009 | Phase 2 |
| NCT01494415 | First People´s Hospital of Hangzhou |
Carcinoma, Non-Small-Cell Lung|Carcinoma, Squamous Cell
|
July 2012 | Phase 2 |
| NCT00005840 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer
|
July 2000 | Phase 1 |
| NCT01009983 | Wake Forest University Health Sciences |
Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
March 2010 | Phase 2 |
| NCT04698941 | Shanghai Pulmonary Hospital, Shanghai, China|Chinese Academy of Sciences |
Small Cell Lung Cancer
|
July 25, 2021 | Phase 2 |
| NCT01783197 | Canadian Cancer Trials Group|AstraZeneca |
Non Small Cell Lung Cancer
|
January 30, 2013 | Phase 1 |
| NCT02920450 | University of Florida|Pfizer |
Non-Small Cell Lung Cancer
|
September 25, 2017 | Phase 1|Phase 2 |
| NCT00001450 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Carcinoma, Non-Small-Cell Lung|Lung Neoplasms
|
September 1995 | Phase 2 |
| NCT02611700 | Biotech Pharmaceutical Co., Ltd. |
Esophageal Squamous Cell Carcinomas
|
November 2015 | Phase 3 |
| NCT03136055 | University of California, San Francisco|Merck Sharp & Dohme LLC |
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
|
August 10, 2017 | Phase 2 |
| NCT03330106 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Neoplasm
|
November 15, 2017 | Phase 1 |
| NCT00136539 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Genentech, Inc.|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Harvard Vanguard Medical Associates|Brigham and Women´s Hospital |
Breast Cancer
|
March 1999 | Phase 2 |
| NCT00129389 | Spanish Breast Cancer Research Group|Bristol-Myers Squibb |
Breast Cancer
|
September 19, 2003 | Phase 3 |
| NCT05092360 | Alkermes, Inc.|Merck Sharp & Dohme LLC |
Platinum-resistant Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
January 10, 2022 | Phase 3 |
| NCT02383251 | ARCAGY+ GINECO GROUP|Novartis |
Ovarian Cancer
|
June 15, 2015 | Phase 2 |
| NCT04329949 | Corcept Therapeutics |
Metastatic Pancreatic Ductal Adenocarcinoma
|
June 30, 2020 | Phase 3 |
| NCT04189588 | TerSera Therapeutics LLC |
Oncology Patients Receiving Chemotherapy
|
March 25, 2020 | Phase 2 |
| NCT00088088 | Synta Pharmaceuticals Corp. |
Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
March 2004 | Phase 1|Phase 2 |
| NCT01843829 | Lisette Nixon|Cancer Research UK|Velindre NHS Trust |
Oesophageal Cancer
|
October 2013 | Phase 2 |
| NCT02039791 | Biotech Pharmaceutical Co., Ltd. |
Cervical Cancer
|
January 2013 | Phase 2 |
| NCT02743923 | The Netherlands Cancer Institute|Dutch Society of Physicians for Pulmonology and Tuberculosis |
Carcinoma, Non-Small Cell Lung
|
April 2016 | Phase 3 |
| NCT04405063 | Genoss Co., Ltd. |
Coronary Artery Disease
|
November 2016 | Not Applicable |
| NCT03595592 | Fondazione Michelangelo|Hoffmann-La Roche |
Invasive Breast Cancer
|
September 7, 2018 | Phase 3 |
| NCT03562533 | Konkuk University Medical Center|Seoul National University Hospital|National Cancer Center, Korea|Asan Medical Center|The Catholic University of Korea|Samsung Medical Center|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|Ajou University|Severance Hospital |
Ovarian Carcinoma
|
May 17, 2018 | |
| NCT03946969 | The First Affiliated Hospital with Nanjing Medical University|Innovent Biologics (Suzhou) Co. Ltd. |
Esophageal Squamous Cell Carcinoma
|
May 9, 2019 | Phase 2 |
| NCT00193310 | SCRI Development Innovations, LLC|Bristol-Myers Squibb|Eli Lilly and Company |
Lung Cancer
|
November 2000 | Phase 2 |
| NCT03329911 | Bio-Thera Solutions |
Non-squamous Non-small Cell Lung Cancer
|
October 20, 2017 | Phase 3 |
| NCT01345279 | GlaxoSmithKline |
Cervical Intraepithelial Neoplasia
|
June 2009 | |
| NCT02568033 | The Cooper Health System |
Non Small Cell Lung Cancer
|
October 2013 | Early Phase 1 |
| NCT00231868 | Montefiore Medical Center |
Uterine Cancer
|
December 2001 | Phase 2 |
| NCT04902261 | Changhai Hospital |
Recurrent Pancreatic Cancer
|
November 20, 2020 | Phase 2 |
| NCT02631876 | ImmunoGen, Inc.|Gynecologic Oncology Group |
Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Ovarian Cancer
|
March 2, 2016 | Phase 3 |
| NCT04135781 | Zhejiang Cancer Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. |
Stomach Cancer
|
March 1, 2020 | Phase 3 |
| NCT02051868 | Royal Marsden NHS Foundation Trust|Cancer Research UK|Australasian Gastro-Intestinal Trials Group|ECOG-ACRIN Cancer Research Group|European Organisation for Research and Treatment of Cancer - EORTC|International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI |
Squamous Cell Carcinoma of the Anus
|
December 2013 | Phase 2 |
| NCT00773695 | Hoffmann-La Roche|Norwegian Radium Hospital |
Breast Cancer
|
November 7, 2008 | Phase 2 |
| NCT00003298 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Gastric Cancer
|
February 1999 | Phase 2 |
| NCT03509012 | AstraZeneca |
Carcinoma, Squamous Cell of Head and Neck|Carcinoma, Non-Small-Cell Lung|Small Cell Lung Carcinoma
|
May 2, 2018 | Phase 1 |
| NCT01156961 | Hoffmann-La Roche |
Breast Cancer
|
October 2010 | Phase 4 |
| NCT05554380 | National Cancer Institute (NCI) |
Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
December 9, 2022 | Phase 2 |
| NCT02707159 | Helse Stavanger HF |
Metastatic Pancreatic Cancer
|
November 2014 | Phase 2 |
| NCT03840902 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Non-small Cell Lung Cancer
|
April 16, 2019 | Phase 2 |
| NCT00352300 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Fallopian Tube Carcinoma|Infectious Disorder|Neutropenia|Ovarian Carcinosarcoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer
|
June 2006 | Phase 1 |
| NCT04164238 | First Affiliated Hospital of Zhejiang University |
Head and Neck Squamous Cell Carcinoma
|
November 7, 2019 | Phase 2 |
| NCT00513786 | David O´Malley|Genentech, Inc.|Ohio State University Comprehensive Cancer Center |
Endometrial Cancer
|
August 1, 2007 | Phase 2 |
| NCT00049790 | CASI Pharmaceuticals, Inc. |
Carcinoma, Non-Small-Cell Lung
|
Phase 2 | |
| NCT00031954 | AGO Study Group |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
August 2001 | Phase 2 |
| NCT01822496 | National Cancer Institute (NCI)|NRG Oncology |
Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7
|
November 4, 2013 | Phase 2 |
| NCT01005329 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group |
Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IA Uterine Corpus Cancer AJCC v7|Stage IB Uterine Corpus Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
November 6, 2009 | Phase 2 |
| NCT02931890 | The Netherlands Cancer Institute |
Gastric Cancer
|
December 21, 2017 | Phase 2 |
| NCT02492867 | University of Michigan Rogel Cancer Center |
Carcinoma, Non-Small-Cell Lung
|
January 14, 2016 | Not Applicable |
| NCT03201861 | RenJi Hospital |
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Duct Carcinoma of Breast
|
July 27, 2017 | Phase 3 |
| NCT04149015 | Fujian Cancer Hospital |
Gastric Cancer
|
November 2019 | Phase 2 |
| NCT02567799 | Humanetics Corporation|National Cancer Institute (NCI)|Henry Ford Health System|Medical College of Wisconsin|University of Maryland, Baltimore|Milwaukee VA Medical Center |
Carcinoma, Non-Small-Cell Lung
|
November 2015 | Phase 1|Phase 2 |
| NCT00077220 | GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI) |
Lung Cancer
|
June 2002 | Phase 3 |
| NCT01204749 | Amgen |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer
|
November 2010 | Phase 3 |
| NCT03430882 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm
|
March 12, 2018 | Phase 1 |
| NCT00063258 | M.D. Anderson Cancer Center |
Lung Cancer
|
June 2003 | Phase 2 |
| NCT01774851 | Merrimack Pharmaceuticals |
HER-2 Gene Amplification|Esophagus Cancer|Gastroesophageal Junction Cancer|Stomach Cancer
|
January 2013 | Phase 2 |
| NCT00031577 | Children´s Hospital of Philadelphia |
Brain and Central Nervous System Tumors
|
August 1999 | Phase 1 |
| NCT04000295 | Jiangsu HengRui Medicine Co., Ltd. |
Ovarian Cancer
|
August 16, 2019 | Phase 3 |
| NCT01454778 | Patrick Kelly|Sanford Health |
Peripheral Vascular Disease
|
April 2011 | Not Applicable |
| NCT01163929 | University of Kansas|Novartis|University of Kansas Medical Center |
Breast Cancer
|
July 2010 | Phase 2 |
| NCT02453282 | AstraZeneca |
Non-Small-Cell Lung Carcinoma NSCLC
|
July 21, 2015 | Phase 3 |
| NCT03107182 | University of Chicago |
HPV-Related Squamous Cell Carcinoma|HNSCC
|
June 27, 2017 | Phase 2 |
| NCT00083057 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Head and Neck Cancer
|
May 2004 | Phase 1 |
| NCT00289263 | MANTA 1 Study Italian Collaborative Group|Bristol-Myers Squibb |
Breast Cancer
|
April 1998 | Phase 3 |
| NCT04251169 | SOLTI Breast Cancer Research Group|Merck Sharp & Dohme LLC |
Metastatic Breast Cancer
|
July 21, 2020 | Phase 2 |
| NCT05386888 | Genfleet Therapeutics (Shanghai) Inc. |
NSCLC, Stage III
|
September 1, 2022 | Phase 2 |
| NCT01270724 | Nationwide Children´s Hospital |
CNS Germ Cell Tumor
|
August 2010 | Phase 2 |
| NCT02041429 | Dana-Farber Cancer Institute|Incyte Corporation |
Recurrent Breast Cancer|Metastatic Breast Cancer
|
February 2014 | Phase 1|Phase 2 |
| NCT04400695 | RemeGen Co., Ltd. |
Breast Cancer
|
September 29, 2020 | Phase 3 |
| NCT04466917 | Amgen|Parexel |
Metastatic Non-small Cell Lung Cancer (NSCLC)|Non-squamous NSCLC
|
May 15, 2021 | Phase 3 |
| NCT02040454 | Englewood Hospital and Medical Center |
Arteriovenous Access Fistula Stenosis
|
March 2014 | Phase 2 |
| NCT02726997 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Stage III Fallopian Tube Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
July 6, 2016 | Phase 1|Phase 2 |
| NCT02124421 | Mercy Medical Center |
Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma
|
April 2014 | Phase 2 |
| NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical |
Breast Cancer
|
January 11, 2019 | Phase 3 |
| NCT03150576 | Cambridge University Hospitals NHS Foundation Trust|AstraZeneca|Cancer Research UK |
Breast Cancer
|
May 2016 | Phase 2|Phase 3 |
| NCT03003962 | AstraZeneca |
Non Small Cell Lung Carcinoma NSCLC
|
January 2, 2017 | Phase 3 |
| NCT03568422 | Canadian Cancer Trials Group|Stand Up To Cancer|Canadian Breast Cancer Foundation|Ontario Institute for Cancer Research |
Breast Cancer
|
October 17, 2018 | Phase 1|Phase 2 |
| NCT00001383 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Cancer|Carcinoma, Renal Cell|Lymphoma|Ovarian Cancer
|
March 1994 | Phase 1 |
| NCT01769391 | Eli Lilly and Company |
Squamous Non Small Cell Lung Cancer
|
January 2013 | Phase 2 |
| NCT00002558 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor
|
January 1994 | Phase 1|Phase 2 |
| NCT00030654 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Southwest Oncology Group|NRG Oncology |
Prostate Cancer
|
October 2002 | Phase 3 |
| NCT04379635 | BeiGene |
Non Small Cell Lung Cancer
|
May 29, 2020 | Phase 3 |
| NCT02287129 | Technical University of Munich |
Adenocarcinoma of the Esophagogastric Junction
|
November 2014 | Phase 2 |
| NCT00432094 | Masonic Cancer Center, University of Minnesota |
Childhood Germ Cell Tumor|Ovarian Cancer|Teratoma
|
December 19, 2006 | Phase 2 |
| NCT00003299 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Eastern Cooperative Oncology Group|Southwest Oncology Group |
Lung Cancer
|
April 1998 | Phase 3 |
| NCT02259621 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
September 2014 | Phase 2 |
| NCT03830385 | Sun Yat-sen University |
Squamous Cell Carcinoma Of The Head And Neck
|
February 15, 2019 | Phase 2 |
| NCT00005046 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
April 2000 | Phase 1 |
| NCT04161664 | The Netherlands Cancer Institute |
Metastatic Squamous Cell Carcinoma of the Vulva
|
January 16, 2020 | Phase 2 |
| NCT04915807 | Hallym University Medical Center |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
June 2021 | |
| NCT01042522 | GOG Foundation|National Cancer Institute (NCI) |
Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified|Ovarian Steroid Cell Tumor
|
February 8, 2010 | Phase 2 |
| NCT02615730 | Yonsei University |
Advanced Gastric Adenocarcinoma
|
February 2016 | Phase 1|Phase 2 |
| NCT04917900 | West China Hospital |
Breast Cancer
|
December 1, 2020 | Phase 2 |
| NCT02694224 | Clinica Universidad de Navarra, Universidad de Navarra |
Breast Cancer
|
April 2016 | Phase 2 |
| NCT00583830 | Human Genome Sciences Inc. |
Non Small Cell Lung Cancer
|
January 2007 | Phase 2 |
| NCT00093756 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
September 2004 | Phase 1|Phase 2 |
| NCT03498521 | Hoffmann-La Roche|Foundation Medicine, Inc. |
Cancer of Unknown Primary Site
|
July 10, 2018 | Phase 2 |
| NCT05113251 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer
|
October 25, 2021 | Phase 3 |
| NCT00168883 | Charite University, Berlin, Germany|Bristol-Myers Squibb|Pierre Fabre Pharma GmbH |
Carcinoma, Non-Small-Cell Lung
|
October 2002 | Phase 2 |
| NCT00004934 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit|European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
August 1999 | Phase 3 |
| NCT02109341 | Gruppo Oncologico Italiano di Ricerca Clinica |
Metastatic Pancreatic Cancer
|
February 2014 | Phase 1|Phase 2 |
| NCT01357161 | Merck Sharp & Dohme LLC |
Ovarian Cancer
|
July 26, 2011 | Phase 2 |
| NCT00107250 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Colorectal Cancer|Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
January 13, 2005 | Phase 1 |
| NCT00788931 | Novartis Pharmaceuticals|Novartis |
HER-2 Positive Breast Cancer|Metastatic Breast Cancer
|
December 2008 | Phase 1 |
| NCT02182232 | Boehringer Ingelheim |
Carcinoma, Non-Small-Cell Lung
|
June 2005 | Phase 1 |
| NCT00662311 | University of Washington|National Cancer Institute (NCI) |
Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
March 2008 | Phase 1|Phase 2 |
| NCT00002587 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 1994 | Phase 1 |
| NCT00262847 | National Cancer Institute (NCI)|NRG Oncology |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma
|
September 2005 | Phase 3 |
| NCT02044601 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lung Cancer
|
June 2014 | Phase 1|Phase 2 |
| NCT04027764 | Dai, Guanghai|Chinese PLA General Hospital |
Advanced Biliary Tract Cancer
|
May 1, 2019 | Phase 2 |
| NCT05333640 | Singapore General Hospital |
Dialysis Access Malfunction|Stenosis
|
April 18, 2022 | |
| NCT00647218 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
February 2000 | Not Applicable |
| NCT04672772 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
Squamous Cell Carcinoma of the Head and Neck
|
December 18, 2020 | |
| NCT01493843 | Genentech, Inc. |
Non-Small Cell Lung Cancer
|
January 20, 2012 | Phase 2 |
| NCT00072319 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pharmacia|Amgen |
Breast Cancer
|
August 2003 | Phase 2 |
| NCT02419742 | Hoffmann-La Roche |
Breast Cancer
|
August 18, 2015 | Phase 4 |
| NCT00680758 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 2008 | Phase 1 |
| NCT04736173 | Arcus Biosciences, Inc.|Gilead Sciences |
Non Small Cell Lung Cancer|Nonsquamous Non Small Cell Lung Cancer|Squamous Non-small-cell Lung Cancer|Lung Cancer
|
February 8, 2021 | Phase 3 |
| NCT01170663 | Eli Lilly and Company |
Gastric Cancer
|
December 2010 | Phase 3 |
| NCT05235542 | Akeso |
Advanced Malignant Tumors
|
July 12, 2022 | Phase 1|Phase 2 |
| NCT03519971 | AstraZeneca |
Non-Small Cell Lung Cancer
|
March 29, 2018 | Phase 3 |
| NCT03128008 | Duke University |
Carcinoma, Non Small Cell Lung (NSCLC)
|
December 7, 2017 | Phase 2 |
| NCT05400915 | Yonsei University |
Gastric Cancer
|
July 23, 2019 | Phase 1|Phase 2 |
| NCT03756818 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|KRAS Gene Mutation|Ovarian Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Ovarian Carcinoma
|
March 5, 2019 | Phase 1 |
| NCT00003385 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
March 1999 | Phase 1 |
| NCT00753038 | Oncolytics Biotech |
Carcinoma, Squamous Cell of the Head and Neck
|
August 2008 | Phase 2 |
| NCT05173857 | Skane University Hospital |
Vascular Diseases|Kidney Diseases
|
March 1, 2014 | Not Applicable |
| NCT00022230 | Roger Williams Medical Center |
Breast Cancer
|
January 2000 | Phase 1|Phase 2 |
| NCT00738699 | Morphotek |
Ovarian Cancer
|
September 2008 | Phase 2 |
| NCT02135042 | NRG Oncology|National Cancer Institute (NCI) |
Epstein-Barr Virus Infection|Stage II Nasopharyngeal Carcinoma|Stage III Nasopharyngeal Carcinoma|Stage IVA Nasopharyngeal Carcinoma|Stage IVB Nasopharyngeal Carcinoma
|
April 2014 | Phase 2|Phase 3 |
| NCT02308553 | Prof. Dr. med. Dirk Schadendorf|Boehringer Ingelheim|medac GmbH|Alcedis GmbH|University Hospital, Essen |
Cutaneous Malignant Melanoma
|
March 17, 2015 | Phase 1|Phase 2 |
| NCT05298020 | The Affiliated Hospital of Xuzhou Medical University |
Advanced Pancreatic Cancer
|
April 1, 2022 | Phase 2 |
| NCT00686114 | Wenzhou Medical University |
Esophageal Cancer
|
May 2008 | Phase 3 |
| NCT00539331 | AstraZeneca |
Carcinoma, Non-Small-Cell Lung
|
September 2007 | Phase 1 |
| NCT01654146 | Medical Research Council|Cancer Research UK |
Ovarian Cancer
|
June 2011 | Phase 3 |
| NCT03884556 | Trishula Therapeutics, Inc. |
Solid Tumor|Lymphoma
|
April 10, 2019 | Phase 1 |
| NCT04220827 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Peritoneal Carcinomatosis|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
|
December 6, 2019 | Phase 1 |
| NCT00022191 | European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)|Groupe D´Etude des Tumeurs Uro-Genitales|Institute of Cancer Research, United Kingdom|Central European Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group|German Association of Urologic Oncology|Spanish Oncology Genito-Urinary Group|Medical Research Council |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer
|
May 2001 | Phase 3 |
| NCT02307812 | Eli Lilly and Company |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
||
| NCT04203511 | Incyte Corporation |
Non-small Cell Lung Cancer
|
July 31, 2020 | Phase 3 |
| NCT00391118 | Eli Lilly and Company |
Ovarian Cancer|Fallopian Tube Neoplasms|Peritoneal Neoplasm
|
November 2006 | Phase 2 |
| NCT00821028 | University of Oklahoma |
Atherosclerosis|Angioplasty|Peripheral Arterial Disease
|
January 2009 | Not Applicable |
| NCT03725436 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2+Neu Negative|Metastatic Malignant Solid Neoplasm|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Recurrent Breast Carcinoma|TP53 wt Allele|Unresectable Malignant Solid Neoplasm
|
January 24, 2019 | Phase 1 |
| NCT03806049 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
Ovarian Cancer
|
December 2019 | Phase 3 |
| NCT01643460 | Indiana University |
Pancreatic Cyst|Pancreatic Intraductal Papillary-Mucinous Neoplasm|Cystadenoma, Mucinous|Papillary Mucinous Cystadenoma, Borderline Malignancy
|
September 2009 | Not Applicable |
| NCT02513355 | Nanjing NingQi Medicine Science and Technology Co., Ltd. |
Non-small Cell Lung Cancer
|
February 2015 | Phase 4 |
| NCT00003284 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
January 1998 | Phase 2 |
| NCT02834975 | Marilyn Huang, MD, MS|Merck Sharp & Dohme LLC|University of Miami |
Fallopian Tube Cancer|Peritoneum Cancer|Epithelial Ovarian Cancer
|
December 22, 2016 | Phase 2 |
| NCT04888663 | Yonsei University |
Recurrent+Metastatic Gastric Cancer
|
February 13, 2018 | Phase 1|Phase 2 |
| NCT00003592 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
September 1998 | Phase 3 |
| NCT00003691 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Cancer
|
December 1998 | Phase 3 |
| NCT02435186 | Shenzhen SiBiono GeneTech Co.,Ltd |
Ovarian Epithelial Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
June 2015 | Phase 2 |
| NCT04821843 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Cancer|Chemotherapy Effect|Chemoradiation|Surgery|Targeted Therapy|Immunotherapy|Esophagogastric Juction Cancer
|
January 1, 2002 | Phase 3 |
| NCT03030287 | OncoMed Pharmaceuticals, Inc.|Mereo BioPharma |
Cancer Ovaries|Cancer Peritoneal|Cancer, Fallopian Tube
|
December 2016 | Phase 1 |
| NCT00515073 | M.D. Anderson Cancer Center |
Endometrial Cancer
|
April 2001 | Phase 2 |
| NCT02125344 | German Breast Group|Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma |
Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer
|
December 2014 | Phase 3 |
| NCT00329641 | National Cancer Institute (NCI) |
Ciliary Body and Choroid Melanoma, Medium+Large Size|Extraocular Extension Melanoma|Iris Melanoma|Metastatic Intraocular Melanoma|Recurrent Intraocular Melanoma
|
February 2011 | Phase 2 |
| NCT04682158 | Roswell Park Cancer Institute |
Esophageal Adenocarcinoma
|
April 1, 2021 | Phase 2 |
| NCT00322400 | Amgen |
Locally Recurrent and Metastatic Breast Cancer
|
March 2006 | Phase 1 |
| NCT00003281 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
April 1998 | Phase 2 |
| NCT00001387 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Neoplasms
|
September 1994 | Phase 1 |
| NCT03400306 | AbbVie |
Cancer - Ovarian
|
November 15, 2021 | Phase 1 |
| NCT03894007 | Renske Altena|Karolinska University Hospital |
Early-stage Breast Cancer|HER2-positive Breast Cancer
|
May 23, 2019 | Phase 2 |
| NCT00079430 | National Cancer Institute (NCI)|Gynecologic Oncology Group |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Stage II Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer
|
June 2004 | Phase 1 |
| NCT00198354 | Intergroupe Francophone de Cancerologie Thoracique |
Non-small Cell Lung Cancer Stage I and II|Peri-operative Chemotherapy
|
May 2001 | Phase 3 |
| NCT05044871 | Tongji Hospital|Qilu Hospital of Shandong University|Hubei Cancer Hospital|Hunan Cancer Hospital|Peking University Cancer Hospital & Institute|Obstetrics and Gynecology Hospital of Zhejiang University|Sun Yat-sen University|Anhui Provincial Cancer Hospital|Jilin Provincial Tumor Hospital|First Affiliated Hospital, Sun Yat-Sen University|Affiliated Hospital of Jiangnan University |
Ovarian Cancer
|
January 1, 2023 | Phase 2 |
| NCT02370238 | Dompé Farmaceutici S.p.A|PRA Health Sciences |
Metastatic Breast Cancer
|
July 29, 2015 | Phase 2 |
| NCT03329378 | Icahn School of Medicine at Mount Sinai |
Locally Advanced Breast Cancer
|
January 30, 2019 | Phase 2 |
| NCT00003253 | Oncotech|National Cancer Institute (NCI) |
Breast Cancer
|
July 1997 | Phase 2 |
| NCT00093795 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
October 2004 | Phase 3 |
| NCT00507429 | Mateon Therapeutics |
Anaplastic Thyroid Cancer
|
August 2007 | Phase 2|Phase 3 |
| NCT00003214 | Swiss Group for Clinical Cancer Research |
Ovarian Cancer
|
July 1996 | Phase 3 |
| NCT01351350 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Malignancies|Hematologic Malignancies
|
February 28, 2011 | Phase 1 |
| NCT00971841 | Bristol-Myers Squibb |
Esophageal Cancer
|
March 2008 | Phase 2 |
| NCT03285607 | Washington University School of Medicine|Novartis Pharmaceuticals |
Breast Cancer|Cancer of Breast
|
September 30, 2018 | Phase 1 |
| NCT01486602 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
March 2012 | Phase 1 |
| NCT01402271 | European Organisation for Research and Treatment of Cancer - EORTC |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
July 2012 | Phase 1|Phase 2 |
| NCT02677597 | Fudan University |
Esophageal Squamous Cell Carcinoma
|
January 2016 | Phase 3 |
| NCT02911350 | NYU Langone Health |
Prostate Cancer
|
May 2000 | Phase 1 |
| NCT01847326 | University of Chicago|National Cancer Institute (NCI) |
Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Tongue Cancer
|
March 26, 2013 | Phase 1 |
| NCT03342911 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University |
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Laryngeal Squamous Cell Carcinoma|Stage IV Oral Cavity Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Hypopharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Oral Cavity Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Hypopharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Oral Cavity Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma
|
November 13, 2017 | Phase 2 |
| NCT01980810 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Gastric Cancer
|
September 2013 | Phase 2 |
| NCT04337632 | Hunan Cancer Hospital |
Ovarian Cancer
|
August 1, 2017 | Phase 3 |
| NCT00006018 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 2000 | Phase 1 |
| NCT00256243 | Rita Sanghvi, Mehta|University of California, Irvine |
Breast Cancer
|
April 2004 | Phase 2 |
| NCT03876886 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Triple Negative Breast Cancer
|
February 22, 2019 | Phase 3 |
| NCT01279291 | Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin, Inc. |
Neoplasms|Ovarian Neoplasms|Fallopian Tube Neoplasms|Primary Peritoneal Neoplasm
|
January 2011 | Phase 1 |
| NCT01911598 | Genentech, Inc. |
Head and Neck Cancer
|
September 19, 2013 | Phase 1 |
| NCT01506856 | Gynecologic Oncology Trial & Investigation Consortium|Japanese Gynecologic Oncology Group |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma
|
May 2010 | Phase 2|Phase 3 |
| NCT01667211 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Uterine Cervical Cancer
|
November 2011 | Phase 2 |
| NCT01253681 | Amgen |
Carcinoma|Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer
|
November 2010 | Phase 1 |
| NCT02599363 | Abramson Cancer Center of the University of Pennsylvania |
Advanced Breast Cancer
|
January 2016 | Phase 1 |
| NCT00201435 | Norwegian Breast Cancer Group |
Breast Neoplasm
|
March 2005 | Phase 2|Phase 3 |
| NCT05327582 | Chinese PLA General Hospital |
Pancreatic Cancer|Biliary Tract Cancer
|
April 12, 2022 | Phase 1|Phase 2 |
| NCT00003042 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 30, 1997 | Phase 2 |
| NCT02227940 | Roswell Park Cancer Institute|Novartis |
Advanced Malignant Solid Neoplasm|ALK Positive|Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer
|
January 8, 2015 | Phase 1 |
| NCT00129727 | Massachusetts General Hospital|Women and Infants Hospital of Rhode Island |
Ovarian Cancer
|
June 2005 | Phase 2 |
| NCT00062062 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
October 2004 | Phase 2 |
| NCT00512096 | M.D. Anderson Cancer Center |
Penile Cancer
|
August 1999 | Phase 2 |
| NCT02662634 | GU Research Network, LLC |
Non-small Cell Lung Cancer (NSCLC)
|
March 2016 | Phase 2 |
| NCT03814005 | Takeda |
Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute|Renal Insufficiency|Liver Disease|Neoplasms
|
July 10, 2019 | Phase 1 |
| NCT00002711 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer
|
October 1995 | Phase 1 |
| NCT02279576 | Spanish Oncology Genito-Urinary Group |
Penile Squamous Cell Carcinoma Stage IV
|
January 2015 | Phase 2 |
| NCT00272987 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
December 13, 2005 | Phase 3 |
| NCT02272699 | Peking University |
Esophageal Squamous Cell Carcinoma
|
November 2014 | Phase 2|Phase 3 |
| NCT00021320 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer
|
May 2000 | Phase 2 |
| NCT00347412 | Cellectar Biosciences, Inc. |
Non Small Cell Lung Cancer
|
November 2006 | Phase 3 |
| NCT00660842 | National Cancer Institute, Naples |
Ovarian Cancer
|
November 2008 | Phase 3 |
| NCT00003944 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
August 1998 | Phase 2 |
| NCT01147016 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Breast Cancer
|
July 2010 | Phase 2 |
| NCT00626561 | M.D. Anderson Cancer Center|Genentech, Inc. |
Cervical Cancer|Uterine Cancer
|
February 2008 | Phase 2 |
| NCT00482391 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|GlaxoSmithKline |
Breast Cancer
|
March 2007 | Phase 2 |
| NCT03940196 | NovoCure Ltd. |
Ovarian Cancer
|
March 22, 2019 | Phase 3 |
| NCT00970580 | Biogen |
Non-Small Cell Lung Cancer
|
October 2009 | Phase 1 |
| NCT03943667 | UNICANCER |
Metastatic Pancreatic Adenocarcinoma
|
May 23, 2019 | Phase 3 |
| NCT00004921 | EBMT Solid Tumors Working Party|National Cancer Institute (NCI) |
Ovarian Cancer
|
September 1998 | Phase 3 |
| NCT02041533 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Stage IV or Recurrent Non-Small Cell Lung Cancer
|
March 27, 2014 | Phase 3 |
| NCT00976911 | Hoffmann-La Roche |
Ovarian Cancer
|
October 29, 2009 | Phase 3 |
| NCT04804696 | Peking University |
Esophageal Squamous Cell Cancer
|
April 2021 | Phase 2 |
| NCT00807612 | NantCell, Inc. |
Advanced Squamous Non-Small Cell Lung Cancer
|
January 2009 | Phase 1|Phase 2 |
| NCT00040794 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
May 2002 | Phase 2 |
| NCT02186847 | NRG Oncology|National Cancer Institute (NCI) |
Adenosquamous Lung Carcinoma|Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer
|
August 2014 | Phase 2 |
| NCT04067102 | Hebei Medical University Fourth Hospital |
Triple Negative Breast Cancer
|
May 10, 2019 | Not Applicable |
| NCT00752115 | Hamamatsu University |
Non-small Cell Lung Cancer
|
February 2007 | Phase 2|Phase 3 |
| NCT00876395 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
September 10, 2009 | Phase 3 |
| NCT04694183 | Quan Wang|The First Hospital of Jilin University |
Gastric Cancer
|
December 30, 2020 | Phase 2 |
| NCT00003992 | National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 2 |
| NCT01711970 | Vascular Biogenics Ltd. operating as VBL Therapeutics |
Platinum Resistant Ovarian Cancer
|
November 2012 | Phase 1|Phase 2 |
| NCT05605535 | CanariaBio Inc.|Raptim Research Pvt. Ltd |
Ovarian Neoplasm Epithelial|Ovarian Cancer|Fallopian Tube Neoplasms|Peritoneal Carcinoma|Ovarian Serous Adenocarcinoma
|
November 15, 2022 | Phase 2 |
| NCT00005646 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
April 2000 | Phase 2 |
| NCT01001676 | University Health Network, Toronto |
Renal Failure
|
February 2012 | Phase 2 |
| NCT00189566 | ARCAGY+ GINECO GROUP |
Ovarian Cancer|Fallopian Tube Cancer|Malignant Tumor of Peritoneum
|
April 2004 | Phase 2 |
| NCT04541108 | Presage Biosciences|Takeda|Merck Sharp & Dohme LLC |
Solid Tumor
|
July 26, 2021 | Early Phase 1 |
| NCT01107626 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lung Cancer
|
August 12, 2010 | Phase 3 |
| NCT05613088 | Bristol-Myers Squibb |
Neoplasms, Ovarian
|
November 11, 2022 | Phase 2 |
| NCT00003035 | Georgetown University|National Cancer Institute (NCI) |
Breast Cancer
|
March 1997 | Phase 2 |
| NCT02617849 | Wilson Miller|Jewish General Hospital |
Metastatic Malignant Melanoma
|
May 19, 2016 | Phase 2 |
| NCT02033538 | Zhejiang University |
Squamous Cell Carcinoma of Esophagus
|
January 2014 | Phase 2 |
| NCT00832819 | Eisai Co., Ltd.|Eisai Inc. |
Non-small-cell Lung Cancer
|
February 2009 | Phase 1 |
| NCT00542451 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc. |
Breast Cancer|Carcinoma of the Breast
|
October 2007 | Phase 2 |
| NCT00003105 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter
|
September 1997 | Phase 1|Phase 2 |
| NCT02072317 | Fudan University |
Advanced Gastric Cancer
|
November 2013 | Phase 2 |
| NCT00373620 | Korean Gynecologic Oncology Group |
Endometrial Cancer
|
January 2006 | Phase 2 |
| NCT01690572 | Prof. Dr. med. Christoph Hehrlein|Herz-Zentrums Bad Krozingen |
Coronary Disease|Diabetes Mellitus
|
October 2012 | Not Applicable |
| NCT01924533 | AstraZeneca |
Gastric Cancer
|
September 3, 2013 | Phase 3 |
| NCT03512834 | Sung Yong Oh|Merck KGaA, Darmstadt, Germany|Dong-A University Hospital |
Angiosarcoma Metastatic
|
June 1, 2018 | Phase 2 |
| NCT00003397 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Lymphoma
|
September 1998 | Phase 2 |
| NCT00191854 | Eli Lilly and Company |
Breast Cancer
|
March 2005 | Phase 2 |
| NCT03264547 | Japan Breast Cancer Research Group|Eisai Co., Ltd. |
Breast Cancer
|
August 28, 2017 | Phase 3 |
| NCT01633970 | Genentech, Inc. |
Cancer
|
July 11, 2012 | Phase 1 |
| NCT04729608 | Aravive, Inc.|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Platinum-resistant Ovarian Cancer
|
April 22, 2021 | Phase 3 |
| NCT03087864 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|UMC Utrecht |
Esophageal Cancer, Stage II|Esophageal Cancer Stage III
|
June 28, 2017 | Phase 2 |
| NCT00023673 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
July 2001 | Phase 1|Phase 2 |
| NCT02178956 | Sumitomo Pharma Oncology, Inc. |
Gastric Cancer|Gastroesophageal Junction Cancer
|
October 2014 | Phase 3 |
| NCT00997906 | National Cancer Centre, Singapore |
Head and Neck Cancer
|
September 15, 2009 | Phase 2|Phase 3 |
| NCT00136175 | University of Michigan Rogel Cancer Center |
Bladder Cancer
|
November 1999 | Phase 2 |
| NCT00113438 | Mateon Therapeutics |
Cancer|Tumor
|
March 2005 | Phase 2 |
| NCT04190745 | Zhejiang Cancer Hospital |
Gastric Adenocarcinoma
|
November 29, 2019 | Phase 2 |
| NCT02734290 | Providence Health & Services|Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer
|
February 23, 2016 | Phase 1|Phase 2 |
| NCT02009449 | Eli Lilly and Company|ARMO BioSciences |
Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer
|
November 15, 2013 | Phase 1 |
| NCT00093145 | Celgene |
Breast Cancer
|
June 1, 2004 | Phase 2 |
| NCT02689427 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Invasive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
September 22, 2016 | Phase 2 |
| NCT04827953 | Nelum Corp|Apices Soluciones S.L.|Agenus Inc. |
Pancreatic Ductal Adenocarcinoma
|
September 1, 2021 | Phase 1|Phase 2 |
| NCT01275677 | National Cancer Institute (NCI)|NRG Oncology |
HER2+Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
January 6, 2011 | Phase 3 |
| NCT00148356 | Abbott Medical Devices |
Coronary Disease|Coronary Artery Disease|Coronary Restenosis
|
September 2004 | Phase 2|Phase 3 |
| NCT00537173 | Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|University of Colorado, Denver|Baylor University|McGill University |
Breast Cancer
|
September 2007 | |
| NCT04893109 | Dana-Farber Cancer Institute|Genentech, Inc. |
Breast Cancer|HER2-positive Breast Cancer
|
June 16, 2021 | Phase 2 |
| NCT05562089 | Chinese University of Hong Kong |
Myocardial Infarction|Drug-Coated Balloon
|
April 29, 2022 | Not Applicable |
| NCT01024101 | Bristol-Myers Squibb |
Head and Neck Cancer
|
January 2004 | Phase 2 |
| NCT00045630 | Southwest Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer
|
January 2003 | Phase 2 |
| NCT04807673 | Tianjin Medical University Cancer Institute and Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Shanghai Chest Hospital|Ruijin Hospital|Hebei Medical University Fourth Hospital|Harbin Medical University|Liaoning Tumor Hospital & Institute|Shanxi Province Cancer Hospital|Shandong Jining No.1 People´s Hospital|Weifang People´s Hospital|Tianjin Medical University General Hospital|Shandong Provincial Hospital |
Esophageal Squamous Cell Carcinoma
|
December 1, 2021 | Phase 3 |
| NCT02569489 | HUYABIO International, LLC. |
Breast Cancer
|
December 2015 | Phase 1 |
| NCT00550537 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
October 2007 | Phase 2 |
| NCT02625740 | University of Rome Tor Vergata |
Peripheral Arterial Disease, Angioplasty
|
November 2013 | Not Applicable |
| NCT01225302 | AbbVie |
Non-Small Cell Lung Cancer
|
September 2010 | Phase 1 |
| NCT01090128 | University of Utah|Celgene Corporation |
Stages II-III Breast Cancer
|
September 2008 | Phase 1 |
| NCT05054439 | Sichuan Baili Pharmaceutical Co., Ltd. |
Head and Neck Squamous Cell Carcinoma
|
December 22, 2021 | Phase 2 |
| NCT00343291 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
December 2006 | Phase 2 |
| NCT04646837 | Peking Union Medical College Hospital|AstraZeneca |
Non-small Cell Lung Cancer
|
May 1, 2021 | Phase 1|Phase 2 |
| NCT01326767 | Central European Society for Anticancer Drug Research|Saladax Biomedical, Inc.|Cantonal Hospital of St. Gallen|University Hospital, Basel, Switzerland|Assign Data Management and Biostatistics GmbH|Wake Forest University|University Hospital, Essen |
Carcinoma, Non-Small-Cell Lung
|
March 2011 | Phase 3 |
| NCT00006454 | AGO Study Group |
Fallopian Tube Cancer|Ovarian Cancer
|
December 1999 | Phase 3 |
| NCT04754815 | Shirish Gadgeel|Merck Sharp & Dohme LLC|Henry Ford Health System |
Non Small Cell Lung Cancer|Advanced Lung Non-Small Cell Carcinoma|PD-L1 Gene Mutation
|
April 1, 2021 | Phase 2 |
| NCT03636685 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
NSCLC|Adenocarcinoma|Squamous Cell Carcinoma
|
August 15, 2018 | Phase 1|Phase 2 |
| NCT00520013 | Dana-Farber Cancer Institute|Genentech, Inc.|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Massachusetts General Hospital |
Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|Papillary Serous Mullerian Tumor|Clear Cell Mullerian Tumor
|
August 2007 | Phase 2 |
| NCT04166487 | Dana-Farber Cancer Institute|Inivata |
NSCLC Stage IV|Metastatic Non-Small Cell Lung Cancer
|
January 13, 2020 | Phase 2 |
| NCT01435018 | AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|National Cancer Institute (NCI)|National Institute of Dental and Craniofacial Research (NIDCR)|AIDS Malignancy Consortium |
HIV-1 Infection
|
October 1, 2013 | Phase 3 |
| NCT05108870 | University of Chicago |
Human Papilloma Virus|HPV|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Head and Neck Cancer
|
August 4, 2022 | Phase 1|Phase 2 |
| NCT05489848 | Fudan University |
Endometrial Cancer
|
August 20, 2022 | Phase 2|Phase 3 |
| NCT00002928 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Ovarian Cancer
|
January 1997 | Phase 2 |
| NCT03884101 | Merck Sharp & Dohme LLC|Eisai Inc. |
Endometrial Neoplasms
|
April 11, 2019 | Phase 3 |
| NCT03395080 | Leap Therapeutics, Inc. |
Endometrial Cancer|Uterine Cancer|Ovarian Cancer|Carcinosarcoma
|
March 5, 2018 | Phase 2 |
| NCT05283226 | NATCO Pharma Ltd. |
Carcinoma|Recurrent and+or Metastatic Head and Neck Squamous Cell Carcinoma
|
September 30, 2022 | Phase 2 |
| NCT03810872 | AZ-VUB |
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
|
June 21, 2017 | Phase 2 |
| NCT00003591 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Pancreatic Cancer
|
November 1998 | Phase 2 |
| NCT04868708 | Akeso |
Recurrent or Metastatic Cervical Cancer
|
April 1, 2021 | Phase 2 |
| NCT00584857 | University of Alabama at Birmingham |
Uterine Cancer
|
July 2004 | Phase 2 |
| NCT02625623 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Gastric Cancer Third Line
|
December 28, 2015 | Phase 3 |
| NCT02364999 | Pfizer |
Non-Small Cell Lung Cancer
|
April 2015 | Phase 3 |
| NCT01755897 | Huazhong University of Science and Technology|Zhejiang University|Shandong University |
Uterine Cervical Neoplasms|Cervical Cancer|Uterine Cervical Cancer
|
November 2012 | Not Applicable |
| NCT01166542 | Oncolytics Biotech |
Carcinoma, Squamous Cell of the Head and Neck
|
June 2010 | Phase 3 |
| NCT02280252 | NYU Langone Health |
Breast Cancer
|
March 2005 | Phase 2 |
| NCT02312661 | University Medical Center Groningen |
Epithelial Ovarian Cancer
|
October 5, 2015 | Phase 1 |
| NCT05420467 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer
|
July 10, 2022 | Phase 4 |
| NCT02584478 | Advenchen Laboratories, LLC |
Endometrial Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Cervical Carcinoma
|
December 2015 | Phase 3 |
| NCT00466960 | University of Washington|National Cancer Institute (NCI) |
Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer
|
May 2006 | Phase 2 |
| NCT02477826 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Non-Small Cell Lung Cancer
|
August 5, 2015 | Phase 3 |
| NCT04767022 | Genoss Co., Ltd. |
Coronary Artery Disease
|
August 25, 2020 | Not Applicable |
| NCT05018962 | Singapore General Hospital|Boston Scientific Corporation |
Dialysis Access Malfunction
|
September 8, 2017 | Phase 2 |
| NCT01836679 | Chipscreen Biosciences, Ltd. |
Non-small-cell Lung Cancer
|
April 2013 | Phase 2 |
| NCT00006004 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
May 2000 | Phase 2 |
| NCT02195336 | Karl Kölbeck|Karolinska University Hospital |
Non-small Cell Lung Cancer
|
August 2014 | Not Applicable |
| NCT05358548 | Rutgers, The State University of New Jersey |
Head and Neck Cancer|Lung Cancer
|
April 28, 2022 | Phase 2 |
| NCT00174356 | Pfizer |
Carcinoma, Non-Small Cell Lung
|
December 2002 | Phase 1 |
| NCT00396929 | University Hospital Tuebingen|Acrostak |
Stable or Unstable Angina Pectoris|Myocardial Ischemia
|
August 2005 | Phase 3 |
| NCT03169738 | ImmunityBio, Inc. |
Non-small Cell Lung Cancer
|
February 2018 | Phase 1|Phase 2 |
| NCT02414685 | National Cancer Institute, Slovakia |
Germ Cell Tumor
|
April 2015 | Phase 2 |
| NCT03966118 | P. C. Thuss-Patience|Charite University, Berlin, Germany |
Gastroesophageal Junction Adenocarcinoma|Adenocarcinoma of the Stomach
|
April 1, 2019 | Phase 2 |
| NCT00003399 | University of Maryland, Baltimore |
Multiple Myeloma and Plasma Cell Neoplasm
|
September 1998 | Phase 2 |
| NCT00634595 | Sun Yat-sen University|Doublle Bioproduct Inc |
Head and Neck Squamous Carcinoma|Nasopharyngeal Carcinoma
|
March 2008 | Phase 2 |
| NCT00731861 | Indiana University School of Medicine|Novartis|Indiana University |
Neoplasm Metastasis|Carcinoma
|
May 2005 | Phase 1 |
| NCT01616303 | Quest PharmaTech Inc. |
Ovarian Neoplasms
|
June 15, 2012 | Phase 2 |
| NCT02199418 | RenJi Hospital |
Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer
|
January 2013 | Phase 2 |
| NCT01295502 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB Cervical Cancer AJCC v6 and v7|Stage IIA Cervical Cancer AJCC v7|Stage IIB Cervical Cancer AJCC v6 and v7|Stage IIIA Cervical Cancer AJCC v6 and v7|Stage IIIB Cervical Cancer AJCC v6 and v7|Stage IVA Cervical Cancer AJCC v6 and v7
|
April 4, 2011 | Phase 1 |
| NCT01468909 | National Cancer Institute (NCI)|NRG Oncology |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 12, 2011 | Phase 2 |
| NCT00054028 | National Cancer Institute (NCI) |
Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer
|
December 2002 | Phase 1|Phase 2 |
| NCT04481256 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|UMC Utrecht|Catharina Ziekenhuis Eindhoven|Verbeeten Insituut Tilburg|Elisabeth-TweeSteden Ziekenhuis|Leiden University Medical Center|Radiotherapeutic Institute Friesland|Medisch Centrum Leeuwarden|Radiotherapy Group Deventer|Deventer Ziekenhuis|Rijnstate Hospital|Erasmus Medical Center|The Netherlands Cancer Institute|Maastro Clinic, The Netherlands|Zuyderland Medisch Centrum|Isala|University Medical Center Groningen|ZGT |
Carcinoma, Squamous Cell|Oesophageal Cancer
|
November 11, 2020 | Not Applicable |
| NCT00055133 | Angiotech Pharmaceuticals |
Rheumatoid Arthritis
|
September 2002 | Phase 2 |
| NCT00193596 | SCRI Development Innovations, LLC|AstraZeneca|Pharmacia and Upjohn|Eli Lilly and Company |
Neoplasms, Unknown Primary
|
September 2003 | Phase 3 |
| NCT01016769 | Memorial Sloan Kettering Cancer Center|NATL COMP CA NETWORK|Pfizer |
Squamous Cell Cancer|Head and Neck Cancer
|
November 2009 | Phase 1|Phase 2 |
| NCT01484080 | Centro Nacional de Investigaciones Oncologicas CARLOS III|Hospital Universitario de Fuenlabrada|M.D. Anderson Cancer Center|Hospital Universitari de Bellvitge|Grupo Espanol de Investigacion del Cancer de Mama |
Breast Cancer
|
October 2011 | Phase 1|Phase 2 |
| NCT00009828 | University of Pittsburgh|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
December 1999 | Phase 1 |
| NCT02525757 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lung Cancer|Non-Small Cell Lung Cancer
|
January 26, 2016 | Phase 2 |
| NCT01336062 | Peking University |
Gastric Adenocarcinoma
|
April 2011 | Phase 1|Phase 2 |
| NCT01989676 | Pfizer |
Metastatic Breast Cancer
|
February 24, 2014 | Phase 3 |
| NCT00096291 | Massachusetts General Hospital|National Cancer Institute (NCI) |
Breast Cancer
|
February 2000 | Phase 2 |
| NCT00003317 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
May 1998 | Phase 3 |
| NCT05226598 | Merck Sharp & Dohme LLC |
Metastatic Non-Small Cell Lung Cancer
|
March 24, 2022 | Phase 3 |
| NCT03117049 | Ono Pharmaceutical Co. Ltd|Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
June 13, 2017 | Phase 3 |
| NCT03703063 | Benaroya Research Institute |
Pancreatic Adenocarcinoma
|
September 17, 2018 | Phase 1 |
| NCT05564377 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Locally Advanced Malignant Solid Neoplasm
|
December 9, 2022 | Phase 2 |
| NCT01632371 | Deutsches Herzzentrum Muenchen|Biotronik AG |
Restenosis|Stable Angina Pectoris|Acute Coronary Syndrome
|
June 2012 | Phase 4 |
| NCT00889382 | Astellas Pharma Inc |
Ovarian Cancer|Solid Tumors
|
August 5, 2009 | Phase 1|Phase 2 |
| NCT00881816 | Nanjing Sike Pharmaceutical Co., Ltd. |
Advanced Gastric Carcinoma
|
April 2009 | Phase 1 |
| NCT03901118 | Chipscreen Biosciences, Ltd. |
Ovarian Cancer
|
July 1, 2019 | Phase 2 |
| NCT01971034 | Instituto do Cancer do Estado de São Paulo |
Pancreatic Adenocarcinoma Advanced or Metastatic
|
June 2011 | Phase 2 |
| NCT02432365 | Chang Gung Memorial Hospital|Asian Gynecologic Oncology Group|Taiwanese Gynecologic Oncology Group |
Cervical Cancer
|
February 2015 | Phase 2 |
| NCT01179269 | Loyola University|GlaxoSmithKline |
Non-small Cell Lung Cancer
|
March 2010 | Phase 2 |
| NCT05179239 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Cervical Cancer
|
February 26, 2022 | Phase 3 |
| NCT03556839 | Grupo Español de Investigación en Cáncer de Ovario|Hoffmann-La Roche|ARCAGY+ GINECO GROUP|Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies|MaNGO|NSGO|Japanese Gynecologic Oncology Group|Gynecologic Oncology Group Foundation|AGO Study Group |
Carcinoma of the Cervix, Stage IVB
|
September 25, 2018 | Phase 3 |
| NCT03705429 | Lawson Health Research Institute|The Ottawa Hospital |
Breast Neoplasms
|
May 1, 2019 | Phase 3 |
| NCT00373217 | Craig L Slingluff, Jr|National Cancer Institute (NCI)|University of Virginia |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
April 13, 2006 | Phase 2 |
| NCT03321188 | Andrea Jewell|University of Kansas Medical Center |
Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer
|
December 15, 2017 | Phase 2 |
| NCT03609047 | European Organisation for Research and Treatment of Cancer - EORTC|Pfizer|Swedish Association of Breast Oncologists|ETOP IBCSG Partners Foundation|German Adjuvant Breast Cancer Group|SOLTI Breast Cancer Research Group|UNICANCER|Gruppo Oncologico Italiano di Ricerca Clinica|Breast International Group |
Breast Cancer Stage II|Breast Cancer Stage III
|
June 14, 2019 | Phase 2 |
| NCT04210037 | Ascentage Pharma Group Inc. |
Small Cell Lung Cancer
|
August 20, 2020 | Phase 1|Phase 2 |
| NCT04324346 | Swedish Red Cross University College|Karolinska Institutet|KTH Royal Institute of Technology|Karolinska University Hospital|Stockholm South General Hospital|Norwegian University of Science and Technology |
Catheter Related Complications
|
April 1, 2016 | Not Applicable |
| NCT00281658 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
January 2, 2006 | Phase 3 |
| NCT00038168 | M.D. Anderson Cancer Center |
Prostate Cancer
|
June 2000 | Phase 1|Phase 2 |
| NCT01055028 | Stanford University|Genentech, Inc. |
Angiosarcomas|Soft Tissue Sarcoma
|
February 2010 | Phase 2 |
| NCT01755845 | xie congying|Wenzhou Medical University |
Cervical Cancer
|
January 2011 | Phase 3 |
| NCT01271725 | Boehringer Ingelheim |
Breast Neoplasms
|
May 24, 2011 | Phase 2 |
| NCT01194869 | Emory University|Amgen|Bayer |
Breast Cancer
|
June 2010 | Phase 2 |
| NCT03944304 | Asan Medical Center |
Gastrointestinal Stromal Tumors
|
May 20, 2019 | Phase 2 |
| NCT01646762 | Mayo Clinic|National Cancer Institute (NCI) |
Refractory Plasma Cell Myeloma
|
November 5, 2012 | Phase 2 |
| NCT01303926 | Gruppo Oncologico Italia Meridionale |
Non-squamous Nonsmall Cell Neoplasm of Lung
|
January 2010 | Phase 3 |
| NCT00004173 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
October 1999 | Phase 1 |
| NCT00003237 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
March 1998 | Phase 2 |
| NCT01901146 | Amgen|Actavis Inc. |
Breast Cancer
|
April 29, 2013 | Phase 3 |
| NCT01258192 | Zhejiang Cancer Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University |
Esophageal Squamous Cell Carcinoma
|
January 2011 | Phase 2 |
| NCT03981796 | Tesaro, Inc.|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation |
Neoplasms
|
July 18, 2019 | Phase 3 |
| NCT03467178 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Recurrent, Platinum-resistant Ovarian Cancer
|
July 30, 2018 | Phase 2 |
| NCT02264990 | AbbVie |
Non-squamous Non-small Cell Lung Cancer
|
September 30, 2014 | Phase 3 |
| NCT03248427 | SOLTI Breast Cancer Research Group|Novartis |
Breast Cancer
|
July 13, 2017 | Phase 2 |
| NCT00003087 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer
|
August 1997 | Phase 2 |
| NCT04022200 | Beijing Hospital |
Coronary Disease
|
August 1, 2019 | |
| NCT00077688 | Achieve Life Sciences |
Bladder Neoplasms|Ureteral Neoplasms|Urethral Neoplasms|Carcinoma, Transitional Cell
|
November 2003 | Phase 2 |
| NCT00800202 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
April 2009 | Phase 2 |
| NCT00496028 | AstraZeneca |
Neoplasms
|
March 2007 | Phase 1 |
| NCT01183559 | Fox Chase Cancer Center|AstraZeneca |
Cancer of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Cancer of the Stomach
|
August 7, 2008 | Phase 1 |
| NCT00310011 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter
|
June 1998 | Phase 2 |
| NCT04489888 | Merck Sharp & Dohme LLC |
Squamous Cell Carcinoma of Head and Neck
|
October 27, 2020 | Phase 4 |
| NCT04209855 | ImmunoGen, Inc.|Gynecologic Oncology Group|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer
|
December 31, 2019 | Phase 3 |
| NCT03648489 | Imperial College London|Takeda Pharmaceuticals International, Inc.|North Eastern German Society of Gynaecological Oncology |
Ovarian Cancer|Ovarian Neoplasms|Ovarian Carcinosarcoma|Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Fallopian Tube Cancer|Fallopian Tube Neoplasms|Primary Peritoneal Carcinoma|Primary Peritoneal Serous Adenocarcinoma
|
September 21, 2018 | Phase 2 |
| NCT02546232 | Oslo University Hospital |
Breast Cancer
|
April 1, 2015 | Phase 2 |
| NCT02525653 | Memorial Sloan Kettering Cancer Center|Celgene Corporation|Miami Cancer Institute |
Lung Cancer|Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
|
August 2015 | Phase 2 |
| NCT00001569 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Carcinoma|Peritoneal Neoplasm
|
January 1997 | Phase 1 |
| NCT00453076 | Asan Medical Center |
Bile Duct Obstruction
|
November 2006 | Phase 3 |
| NCT00152477 | UCB Pharma |
Carcinoma|Non-Squamous Non-Small-Cell Lung Cancer
|
August 15, 2005 | Phase 2 |
| NCT02639650 | Weiguo Lv|Shandong University|Huazhong University of Science and Technology|First Affiliated Hospital of Zhongshan Medical University|Women´s Hospital School Of Medicine Zhejiang University |
Gestational Trophoblastic Neoplasms
|
March 1, 2016 | Phase 3 |
| NCT04808466 | Wuhan Union Hospital, China |
Gastric Cancer|Chemotherapy Effect|Surgery|Metastasis|Survival
|
September 18, 2021 | Phase 2 |
| NCT01507428 | National Cancer Institute (NCI)|NRG Oncology |
Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7
|
February 22, 2012 | Phase 2 |
| NCT00231582 | Assistance Publique - Hôpitaux de Paris|Ministry of Health, France|Amgen|Baxter Healthcare Corporation |
Testicular Neoplasms
|
September 2004 | Phase 2 |
| NCT00038402 | M.D. Anderson Cancer Center|Genentech, Inc. |
Breast Cancer
|
April 2001 | Phase 3 |
| NCT00005649 | Hoffmann-La Roche |
Breast Cancer
|
July 1998 | Phase 2 |
| NCT01144442 | Masonic Cancer Center, University of Minnesota |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma
|
July 27, 2010 | Not Applicable |
| NCT01792050 | NewLink Genetics Corporation|Lumos Pharma |
Metastatic Breast Cancer
|
February 2013 | Phase 2 |
| NCT00003322 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
March 1998 | Phase 3 |
| NCT00017303 | Cytran|National Cancer Institute (NCI) |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
January 2001 | Phase 2 |
| NCT05039801 | M.D. Anderson Cancer Center |
Advanced Endometrial Carcinoma|Advanced Head and Neck Squamous Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Clear Cell Adenocarcinoma|Chondrosarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Refractory Endometrial Carcinoma|Refractory Head and Neck Squamous Cell Carcinoma|Refractory High Grade Ovarian Serous Adenocarcinoma|Refractory Melanoma|Refractory Ovarian Clear Cell Adenocarcinoma|Stage III Ovarian Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8
|
September 9, 2021 | Phase 1 |
| NCT00301028 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Head and Neck Cancer
|
April 2006 | Phase 2 |
| NCT00034151 | Achieve Life Sciences |
Ovarian Cancer
|
March 2002 | Phase 2 |
| NCT01820325 | Novartis Pharmaceuticals|Novartis |
Non-Small Cell Lunch Cancer
|
September 9, 2013 | Phase 1 |
| NCT03598270 | Grupo Español de Investigación en Cáncer de Ovario|Hoffmann-La Roche|GlaxoSmithKline|AGO Study Group|Belgian Gynaecological Oncology Group|ARCAGY+ GINECO GROUP|Israeli Society of Gynecologic Oncology|MaNGO |
Recurrent Ovarian Carcinoma
|
November 21, 2018 | Phase 3 |
| NCT00353717 | Hadassah Medical Organization |
Breast Neoplasms
|
November 2006 | Phase 1|Phase 2 |
| NCT05316376 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Ovarian Cancer
|
May 1, 2022 | Phase 2 |
| NCT01515306 | Eli Lilly and Company |
Malignant Solid Tumor
|
July 19, 2012 | Phase 2 |
| NCT00176267 | Susanne Arnold|Bristol-Myers Squibb|University of Kentucky |
Squamous Cell Carcinoma
|
September 2002 | Phase 2 |
| NCT05296798 | Hoffmann-La Roche |
Locally Advanced or Metastatic Breast Cancer
|
July 4, 2022 | Phase 3 |
| NCT01732640 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Vanderbilt-Ingram Cancer Center|National Comprehensive Cancer Network |
Squamous Cell Carcinoma of the Head and Neck
|
December 2012 | Phase 1|Phase 2 |
| NCT00616031 | Kyoto University|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|National Cancer Institute (NCI) |
Lung Cancer
|
January 2008 | Phase 2 |
| NCT05310344 | Lei Li|Peking Union Medical College Hospital |
Ovarian Carcinoma|Platinum-resistant Ovarian Cancer|Recurrent Ovarian Carcinoma|Albumin-bound Paclitaxel|Bevacizumab|Survival Outcomes|Adverse Events
|
March 27, 2022 | Phase 2 |
| NCT00789581 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Breast Cancer
|
December 2008 | Phase 3 |
| NCT00369551 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Stage II Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
June 2006 | Phase 1 |
| NCT05603065 | First Affiliated Hospital Xi´an Jiaotong University |
Esophageal Squamous Cell Carcinoma
|
October 10, 2022 | Not Applicable |
| NCT00002772 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B |
Breast Cancer
|
July 1996 | Phase 3 |
| NCT00844649 | Celgene |
Metastatic Pancreatic Cancer
|
March 1, 2009 | Phase 3 |
| NCT01433614 | Thomas Hatschek|Karolinska University Hospital |
Metastatic Breast Cancer
|
December 2002 | Phase 3 |
| NCT01131195 | Swiss Group for Clinical Cancer Research |
Breast Cancer
|
July 19, 2010 | Phase 3 |
| NCT02788708 | Floor Backes|Eisai Inc.|Ohio State University Comprehensive Cancer Center |
Fallopian Tube Carcinoma|Recurrent Ovarian Cancer|Primary Peritoneal Carcinoma|Recurrent Endometrial Cancer
|
May 27, 2016 | Phase 1 |
| NCT04638582 | McGill University Health Centre+Research Institute of the McGill University Health Centre |
Lung Cancer, Nonsmall Cell
|
June 2021 | Phase 2 |
| NCT00001426 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Ovarian Neoplasm
|
February 3, 1995 | Phase 2 |
| NCT05173987 | Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Gynecologic Oncology Group |
Endometrial Neoplasms
|
February 3, 2022 | Phase 3 |
| NCT00006484 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
November 2000 | Phase 3 |
| NCT02065687 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Endometrial Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IIIA Uterine Corpus Cancer AJCC v7|Stage IIIB Uterine Corpus Cancer AJCC v7|Stage IIIC Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Stage IVA Uterine Corpus Cancer AJCC v7|Stage IVB Uterine Corpus Cancer AJCC v7
|
March 17, 2014 | Phase 2|Phase 3 |
| NCT01641783 | Yanqiao Zhang|The Third Affiliated Hospital of Harbin Medical University |
Gastric Adenocarcinoma
|
July 2012 | Phase 2 |
| NCT05189067 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
HER2-positive Breast Cancer|Adjuvant Therapy
|
January 31, 2022 | Phase 2|Phase 3 |
| NCT05381909 | BeiGene |
Solid Tumor, Adult
|
July 6, 2022 | Phase 1 |
| NCT03965468 | ETOP IBCSG Partners Foundation|AstraZeneca |
Non-small Cell Lung Cancer|Stage IV|Oligometastasis
|
November 19, 2019 | Phase 2 |
| NCT01081951 | AstraZeneca |
Ovarian Cancer
|
February 12, 2010 | Phase 2 |
| NCT00004094 | National Cancer Institute (NCI) |
Head and Neck Cancer
|
August 1999 | Phase 2 |
| NCT00667641 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey |
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
March 2007 | Phase 1 |
| NCT00945191 | Daiichi Sankyo, Inc. |
Ovarian Cancer Stage IIIC|Ovarian Cancer Stage IV
|
October 6, 2009 | Phase 2 |
| NCT01364012 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
May 23, 2011 | Phase 3 |
| NCT00094835 | Amgen |
Lung Cancer|Non-Small Cell Lung Cancer
|
January 2005 | Phase 1|Phase 2 |
| NCT01578551 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Carcinoma, Non-Small-Cell Lung|Lung Adenocarcinoma
|
May 2012 | Phase 2 |
| NCT00717340 | AVEO Pharmaceuticals, Inc. |
Metastatic Breast Cancer
|
February 2009 | Phase 1 |
| NCT02403895 | AstraZeneca |
Squamous Non Small Cell Lung Cancer
|
April 15, 2015 | Phase 2 |
| NCT00864318 | Institut Claudius Regaud |
Germ Cell Tumors
|
March 13, 2009 | Phase 2 |
| NCT00974584 | Genentech, Inc. |
Non-Squamous Non-Small Cell Lung Cancer
|
October 2009 | Phase 1 |
| NCT01414608 | GOG Foundation|National Cancer Institute (NCI) |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB Cervical Cancer AJCC v6 and v7|Stage IIA Cervical Cancer AJCC v7|Stage IIB Cervical Cancer AJCC v6 and v7|Stage IIIB Cervical Cancer AJCC v6 and v7|Stage IVA Cervical Cancer AJCC v6 and v7
|
January 9, 2012 | Phase 3 |
| NCT00094861 | Swedish Orphan Biovitrum|Amgen |
Dysphagia|Non-Small Cell Lung Cancer|Lung Cancer
|
January 2005 | Phase 2 |
| NCT01964391 | Hoffmann-La Roche |
Breast Cancer
|
February 21, 2014 | Phase 3 |
| NCT02057380 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
Advanced Solid Tumors
|
April 16, 2014 | Phase 2 |
| NCT04778839 | First Affiliated Hospital of Zhejiang University|Hangzhou Dihua Biotechnology Co., LTD. |
Advanced Solid Tumors
|
March 1, 2021 | Phase 1 |
| NCT02876107 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Breast Carcinoma|Breast Lump|Edema|Erythema|Estrogen Receptor Negative|HER2+Neu Negative|Inflammatory Breast Carcinoma|Invasive Breast Carcinoma|Peau d´Orange|Progesterone Receptor Negative|Triple-Negative Breast Carcinoma
|
October 6, 2016 | Phase 2 |
| NCT00108745 | GOG Foundation|National Cancer Institute (NCI) |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
March 21, 2005 | Phase 3 |
| NCT05007145 | Fujian Cancer Hospital|Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Esophageal Neoplasms|Esophageal Squamous Cell Carcinoma
|
August 15, 2021 | Phase 2 |
| NCT01090830 | Holy Cross Hospital, Florida |
Non-Small-Cell Lung Carcinoma
|
April 2010 | Phase 1|Phase 2 |
| NCT01968915 | Novartis Pharmaceuticals|Novartis |
Neoplasms
|
November 2013 | Phase 1 |
| NCT00066716 | Weill Medical College of Cornell University|Pfizer |
Esophageal Cancer
|
June 2003 | Phase 2 |
| NCT01779206 | West German Study Group |
Breast Cancer
|
May 2012 | Phase 2|Phase 3 |
| NCT00003644 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|GOG Foundation |
Ovarian Cancer
|
October 1998 | Phase 3 |
| NCT00003402 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Leukemia|Lymphoma
|
January 1999 | Phase 2 |
| NCT02033993 | Canadian Cancer Trials Group|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Celgene |
Urothelial Cancer
|
January 27, 2014 | Phase 2 |
| NCT05128617 | Institut de cancérologie Strasbourg Europe|Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire |
Breast Cancer
|
November 4, 2021 | |
| NCT02419495 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Fallopian Tube Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Ovarian Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Primary Peritoneal Carcinoma|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Melanoma|Unresectable Renal Cell Carcinoma
|
June 26, 2015 | Phase 1 |
| NCT05554341 | National Cancer Institute (NCI) |
Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm
|
December 9, 2022 | Phase 2 |
| NCT03574779 | Tesaro, Inc. |
Ovarian Neoplasms
|
November 15, 2018 | Phase 1|Phase 2 |
| NCT00003350 | National Cancer Institute (NCI) |
AIDS-related Kaposi Sarcoma
|
March 1999 | Phase 3 |
| NCT02822157 | Universitaire Ziekenhuizen KU Leuven|AstraZeneca |
Ovarian Epithelial Cancer
|
August 2016 | Phase 2 |
| NCT00006469 | Medstar Health Research Institute |
Lung Cancer
|
August 1999 | Phase 2 |
| NCT00009802 | University of Pittsburgh|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
June 1998 | Phase 1 |
| NCT02713386 | NRG Oncology|National Cancer Institute (NCI) |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube High Grade Serous Adenocarcinoma|FIGO Stage III Ovarian Cancer|FIGO Stage IIIA Ovarian Cancer|FIGO Stage IIIA1 Ovarian Cancer|FIGO Stage IIIA2 Ovarian Cancer|FIGO Stage IIIB Ovarian Cancer|FIGO Stage IIIC Ovarian Cancer|FIGO Stage IVA Ovarian Cancer|FIGO Stage IVB Ovarian Cancer|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Primary Peritoneal Endometrioid Adenocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Stage III Fallopian Tube Cancer AJCC v7|Stage III Primary Peritoneal Cancer AJCC v7|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7
|
November 14, 2016 | Phase 1|Phase 2 |
| NCT00003701 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer|Urethral Cancer
|
March 1999 | Phase 3 |
| NCT01281176 | National Cancer Institute (NCI) |
Adult Solid Neoplasm
|
February 9, 2011 | Phase 1 |
| NCT01220128 | GlaxoSmithKline |
Neoplasms, Breast
|
April 11, 2011 | Phase 2 |
| NCT03740165 | Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Gynecologic Oncology Group |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms
|
December 18, 2018 | Phase 3 |
| NCT03002103 | SynCore Biotechnology Co., Ltd. |
Triple-Negative Breast Cancer
|
November 23, 2016 | Phase 3 |
| NCT02333188 | University of Chicago|National Cancer Institute (NCI) |
Adenocarcinoma of Unknown Primary|Adult Cholangiocarcinoma|Gallbladder Carcinoma|Gastric Adenocarcinoma|Malignant Gastrointestinal Neoplasm|Metastatic Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage III Ampulla of Vater Cancer|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Gastric Cancer|Stage IV Ampulla of Vater Cancer|Stage IV Gallbladder Cancer|Stage IV Gastric Cancer|Stage IV Pancreatic Cancer
|
December 2014 | Phase 1|Phase 2 |
| NCT00900627 | AstraZeneca |
Neoplasms|Breast Neoplasms|Breast Cancer
|
June 2009 | Phase 1|Phase 2 |
| NCT01940497 | Hoffmann-La Roche |
Breast Cancer
|
November 15, 2013 | Phase 3 |
| NCT01024062 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
December 2002 | Phase 2 |
| NCT00004097 | National Cancer Institute (NCI) |
Head and Neck Cancer
|
August 1999 | Phase 1 |
| NCT00194753 | University of Washington|Amgen|Bristol-Myers Squibb |
Breast Neoplasm
|
December 2001 | Phase 2 |
| NCT00356681 | Amgen |
Breast Neoplasms|Breast Tumors|Breast Cancer|Locally Recurrent and Metastatic Breast Cancer
|
December 2006 | Phase 2 |
| NCT00980954 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Cervical Cancer
|
September 2009 | Phase 3 |
| NCT04443036 | China Medical University, China |
Gastric Carcinoma
|
June 11, 2020 | Not Applicable |
| NCT03356860 | Grand Hôpital de Charleroi|Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Breast Cancer|Triple Negative Breast Cancer|Luminal B
|
April 13, 2017 | Phase 1|Phase 2 |
| NCT05394415 | Jiangsu Cancer Institute & Hospital |
Esophageal Squamous Cell Carcinoma|Tislelizumab|Chemoradiation
|
May 1, 2022 | Phase 1|Phase 2 |
| NCT03580395 | Hebei Medical University Fourth Hospital |
Breast Cancer
|
June 1, 2017 | Phase 2|Phase 3 |
| NCT02102438 | Instituto do Cancer do Estado de São Paulo |
Breast Cancer|HER-2 Positive Breast Cancer
|
April 2014 | Not Applicable |
| NCT02492503 | All India Institute of Medical Sciences, New Delhi |
Metastatic Carcinoma to the Uterine Cervix|Recurrent Carcinoma Cervix|Cervix Carcinoma Recurrent
|
November 2013 | Phase 1|Phase 2 |
| NCT04770272 | Palleos Healthcare GmbH|Roche Pharma AG|Phaon Scientific GmbH|University Hospital, Essen|University Hospital Erlangen |
Triple-negative Breast Cancer
|
March 1, 2021 | Phase 2 |
| NCT02915744 | Nektar Therapeutics |
Metastasis|Breast Cancer
|
November 2016 | Phase 3 |
| NCT02620865 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer
|
December 2015 | Phase 1|Phase 2 |
| NCT01646788 | N.M.B. Medical Applications Ltd |
Obstructive Lesions of Arteriovenous Dialysis Fistulae
|
January 2013 | Not Applicable |
| NCT00070564 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
November 2003 | Phase 3 |
| NCT04986098 | Second Affiliated Hospital of Soochow University |
Peripheral Vascular Diseases
|
August 1, 2021 | |
| NCT00585052 | University of Iowa |
Ovarian Cancer
|
August 2003 | Phase 2 |
| NCT02163291 | Peking University |
Advanced Gastric Carcinoma
|
December 2013 | Phase 2 |
| NCT05247684 | Akeso |
Resectable Non-small Cell Lung Cancer
|
February 20, 2022 | Phase 2 |
| NCT03132532 | Mayo Clinic|National Cancer Institute (NCI) |
Non Small Cell Lung Cancer
|
July 31, 2017 | Phase 2 |
| NCT00506779 | M.D. Anderson Cancer Center |
Uterine Cancer
|
December 29, 2003 | Phase 1|Phase 2 |
| NCT03215706 | Bristol-Myers Squibb |
Non-Small Cell Lung Cancer
|
August 24, 2017 | Phase 3 |
| NCT01616888 | University Health Network, Toronto |
In-stent Arterial Restenosis
|
June 2012 | Not Applicable |
| NCT04764227 | Fudan University |
Esophagus Cancer|Esophageal Squamous Cell Carcinoma|Chemoradiotherapy|Radiation Therapy|Postoperative
|
May 30, 2020 | Phase 2 |
| NCT00476827 | Duke University|Genentech, Inc. |
Breast Cancer
|
May 2007 | Phase 2 |
| NCT04899583 | Acotec Scientific Co., Ltd|Shanghai Zhongshan Hospital |
Coronary Bifurcation Lesions
|
November 10, 2021 | Not Applicable |
| NCT05395910 | National University Hospital, Singapore |
Peritoneal Carcinomatosis
|
October 2022 | Phase 1 |
| NCT04931342 | Hoffmann-La Roche|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Ovarian Cancer
|
October 7, 2021 | Phase 2 |
| NCT01423695 | WiSP Wissenschaftlicher Service Pharma GmbH|Bristol-Myers Squibb|Roche Pharma AG |
Metastatic Breast Cancer
|
February 2001 | Phase 2 |
| NCT03053856 | Samsung Medical Center |
Stage IIIA Non-small Cell Lung Cancer
|
February 14, 2017 | Phase 2 |
| NCT04444921 | National Cancer Institute (NCI) |
Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Metastatic Anal Squamous Cell Carcinoma|Recurrent Anal Squamous Cell Carcinoma|Stage III Anal Cancer AJCC v8|Stage IV Anal Cancer AJCC v8|Unresectable Anal Squamous Cell Carcinoma
|
October 15, 2020 | Phase 3 |
| NCT05116462 | Innovent Biologics (Suzhou) Co. Ltd. |
Non-small Cell Lung Cancer (NSCLC)
|
November 11, 2021 | Phase 3 |
| NCT00004221 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Malignant Ovarian Mixed Epithelial Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Undifferentiated Ovarian Carcinoma
|
November 1999 | Phase 2 |
| NCT00888615 | GOG Foundation|National Cancer Institute (NCI) |
Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 13, 2010 | Phase 2 |
| NCT03791905 | Mian XI|Sun Yat-sen University |
Neoplasm, Esophageal|Squamous Cell Carcinoma
|
January 15, 2019 | Phase 2 |
| NCT02344472 | Prof. W. Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation|University of Ulm |
Metastatic Breast Cancer
|
September 2015 | Phase 3 |
| NCT04690686 | Immunicom Inc |
Non Small Cell Lung Cancer
|
October 1, 2020 | Phase 2 |
| NCT01797900 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Nasopharyngeal Neoplasms
|
March 2013 | Phase 2 |
| NCT04310007 | National Cancer Institute (NCI) |
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
|
May 22, 2020 | Phase 2 |
| NCT04761601 | 1200 Pharma, LLC |
Advanced Solid Tumor
|
March 3, 2021 | Phase 1 |
| NCT00666991 | CritiTech, Inc.|University of Kansas Medical Center|Beckloff Associates, Inc. |
Peritoneal Neoplasms
|
July 2008 | Phase 1 |
| NCT03618758 | Seoul National University Bundang Hospital|Boryung Pharmaceutical Co., Ltd|B. Braun Korea Co., Ltd. |
Gastric Cancer Stage IV|Peritoneal Carcinomatosis|Intraperitoneal Paclitaxel|mFOLFOX6
|
December 24, 2018 | Phase 1|Phase 2 |
| NCT02367794 | Hoffmann-La Roche |
Squamous Non-Small Cell Lung Cancer
|
June 11, 2015 | Phase 3 |
| NCT04908787 | Jiangsu Simcere Pharmaceutical Co., Ltd. |
Ovarian Cancer
|
June 11, 2021 | Phase 3 |
| NCT00081302 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
March 2004 | Phase 2 |
| NCT04644068 | AstraZeneca |
Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer|Additional Indications Below for Module 4 and 5|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Colorectal Cancer|Bladder Cancer|Gastric Cancer|Biliary Cancer|Cervical Cancer|Endometrial Cancer
|
November 12, 2020 | Phase 1|Phase 2 |
| NCT00490711 | Eli Lilly and Company |
Epithelial Ovarian Cancer
|
July 2003 | Phase 2 |
| NCT01594099 | Health Science Center of Xi´an Jiaotong University |
Cervical Cancer
|
April 2012 | Phase 2 |
| NCT03639246 | Aravive, Inc. |
Ovarian Cancer
|
December 6, 2018 | Phase 1 |
| NCT00567554 | German Breast Group|AGO Study Group |
Breast Cancer
|
October 2007 | Phase 3 |
| NCT02440425 | H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme LLC |
Ovarian Cancer
|
October 20, 2015 | Phase 2 |
| NCT00003812 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
March 1999 | Phase 2 |
| NCT03694002 | Southwest Oncology Group|National Cancer Institute (NCI) |
Locally Advanced Thymic Carcinoma|Metastatic Thymic Carcinoma|Recurrent Thymic Carcinoma|Unresectable Thymic Carcinoma
|
August 9, 2018 | Phase 2 |
| NCT01358877 | Hoffmann-La Roche|Genentech, Inc.|Breast International Group |
Breast Cancer
|
November 8, 2011 | Phase 3 |
| NCT02483247 | Sumitomo Pharma Oncology, Inc. |
Cancer
|
September 2015 | Phase 1 |
| NCT00147537 | Pfizer |
Carcinoma, Non-Small-Cell Lung
|
February 2005 | Phase 1|Phase 2 |
| NCT05214976 | Jiangsu HengRui Medicine Co., Ltd. |
Advanced Solid Tumors
|
April 30, 2022 | Phase 2 |
| NCT03734029 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
December 27, 2018 | Phase 3 |
| NCT00011960 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
May 2001 | Phase 2 |
| NCT05552807 | Sinocelltech Ltd. |
Head and Neck Squamous Carcinoma
|
June 15, 2022 | Phase 1 |
| NCT02621398 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Merck Sharp & Dohme LLC |
Stage II Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer
|
April 11, 2016 | Phase 1 |
| NCT01938846 | Boehringer Ingelheim |
Neoplasms
|
September 5, 2013 | Phase 1 |
| NCT01688700 | Zhejiang Cancer Hospital |
Esophageal Squamous Cell Carcinoma Resectable
|
September 2012 | Phase 2 |
| NCT00334321 | Washington University School of Medicine |
Endometrial Cancer
|
April 2006 | Phase 1 |
| NCT05624996 | NRG Oncology|National Cancer Institute (NCI) |
Locally Advanced Lung Non-Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8
|
June 9, 2023 | Phase 3 |
| NCT00003440 | National Cancer Institute (NCI) |
HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
July 1998 | Phase 3 |
| NCT05244993 | Liaoning Tumor Hospital & Institute|Huludao central hospital|Anshan Tumor Hospital|Chaoyang Central Hospital|Fukuang General Hospital of Liaoning health industry group |
Breast Neoplasm Female
|
July 2022 | Phase 2 |
| NCT00918203 | Eli Lilly and Company |
Non-Small Cell Lung Cancer
|
January 2010 | Phase 2 |
| NCT00002628 | St. Louis University|National Cancer Institute (NCI) |
Breast Cancer
|
November 1994 | Phase 1|Phase 2 |
| NCT02879097 | Cipla BioTec Pvt. Ltd. |
Non-Small Cell Lung Carcinoma
|
December 2016 | Phase 3 |
| NCT04217096 | Fudan University |
Advanced Pancreatic Cancer
|
January 1, 2020 | Phase 4 |
| NCT00912639 | Korean Breast Cancer Study Group |
Recurrent Breast Cancer
|
May 2009 | Phase 4 |
| NCT02240212 | Novartis Pharmaceuticals|Novartis |
Cancer
|
October 2014 | Phase 1 |
| NCT01953536 | Endocyte |
Breast Neoplasms
|
April 2014 | Phase 2 |
| NCT00459121 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Lung Cancer
|
July 2007 | Phase 2 |
| NCT04446663 | First People´s Hospital of Foshan |
Nasopharyngeal Neoplasms
|
July 15, 2020 | Phase 2 |
| NCT04354961 | Fujian Cancer Hospital|Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Pulmonary Adenosquamous Carcinoma
|
June 2020 | Phase 2 |
| NCT00368992 | National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
August 2006 | Phase 2 |
| NCT04602117 | QuantumLeap Healthcare Collaborative|Byondis B.V. |
HER2-positive Breast Cancer|HER2 Low|SYD-985|SYD985|Vic-trastuzumab Duocarmazine|Metastatic Cancer|Metastatic Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic|HER2 Low Breast Cancer|GastroEsophageal Cancer|Gastroesophageal Adenocarcinoma|Endometrium Tumor|Ovarian Cancer|Ovarian Carcinoma|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer|HER2 Mutation-Related Tumors|HER-2 Protein Overexpression|HER2 Low HR Positive|HR Positive|Hormone Receptor-positive Breast Cancer|Estrogen Receptor Positive Tumor|Progesterone Receptor-positive Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Negative Breast Carcinoma|Bladder Cancer
|
July 28, 2021 | Phase 1 |
| NCT00003392 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 1997 | Phase 2 |
| NCT04165070 | Merck Sharp & Dohme LLC |
Carcinoma, Non-Small-Cell Lung
|
December 19, 2019 | Phase 2 |
| NCT02503358 | OHSU Knight Cancer Institute|Oregon Health and Science University|AstraZeneca |
Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7
|
July 21, 2016 | Phase 1 |
| NCT00006118 | GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI) |
Bladder Cancer
|
July 1999 | Phase 2 |
| NCT00003957 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 1998 | Phase 2 |
| NCT02048943 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Novartis |
Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
March 2015 | Phase 1 |
| NCT02315196 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey |
Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer
|
December 26, 2014 | Phase 2 |
| NCT02283489 | Renmiao Zhang|West China Hospital|Chengdu Shi Endor Biological Engineering Technology Co., Ltd |
Head and Neck Neoplasms
|
October 2014 | Phase 2 |
| NCT04205968 | Southwest Oncology Group|National Cancer Institute (NCI) |
Metastatic Small Intestinal Adenocarcinoma|Stage III Small Intestinal Adenocarcinoma AJCC v8|Stage IIIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIIB Small Intestinal Adenocarcinoma AJCC v8|Stage IV Small Intestinal Adenocarcinoma AJCC v8
|
December 16, 2019 | Phase 2 |
| NCT04835064 | Fudan University |
Pancreatic Adenocarcinoma
|
April 1, 2021 | Phase 3 |
| NCT03390686 | Prestige Biopharma Limited |
Lung Cancer|Non-small Cell Lung Cancer
|
November 15, 2019 | Phase 3 |
| NCT01868022 | GlaxoSmithKline |
Neoplasms
|
October 9, 2013 | Phase 1 |
| NCT00449657 | Leo W. Jenkins Cancer Center |
Non Small Cell Lung Cancer
|
February 2007 | Phase 2 |
| NCT00006245 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer
|
July 2000 | Phase 2 |
| NCT03579784 | Do-Youn Oh|AstraZeneca|Seoul National University Hospital |
Advanced Gastric Cancer
|
November 26, 2018 | Phase 2 |
| NCT00606515 | Shandong Luye Pharmaceutical Co., Ltd.|Nanjing Sike Pharmaceutical Co., Ltd. |
Cancer
|
February 2008 | Phase 4 |
| NCT04245085 | ETOP IBCSG Partners Foundation|Roche Pharma AG |
EGFRmutant Stage IIIB+C or IV Non-squamous NSCLC
|
September 29, 2020 | Phase 2 |
| NCT03997123 | AstraZeneca |
Triple Negative Breast Neoplasms
|
June 25, 2019 | Phase 3 |
| NCT04498793 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|First Affiliated Hospital Xi´an Jiaotong University|Wuhan Union Hospital, China|Beijing Huanxing Cancer Hospital |
HER2-negative Breast Cancer
|
September 2020 | Phase 2 |
| NCT03337724 | Hoffmann-La Roche |
Breast Cancer
|
January 6, 2018 | Phase 3 |
| NCT00392704 | SCRI Development Innovations, LLC|Genentech, Inc. |
Head and Neck Cancer
|
December 2006 | Phase 2 |
| NCT00311636 | Gruppo Italiano Mammella (GIM)|National Cancer Institute (NCI) |
Breast Cancer
|
September 2003 | Phase 3 |
| NCT00686959 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
September 2008 | Phase 3 |
| NCT03818282 | Huazhong University of Science and Technology |
Ovarian Cancer
|
March 1, 2019 | Phase 2 |
| NCT00041470 | University of Washington|Amgen|Bristol-Myers Squibb|GlaxoSmithKline |
Breast Cancer
|
March 2001 | Phase 1|Phase 2 |
| NCT01770301 | ARCAGY+ GINECO GROUP|Roche Pharma AG |
Ovarian Sex-cord Stromal Tumor
|
February 2013 | Phase 2 |
| NCT02317874 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
July 24, 2015 | Phase 1 |
| NCT05238831 | OHSU Knight Cancer Institute|Oregon Health and Science University|Genentech, Inc. |
Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Ovarian Carcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Refractory Breast Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Ovarian Carcinoma|Stage III Ovarian Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Unresectable Malignant Solid Neoplasm|Unresectable Ovarian Carcinoma
|
December 1, 2022 | Phase 2 |
| NCT00138151 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey |
Cervical Cancer
|
March 2001 | Phase 2 |
| NCT04205903 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8
|
December 11, 2020 | Phase 1 |
| NCT01462890 | AGO Study Group|ARCAGY+ GINECO GROUP|Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
Genital Diseases, Female|Ovarian Diseases|Ovarian Neoplasms|Fallopian Tube Neoplasms|Peritoneal Neoplasms
|
November 2011 | Phase 3 |
| NCT02779855 | H. Lee Moffitt Cancer Center and Research Institute|Amgen |
Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma
|
May 2, 2017 | Phase 1|Phase 2 |
| NCT00268450 | Medical University of South Carolina |
Bladder Cancer
|
September 21, 2005 | Phase 2 |
| NCT03088540 | Regeneron Pharmaceuticals|Sanofi |
Carcinoma?Non-Small-Cell Lung|Lung Carcinomas, Non-Small-Cell|Non-small-cell Lung Carcinoma|Nonsmall Cell Lung Cancer
|
May 29, 2017 | Phase 3 |
| NCT01757288 | University of Texas Southwestern Medical Center|Celgene |
STAGE IIIA+B NSCLC + INOPERABLE LUNG CANCER
|
March 25, 2013 | Phase 1|Phase 2 |
| NCT00954642 | Genentech, Inc. |
Solid Cancers
|
August 2009 | Phase 1 |
| NCT04109066 | Bristol-Myers Squibb |
Breast Cancer
|
December 2, 2019 | Phase 3 |
| NCT04652206 | Scandion Oncology A+S|Alcedis GmbH |
Metastatic Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma|Inoperable Disease|Localized Pancreatic Adenocarcinoma
|
October 27, 2020 | Phase 1|Phase 2 |
| NCT04745975 | Fudan University |
Triple Negative Breast Cancer
|
February 1, 2021 | Phase 2 |
| NCT00337532 | Bristol-Myers Squibb |
Head and Neck Cancer
|
May 2005 | Phase 2|Phase 3 |
| NCT00933374 | Heinrich-Heine University, Duesseldorf |
Bladder Cancer
|
July 2009 | Phase 2 |
| NCT00915005 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Non-Small-Cell Lung Carcinoma
|
June 2009 | Phase 2 |
| NCT01399463 | Medical University of Vienna |
Coronary Artery Disease
|
August 2011 | Not Applicable |
| NCT00093223 | Celgene |
Angina Pectoris|Coronary Artery Disease
|
September 1, 2001 | Phase 2 |
| NCT00019019 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Breast Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Melanoma (Skin)|Ovarian Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
October 1994 | Phase 1 |
| NCT01023204 | Bristol-Myers Squibb |
Breast Cancer
|
October 2002 | Phase 2 |
| NCT00002717 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
March 1996 | Phase 3 |
| NCT00035152 | Bristol-Myers Squibb |
Carcinoma, Non-Small-Cell Lung
|
June 2000 | Phase 3 |
| NCT00861627 | Oncolytics Biotech |
Carcinoma, Non-small Cell Lung
|
March 2009 | Phase 2 |
| NCT02962232 | ZhuHai Cardionovum Medical Device Co., Ltd. |
Peripheral Artery Disease
|
November 2016 | Not Applicable |
| NCT01992341 | Amgen |
Advanced Solid Tumors
|
July 2012 | Phase 1 |
| NCT02069158 | Cristiana Sessa|Oncology Institute of Southern Switzerland |
Breast Cancer|NSCLC|Ovary Cancer|Endometrial Cancer|Small Cell Lung Cancer (SCLC)|Head and Neck (HNSCC)
|
April 2014 | Phase 1 |
| NCT00629278 | Azienda Ospedaliero-Universitaria di Modena|National Cancer Institute (NCI) |
Breast Cancer
|
December 2007 | Phase 3 |
| NCT00874107 | HiberCell, Inc. |
Non-Small Cell Lung Cancer
|
June 2009 | Phase 2 |
| NCT05042128 | Australasian Gastro-Intestinal Trials Group|University of Sydney |
Pancreatic Ductal Adenocarcinoma|Metastatic Pancreatic Cancer
|
April 13, 2022 | Phase 2 |
| NCT03272477 | Palleos Healthcare GmbH|Roche Pharma AG|WSG WOMEN´S HEALTHCARE STUDY GROUP|Cankado GmbH |
Breast Neoplasms
|
October 5, 2017 | Phase 2 |
| NCT00806286 | Daiichi Sankyo, Inc. |
Metastatic Non-small Cell Lung Cancer
|
December 2008 | Phase 2 |
| NCT00445458 | Puma Biotechnology, Inc. |
Advanced Breast Cancer|Advanced Malignant Solid Tumors|Breast Neoplasms
|
September 11, 2007 | Phase 1|Phase 2 |
| NCT00003092 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 1997 | Phase 3 |
| NCT00003064 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
January 1997 | Phase 1|Phase 2 |
| NCT00462631 | Heart Centre Rotenburg|B. Braun Medical SA |
Coronary Stenosis|Diabetes Mellitus
|
May 2007 | Phase 2|Phase 3 |
| NCT00165035 | Cordis Corporation|Conor Medsystems |
Coronary Disease
|
May 2005 | Phase 3 |
| NCT00004125 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Southwest Oncology Group|Cancer and Leukemia Group B |
Breast Cancer
|
October 1999 | Phase 3 |
| NCT00581971 | University of Alabama at Birmingham|Bristol-Myers Squibb|Pharmacia |
Cancer
|
September 2002 | Phase 1|Phase 2 |
| NCT00408070 | UConn Health|Genentech, Inc. |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Stage 3 Cancer|Stage 4 Cancer
|
October 2006 | Phase 2 |
| NCT00005970 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group|Southwest Oncology Group |
Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7
|
May 19, 2000 | Phase 3 |
| NCT03818997 | European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics, Inc. |
Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm
|
December 2019 | Phase 2 |
| NCT05322499 | Zhejiang Cancer Hospital |
Stage IV Esophagus Squamous Cell Carcinoma
|
April 15, 2022 | Phase 2 |
| NCT00041119 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
May 2002 | Phase 3 |
| NCT00003733 | SmithKline Beecham|National Cancer Institute (NCI) |
Ovarian Cancer
|
December 1997 | Phase 2 |
| NCT05227664 | Akeso |
Metastatic Triple-negative Breast Cancer|Locally Advanced Triple-negative Breast Cancer
|
March 23, 2022 | Phase 2 |
| NCT00191646 | Eli Lilly and Company |
Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms
|
October 2002 | Phase 3 |
| NCT02943798 | Shanghai Chest Hospital |
Pulmonary Large Cell Neuroendocrine Carcinoma
|
December 2016 | Phase 2 |
| NCT00023907 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
July 2001 | Phase 2 |
| NCT01891357 | West German Study Group|GlaxoSmithKline |
Carcinoma, Ductal, Breast
|
September 30, 2013 | Phase 2 |
| NCT01618136 | Eisai Limited|Eisai Inc. |
Malignant Solid Tumour|Ovarian Cancer|Triple Negative Breast Cancer|Advanced Melanoma|B-cell Malignancy, Low-grade
|
January 2012 | Phase 1|Phase 2 |
| NCT03719326 | Arcus Biosciences, Inc.|Infinity Pharmaceuticals, Inc. |
TNBC - Triple-Negative Breast Cancer|Ovarian Cancer
|
October 15, 2018 | Phase 1 |
| NCT05328336 | Tianjin Medical University Second Hospital |
Muscle Invasive Bladder Cancer Urothelial Carcinoma
|
November 11, 2021 | Phase 2 |
| NCT05319639 | Fujian Cancer Hospital |
Gastric Cancer Stage IV
|
December 2, 2022 | Phase 1 |
| NCT00535119 | National Cancer Institute (NCI) |
Adult Solid Neoplasm|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Hereditary Breast and Ovarian Cancer Syndrome
|
September 2007 | Phase 1 |
| NCT00652119 | Massachusetts General Hospital|Genentech, Inc.|National Cancer Institute (NCI) |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer
|
February 2008 | Phase 1 |
| NCT05497778 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Pancreas Cancer
|
October 21, 2022 | Phase 1 |
| NCT00025688 | Theradex|National Cancer Institute (NCI) |
Breast Cancer
|
January 2001 | Phase 3 |
| NCT00536939 | Eli Lilly and Company|Genentech, Inc. |
Breast Cancer
|
November 2007 | Phase 2 |
| NCT00505492 | M.D. Anderson Cancer Center |
Uterine Neoplasms
|
February 2002 | Phase 2 |
| NCT00071188 | Genzyme, a Sanofi Company|Sanofi |
Carcinoma, Non-Small-Cell Lung
|
February 2004 | Phase 2 |
| NCT00006227 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Adult Type Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Steroid Cell Tumor
|
November 20, 2000 | Phase 2 |
| NCT05209412 | Xijing Hospital |
De Novo Stenosis|Coronary Artery Disease|Percutaneous Coronary Intervention
|
February 1, 2022 | Not Applicable |
| NCT04958785 | Gilead Sciences |
Triple-Negative Breast Cancer
|
December 14, 2021 | Phase 2 |
| NCT00350025 | Fox Chase Cancer Center|Bristol-Myers Squibb |
Urologic Neoplasm
|
August 2006 | Phase 2 |
| NCT00021333 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Head and Neck Cancer|Lung Cancer
|
September 1999 | Phase 2 |
| NCT05319730 | Merck Sharp & Dohme LLC |
Esophageal Squamous Cell Carcinoma
|
February 27, 2023 | Phase 1|Phase 2 |
| NCT01969955 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Squamous Cell Carcinoma of Lung
|
September 2013 | Phase 2 |
| NCT00003242 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
February 1998 | Phase 1 |
| NCT00334763 | Northwestern University|National Cancer Institute (NCI) |
Lung Cancer
|
May 2006 | Phase 2 |
| NCT01256268 | H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme LLC |
Endometrial Cancer|Ovarian Cancer
|
June 13, 2011 | Phase 1 |
| NCT03908333 | Medical College of Wisconsin|Cancer Research UK|Stand Up To Cancer|Lustgarten Foundation|Destroy Pancreatic Cancer|Translational Genomics Research Institute|HonorHealth Research Institute |
Metastatic Pancreatic Cancer|Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreatic Metastasis
|
May 1, 2019 | Phase 1|Phase 2 |
| NCT00069953 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Esophageal Cancer
|
September 2003 | Phase 2 |
| NCT00158379 | North Eastern German Society of Gynaecological Oncology |
Ovarian Cancer
|
July 2003 | Phase 2 |
| NCT00057863 | National Cancer Institute (NCI) |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer
|
January 2003 | Phase 2 |
| NCT00398086 | Celgene |
Metastatic Pancreatic Cancer
|
November 1, 2006 | Phase 1|Phase 2 |
| NCT02054884 | Philogen S.p.A.|Immatics Biotechnologies GmbH |
Merkel Cell Carcinoma
|
October 25, 2013 | Phase 2 |
| NCT00287989 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lung Cancer
|
November 2004 | Phase 2 |
| NCT02412371 | AbbVie |
Non-small Cell Lung Cancer Stage III
|
April 30, 2015 | Phase 1|Phase 2 |
| NCT04203485 | Jiangsu HengRui Medicine Co., Ltd. |
PD-L1 Positive Non-small Cell Lung Cancer
|
June 15, 2020 | Phase 3 |
| NCT00085501 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
July 2004 | Phase 2 |
| NCT02630199 | Samsung Medical Center |
Refractory Cancer
|
December 2015 | Phase 1 |
| NCT00702572 | Milton S. Hershey Medical Center |
Non-small Cell Lung Cancer
|
April 2008 | Phase 1 |
| NCT05357846 | Sun Yat-sen University|Affiliated Cancer Hospital of Shantou University Medical College |
Squamous Cell Esophageal Carcinoma|Esophageal Cancer|Oesophageal Cancer
|
November 1, 2022 | Phase 3 |
| NCT00448305 | MediGene |
Breast Neoplasms
|
January 2007 | Phase 2 |
| NCT00022217 | Matrix Pharmaceutical|National Cancer Institute (NCI) |
Head and Neck Cancer
|
November 2000 | Phase 2 |
| NCT00025480 | Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI) |
Lung Cancer
|
August 2001 | Phase 1 |
| NCT04338620 | Tang-Du Hospital |
Non-small-cell Lung Cancer (NSCLC)
|
March 12, 2020 | Phase 2 |
| NCT02628132 | King Faisal Specialist Hospital & Research Center|AstraZeneca |
Breast Cancer
|
November 2016 | Phase 1|Phase 2 |
| NCT04046016 | Seoul National University Hospital |
Solid Tumor
|
July 3, 2018 | Early Phase 1 |
| NCT00276588 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lung Cancer
|
July 2005 | Phase 2 |
| NCT00095927 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|MedImmune LLC|AstraZeneca |
Chemotherapeutic Agent Toxicity|Head and Neck Cancer|Mucositis|Radiation Toxicity|Xerostomia
|
May 2003 | Phase 2 |
| NCT02464501 | Horizons International Peripheral Group|Advanced Catheter Therapies, Inc. |
Peripheral Arterial Disease|Cardiovascular Disease|Peripheral Vascular Disease
|
May 20, 2015 | Not Applicable |
| NCT02626520 | Essentia Health |
Ductal Adenocarcinoma of Pancreas|Adenocarcinoma of Ampulla
|
May 11, 2016 | Phase 2 |
| NCT00003558 | Academisch Ziekenhuis Maastricht|National Cancer Institute (NCI) |
Carcinoma of Unknown Primary
|
August 1998 | Phase 3 |
| NCT02619448 | State University of New York - Upstate Medical University |
Non-small Cell Lung Cancer
|
December 2014 | Early Phase 1 |
| NCT04862585 | Ohio State University Comprehensive Cancer Center |
Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8
|
October 7, 2021 | Phase 2|Phase 3 |
| NCT00356811 | GlaxoSmithKline |
Neoplasms, Breast
|
May 2006 | Phase 2 |
| NCT00017407 | Ionis Pharmaceuticals, Inc.|National Cancer Institute (NCI) |
Lung Cancer
|
October 2000 | Phase 3 |
| NCT00005849 | University of Chicago|National Cancer Institute (NCI) |
Lung Cancer
|
April 2000 | Phase 2 |
| NCT00009997 | NYU Langone Health|National Cancer Institute (NCI) |
Breast Cancer
|
March 1999 | Phase 1 |
| NCT01821833 | New Mexico Cancer Care Alliance|Alliance Healthcare Foundation |
Breast Cancer|Ovarian Neoplasm|Pain
|
May 24, 2016 | Not Applicable |
| NCT02178436 | Mohammed Najeeb Al Hallak|National Cancer Institute (NCI)|Barbara Ann Karmanos Cancer Institute |
Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage IV Pancreatic Cancer
|
October 31, 2014 | Phase 1|Phase 2 |
| NCT00004265 | University of Wisconsin, Madison|National Cancer Institute (NCI) |
Lung Cancer
|
February 1999 | Phase 2 |
| NCT03058939 | University of Chicago |
Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III
|
November 2018 | Phase 2 |
| NCT00022620 | European Organisation for Research and Treatment of Cancer - EORTC |
Endometrial Cancer
|
June 2001 | Phase 2 |
| NCT00691379 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
April 2008 | Phase 1|Phase 2 |
| NCT00045682 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma
|
September 2002 | Phase 2 |
| NCT00609791 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
February 11, 2008 | Phase 2 |
| NCT01839773 | Daehwa Pharmaceutical Co., Ltd. |
Stage IV Gastric Cancer
|
March 2013 | Phase 3 |
| NCT03169335 | Qilu Pharmaceutical Co., Ltd. |
Non-squamous Non-small Cell Lung Cancer
|
March 28, 2017 | Phase 3 |
| NCT02142010 | Nanjing Luye Sike Pharmaceutical Co., Ltd. |
Breast Cancer
|
August 2014 | Not Applicable |
| NCT00486954 | GlaxoSmithKline |
Neoplasms, Gastrointestinal Tract
|
July 2007 | Phase 3 |
| NCT02194166 | Hoffmann-La Roche |
Breast Cancer
|
July 18, 2014 | Phase 3 |
| NCT00194792 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
August 2005 | Phase 2 |
| NCT00301730 | National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
October 2005 | Phase 1 |
| NCT01108055 | Sandy Srinivas|GlaxoSmithKline|Stanford University |
Bladder Cancer|Bladder (Urothelial, Transitional Cell) Cancer|Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)|Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)|Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
|
April 2010 | Phase 2 |
| NCT00409981 | University Hospital, Saarland |
Coronary Restenosis
|
July 2004 | Phase 1|Phase 2 |
| NCT02514551 | Eli Lilly and Company |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
October 12, 2015 | Phase 2 |
| NCT00054548 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
October 2002 | Phase 1 |
| NCT01457846 | AstraZeneca |
Gastro-oesophageal Junction Cancer|Gastric Cancer
|
November 2011 | Phase 2 |
| NCT02058433 | Caicun Zhou|Tongji University |
Non-Small Cell Lung Cancer
|
January 2014 | Phase 3 |
| NCT00881101 | Nanjing Sike Pharmaceutical Co., Ltd. |
Solid Tumor
|
April 2009 | Phase 1 |
| NCT00091377 | MEI Pharma, Inc. |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
August 2004 | Phase 1|Phase 2 |
| NCT02392377 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage IB Esophageal Adenocarcinoma|Stage IIA Esophageal Adenocarcinoma|Stage IIB Esophageal Adenocarcinoma|Stage IIIA Esophageal Adenocarcinoma|Stage IIIB Esophageal Adenocarcinoma|Stage IIIC Esophageal Adenocarcinoma
|
February 2015 | Phase 2 |
| NCT00600340 | Central European Cooperative Oncology Group |
Metastatic Breast Cancer
|
April 2008 | Phase 3 |
| NCT03933449 | Merck Sharp & Dohme LLC |
Esophageal Carcinoma|Esophagogastric Junction Carcinoma
|
December 29, 2016 | Phase 3 |
| NCT04194203 | Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
April 9, 2020 | Phase 3 |
| NCT05026905 | National Health Research Institutes, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital |
Phase II, Open-label, Parallel 2-arm, Multi-center
|
December 28, 2021 | Phase 2 |
| NCT04498117 | CanariaBio Inc.|Gynecologic Oncology Group|Iqvia Pty Ltd |
Carcinoma, Ovarian Epithelial|Ovarian Neoplasms|Ovarian Cancer|Ovarian Serous Adenocarcinoma|Fallopian Tube Neoplasms|Fallopian Tube Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Peritoneal Cancer|Peritoneal Carcinoma|Peritoneal Neoplasms
|
August 25, 2020 | Phase 3 |
| NCT00287937 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 2005 | Phase 1 |
| NCT03398655 | Vascular Biogenics Ltd. operating as VBL Therapeutics|GOG Foundation |
Recurrent Platinum Resistant Ovarian Cancer
|
December 19, 2017 | Phase 3 |
| NCT01066832 | Eurocor GmbH |
Instent Restenosis
|
February 2010 | Phase 4 |
| NCT00903942 | University of Rochester|Celgene Corporation |
Non-small Cell Lung Cancer, Stage III
|
March 2008 | Phase 2 |
| NCT01057069 | The Netherlands Cancer Institute |
Breast Cancer
|
January 2010 | Phase 2|Phase 3 |
| NCT00786110 | University of Turin, Italy |
Adrenocortical Carcinoma
|
April 2008 | Phase 2 |
| NCT02429622 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Esophageal Neoplasms
|
January 2015 | Phase 1|Phase 2 |
| NCT00180310 | Abbott Medical Devices |
Coronary Disease|Coronary Artery Disease|Coronary Restenosis
|
July 2005 | Phase 3 |
| NCT00004916 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
February 1999 | Phase 1|Phase 2 |
| NCT00693030 | A.O. Ospedale Papa Giovanni XXIII|Case Western Reserve University|Medtronic Vascular|Boston Scientific Corporation |
Coronary Artery Disease
|
August 2006 | Phase 4 |
| NCT03505528 | EpiAxis Therapeutics|The Canberra Hospital|Southern Medical Day Care Centre|Liverpool Cancer Therapy Centre |
Metastatic Breast Cancer
|
August 17, 2017 | Phase 1 |
| NCT03913832 | Concept Medicals BV |
Coronary Artery Disease|DCB
|
August 28, 2020 | Not Applicable |
| NCT03036488 | Merck Sharp & Dohme LLC |
Triple Negative Breast Neoplasms
|
March 7, 2017 | Phase 3 |
| NCT00001498 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Breast Neoplasms
|
February 1996 | Phase 2 |
| NCT00003230 | Swiss Group for Clinical Cancer Research |
Leukemia
|
January 1998 | Phase 1|Phase 2 |
| NCT02395744 | Horizons International Peripheral Group|Advanced Catheter Therapies, Inc. |
Cardiovascular Diseases|Peripheral Vascular Disease|Arterial Occlusive Diseases|Peripheral Arterial Disease|Critical Limb Ischemia
|
March 11, 2015 | Not Applicable |
| NCT03314740 | Mario Negri Institute for Pharmacological Research|AstraZeneca |
Ovarian Neoplasms
|
June 1, 2017 | Phase 2 |
| NCT02460042 | B. Braun Melsungen AG |
Peripheral Arterial Occlusive Disease
|
May 2015 | |
| NCT02225652 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Women With Primary Breast Cancer
|
September 2010 | Phase 2 |
| NCT04540211 | Hoffmann-La Roche |
Esophageal Cancer
|
October 30, 2020 | Phase 3 |
| NCT00005599 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
February 2000 | Phase 2 |
| NCT01320111 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH|iOMEDICO AG |
Metastatic Breast Cancer
|
July 1, 2010 | Phase 2 |
| NCT03029611 | University of Washington|National Cancer Institute (NCI) |
Stage III Fallopian Tube Cancer|Stage III Ovarian Cancer|Stage III Primary Peritoneal Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer
|
April 3, 2017 | Phase 2 |
| NCT03416153 | University of Michigan Rogel Cancer Center|VA Ann Arbor Healthcare System|National Cancer Institute (NCI) |
Oropharynx Cancer
|
May 21, 2018 | Phase 2 |
| NCT00453167 | National Cancer Center, Korea |
Lung Cancer
|
December 2005 | Phase 2 |
| NCT02526953 | Blokhin´s Russian Cancer Research Center |
Anus Neoplasms|Carcinoma, Squamous Cell|Anus Diseases|Neoplasms|Neoplasms, Squamous Cell|Carcinoma
|
January 2016 | Phase 3 |
| NCT02766582 | Medical College of Wisconsin|The Cleveland Clinic |
Ovarian Cancer
|
October 2016 | Phase 2 |
| NCT04652076 | NETRIS Pharma|Merck Sharp & Dohme LLC|Centre Leon Berard |
Endometrial Carcinoma|Cervix Carcinoma
|
December 14, 2020 | Phase 1|Phase 2 |
| NCT02998528 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Non Small Cell Lung Cancer
|
March 4, 2017 | Phase 3 |
| NCT03797443 | Piedmont Cancer Institute|Cancer Research UK|Stand Up To Cancer|Lustgarten Foundation|Destroy Pancreatic Cancer|Translational Genomics Research Institute |
Metastatic Pancreatic Cancer
|
January 1, 2019 | Phase 1|Phase 2 |
| NCT02409186 | Shandong Cancer Hospital and Institute |
Prosthesis Survival
|
March 2015 | Phase 3 |
| NCT03716180 | Dana-Farber Cancer Institute|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation|Terri Brodeur Breast Cancer Foundation |
Breast Cancer
|
November 5, 2018 | Phase 1 |
| NCT00007904 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 2000 | Phase 2 |
| NCT04073537 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Squamous Non-small Cell Lung Cancer
|
October 31, 2019 | Phase 3 |
| NCT00006120 | GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI) |
Breast Cancer
|
May 2000 | Phase 2 |
| NCT05420636 | Fox Chase Cancer Center |
Small-cell Lung Cancer|Neuroendocrine Carcinoma
|
November 2022 | Phase 2 |
| NCT03567720 | OncoSec Medical Incorporated|Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer
|
October 11, 2018 | Phase 2 |
| NCT00002837 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb |
Breast Cancer
|
September 1995 | Phase 1|Phase 2 |
| NCT00176241 | Susanne Arnold|Eli Lilly and Company|University of Kentucky |
Head and Neck Cancer
|
December 2005 | Phase 1 |
| NCT00553358 | Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis |
Neoplasms, Breast
|
January 5, 2008 | Phase 3 |
| NCT01134250 | Philogen S.p.A. |
Solid Tumor|Breast Cancer|Metastatic Melanoma|Non-small Cell Lung Cancer (NSCLC)
|
August 6, 2008 | Phase 1|Phase 2 |
| NCT00781612 | Genentech, Inc.|Hoffmann-La Roche |
Neoplasm Metastasis
|
October 16, 2008 | Phase 2 |
| NCT00446836 | The Methodist Hospital Research Institute|Cellular Therapeutics |
Prostatic Neoplasms
|
March 2005 | Phase 2 |
| NCT03126812 | The Netherlands Cancer Institute|Merck Sharp & Dohme LLC |
Ovarian Cancer Stage IV|Peritoneal Cancer|Fallopian Tube Cancer
|
November 1, 2017 | Phase 1|Phase 2 |
| NCT00026104 | National Cancer Institute (NCI)|NRG Oncology |
Adenocarcinoma of the Pancreas|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer
|
November 2001 | Phase 2 |
| NCT00399126 | AEterna Zentaris |
Neoplasms
|
November 2004 | Phase 1 |
| NCT00072215 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor
|
April 2004 | Phase 3 |
| NCT00001384 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Breast Neoplasms
|
May 1994 | Phase 2 |
| NCT02586753 | Mianyang Central Hospital |
Esophageal Squamous Cell Carcinoma
|
December 2015 | Phase 2 |
| NCT04460066 | Lee´s Pharmaceutical Limited |
Esophageal Cancer
|
November 18, 2020 | Phase 1|Phase 2 |
| NCT01519804 | Genentech, Inc. |
Non-Squamous Non-Small Cell Lung Cancer
|
April 2012 | Phase 2 |
| NCT00002939 | University of Chicago|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
November 1996 | Phase 1 |
| NCT00057928 | Southwest Oncology Group|National Cancer Institute (NCI) |
Cervical Cancer
|
April 2003 | Phase 3 |
| NCT00003251 | University of Illinois at Chicago|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Head and Neck Cancer|Radiation Toxicity
|
December 1997 | Phase 1|Phase 2 |
| NCT00003852 | UNICANCER |
Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor
|
March 1998 | Phase 2 |
| NCT01325441 | Sumitomo Pharma Oncology, Inc. |
Cancer
|
April 2011 | Phase 1|Phase 2 |
| NCT00550784 | City of Hope Medical Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
January 2001 | Phase 1 |
| NCT00006257 | City of Hope Medical Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
November 2000 | Phase 1 |
| NCT03994107 | Peking Union Medical College|CSPC Ouyi Pharmaceutical Co., Ltd. |
Breast Cancer
|
October 1, 2019 | Phase 1|Phase 2 |
| NCT00005635 | Genentech, Inc.|National Cancer Institute (NCI) |
Breast Cancer
|
January 2000 | Phase 2 |
| NCT00003089 | Sidney Kimmel Cancer Center at Thomas Jefferson University|National Cancer Institute (NCI) |
Drug+Agent Toxicity by Tissue+Organ|Lung Cancer
|
July 1997 | Phase 2 |
| NCT01496742 | Genentech, Inc. |
Non-Squamous Non-Small Cell Lung Cancer
|
April 2012 | Phase 2 |
| NCT04136782 | Shengjing Hospital |
Breast Cancer
|
July 19, 2021 | Phase 4 |
| NCT00770809 | National Cancer Institute (NCI) |
Male Breast Carcinoma|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
December 1, 2008 | Phase 3 |
| NCT00513292 | National Cancer Institute (NCI) |
HER2+Neu Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
July 2007 | Phase 3 |
| NCT02051751 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
|
March 5, 2014 | Phase 1 |
| NCT00062179 | Jonsson Comprehensive Cancer Center|Pharmacia |
Lung Cancer
|
March 2003 | Phase 2 |
| NCT02581943 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
June 17, 2016 | Phase 2 |
| NCT02723955 | GlaxoSmithKline|Merck Sharp & Dohme LLC |
Neoplasms
|
June 23, 2016 | Phase 1 |
| NCT03154294 | Avera McKennan Hospital & University Health Center |
Advanced Solid Tumor
|
July 6, 2017 | Phase 1 |
| NCT05620654 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Ovarian Cancer|Hyperthermic Intraperitoneal Chemotherapy|Paclitaxel
|
December 1, 2022 | Phase 1 |
| NCT03564691 | Merck Sharp & Dohme LLC |
Neoplasms
|
July 11, 2018 | Phase 1 |
| NCT02213497 | Abramson Cancer Center of the University of Pennsylvania |
Esophageal Cancer
|
April 2014 | Phase 1 |
| NCT00201734 | Ohio State University Comprehensive Cancer Center|Roche Pharma AG |
Tumors|Unknown Primary Tumors|Adenocarcinoma
|
June 2005 | Phase 1|Phase 2 |
| NCT01077999 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Squamous Cell Carcinoma|Adenocarcinoma|Esophageal Cancer|Gastro-esophageal Junction Cancer
|
January 2010 | Phase 2 |
| NCT00111787 | GlaxoSmithKline |
Neoplasms, Breast
|
April 11, 2005 | Phase 2 |
| NCT02739698 | Maimónides Biomedical Research Institute of Córdoba |
Peritoneal Carcinomatosis
|
July 2012 | Phase 2 |
| NCT00193297 | SCRI Development Innovations, LLC|GlaxoSmithKline |
Ovary Cancer
|
February 2002 | Phase 2 |
| NCT00148681 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
|
May 2001 | Phase 2 |
| NCT02758847 | Rabih A. Chaer|University of Pittsburgh |
Ischemia
|
September 2016 | Not Applicable |
| NCT00146562 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Lowell General Hospital|Brigham and Women´s Hospital|North Shore Medical Center |
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer
|
July 2003 | Phase 2 |
| NCT00014599 | European Organisation for Research and Treatment of Cancer - EORTC |
Vulvar Cancer
|
February 2001 | Phase 2 |
| NCT00433420 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Gruppo Italiano Mammella (GIM) |
Breast Cancer
|
April 2003 | Phase 3 |
| NCT01235897 | University of California, San Francisco|Merck Sharp & Dohme LLC |
Advanced Solid Tumors|Tumors|Cancer
|
March 2011 | Phase 1 |
| NCT03718624 | Hebei Medical University |
Gastric Cancer With Positive Exfoliative Cancer Cells
|
October 30, 2018 | Phase 2 |
| NCT01404156 | Dr. Gordon Buduhan|CancerCare Manitoba|University of Toronto|London Health Sciences Centre |
Esophageal Cancer|Adenocarcinoma, Esophageal|Adenocarcinoma, Gastroesophageal Junction
|
September 2015 | Phase 2|Phase 3 |
| NCT00004089 | National Cancer Institute (NCI) |
Head and Neck Cancer
|
August 1999 | Phase 2 |
| NCT04090398 | National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor-Positive Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Triple-Negative Breast Carcinoma
|
December 27, 2019 | Phase 2 |
| NCT01493505 | Amgen |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer
|
January 2012 | Phase 3 |
| NCT03990103 | China Medical University, China |
Metastatic Gastric Adenocarcinoma
|
November 1, 2017 | Phase 2 |
| NCT03539328 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Ovarian Cancer
|
June 2018 | Phase 2 |
| NCT02016209 | Zhejiang University |
Non Small Cell Lung Cancer
|
January 2014 | Phase 2 |
| NCT02312245 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
July 21, 2015 | Phase 2 |
| NCT04336098 | Surface Oncology|Merck Sharp & Dohme LLC |
Advanced Solid Tumor
|
March 16, 2020 | Phase 1 |
| NCT01701349 | Mateon Therapeutics |
Anaplastic Thyroid Cancer
|
March 2015 | Phase 3 |
| NCT03887442 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Merck Sharp & Dohme LLC|Pivotal S.L. |
Head and Neck Cancer
|
February 16, 2011 | Phase 2 |
| NCT00004092 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 1999 | Phase 2 |
| NCT05311176 | Imugene Limited |
Gastric Cancer|Cancer of Stomach|Gastric Adenocarcinoma|Stomach Cancer|Stomach Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
August 17, 2022 | Phase 2 |
| NCT01276496 | National Cancer Institute (NCI) |
Adult Solid Neoplasm|Estrogen Receptor Negative|HER2+Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
|
December 2010 | Phase 1 |
| NCT04538742 | AstraZeneca|Daiichi Sankyo Company, Limited |
Metastatic Breast Cancer
|
December 28, 2020 | Phase 1|Phase 2 |
| NCT01205217 | GlaxoSmithKline |
Neoplasms, Breast
|
December 2010 | Phase 2 |
| NCT01075464 | Genentech, Inc. |
Solid Cancers
|
February 2010 | Phase 1 |
| NCT00313768 | Pfizer |
Carcinoma, Non-Small-Cell Lung
|
December 2005 | Phase 2 |
| NCT04308837 | Icahn School of Medicine at Mount Sinai |
Gastric Cancer|Stomach Cancer
|
July 31, 2018 | Phase 2 |
| NCT05498896 | Queen Mary University of London|Westdeutsche Studiengruppe GmbH (WSG)|MedSIR|Hoffmann-La Roche |
Triple Negative Breast Cancer
|
December 19, 2018 | Phase 2 |
| NCT04742036 | AstraZeneca |
Advanced Solid Tumours
|
February 22, 2021 | Phase 1 |
| NCT00294762 | OSI Pharmaceuticals|Astellas Pharma Inc |
Carcinoma, Non-Small-Cell Lung
|
January 2006 | Phase 2 |
| NCT00060359 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Fallopian Tube Carcinoma|Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Undifferentiated Ovarian Carcinoma
|
April 2003 | Phase 1 |
| NCT00467051 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Extracranial Germ Cell Tumor|Childhood Extragonadal Malignant Germ Cell Tumor|Childhood Malignant Ovarian Germ Cell Tumor|Childhood Malignant Testicular Germ Cell Tumor|Ovarian Choriocarcinoma|Ovarian Embryonal Carcinoma|Ovarian Yolk Sac Tumor|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Ovarian Germ Cell Tumor|Testicular Choriocarcinoma|Testicular Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor|Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor|Testicular Yolk Sac Tumor
|
November 5, 2007 | Phase 2 |
| NCT00735696 | Eli Lilly and Company |
Non Small Cell Lung Cancer
|
January 2009 | Phase 2 |
| NCT02395705 | Henan Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Peking University Cancer Hospital & Institute|Hunan Province Tumor Hospital|Sun Yat-sen University |
Esophageal Neoplasm
|
June 2015 | Phase 3 |
| NCT02212015 | Heidelberg University|Universitätsmedizin Mannheim|Helios Klinikum Berlin-Buch|University Hospital Dresden|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Essen|Hannover Medical School|Klinikum der Universitaet Muenchen, Grosshadern|Medical University of Vienna|Medical University of Graz|Medical University Innsbruck|Novartis Pharmaceuticals |
Angiosarcoma
|
July 2014 | Phase 2 |
| NCT00687687 | Sanofi|Gynecologic Oncology Group |
Uterine Carcinosarcoma
|
May 2008 | Phase 2 |
| NCT00653939 | Mateon Therapeutics |
Tumors
|
March 2008 | Phase 2 |
| NCT04938583 | CanariaBio Inc.|Korean Cancer Study Group |
Ovarian Cancer by FIGO Stage|Ovarian Cancer Stage III|Ovarian Cancer Stage IV
|
March 17, 2021 | Phase 1|Phase 2 |
| NCT03636308 | Peking University |
Pancreatic Cancer
|
July 17, 2018 | Phase 2 |
| NCT00801736 | University College, London|Eli Lilly and Company|Cancer Research UK |
Lung Cancer
|
October 2009 | Phase 3 |
| NCT01288261 | University of Arizona|National Cancer Institute (NCI) |
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
January 2011 | Phase 1 |
| NCT02448329 | Samsung Medical Center |
Advanced Gastric Adenocarcinoma
|
January 14, 2015 | Phase 2 |
| NCT00313599 | University of California, San Francisco|National Cancer Institute (NCI) |
Bladder Cancer|Brain and Central Nervous System Tumors|Breast Cancer|Esophageal Cancer|Extragonadal Germ Cell Tumor|Gastric Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer
|
February 2006 | Phase 1 |
| NCT02379416 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Solid Tumors
|
April 13, 2015 | Phase 1 |
| NCT02358200 | Pamela Munster|QuantumLeap Healthcare Collaborative|University of California, San Francisco |
Triple Negative Metastatic Breast Cancer|BRCA-mutated Solid Tumor
|
February 23, 2015 | Phase 1 |
| NCT00003065 | Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI) |
Cervical Cancer
|
January 1997 | Phase 2 |
| NCT05382286 | Gilead Sciences|Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer|PD-L1 Positive
|
July 25, 2022 | Phase 3 |
| NCT00004054 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Prostate Cancer
|
January 2000 | Phase 3 |
| NCT02501603 | Yonsei University |
Gastric Cancer|Gastroesophageal Junction Cancer
|
July 2016 | Phase 2 |
| NCT00460317 | Amgen|Takeda |
Non-Small Cell Lung Cancer
|
July 2007 | Phase 3 |
| NCT03916419 | Washington University School of Medicine |
Stage IIB Non-Small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Non-Small Cell Lung Cancer
|
June 20, 2019 | Phase 2 |
| NCT01779050 | Washington University School of Medicine|Genentech, Inc. |
Breast Neoplasms
|
December 19, 2013 | Phase 2 |
| NCT00873119 | Onxeo|Spectrum Pharmaceuticals, Inc |
Carcinoma of Unknown Primary
|
February 2009 | Phase 2 |
| NCT02215447 | Barwon Health|Specialised Therapeutics Australia|Deakin University|Australasian Gastro-Intestinal Trials Group |
Gastrointestinal Neuroendocrine Carcinomas
|
May 2015 | Phase 2 |
| NCT05185947 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Gynecologic Cancer|Gynecologic Neoplasms|Peritoneal Carcinomatosis|Peritoneal Neoplasms|Ovarian Cancer|Ovarian Neoplasms|Colorectal Cancer|Colorectal Neoplasms|Appendiceal Cancer|Appendiceal Neoplasms
|
October 13, 2022 | Phase 2 |
| NCT01617668 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
August 2012 | Phase 2 |
| NCT00796991 | Bristol-Myers Squibb|Medarex |
Advanced Melanoma
|
February 2009 | Phase 1 |
| NCT03503786 | National Cancer Institute, Naples |
Endometrial Cancer
|
April 1, 2018 | Phase 2 |
| NCT04261465 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
High Grade Serous Ovarian Cancer
|
December 1, 2019 | Phase 2 |
| NCT00004253 | Baptist Health South Florida|National Cancer Institute (NCI) |
Lung Cancer
|
March 2000 | Phase 2 |
| NCT02393898 | Hoffmann-La Roche |
Ovarian Cancer
|
April 23, 2015 | |
| NCT00003376 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer
|
September 1998 | Phase 3 |
| NCT01285466 | Novartis Pharmaceuticals|Novartis |
Metastatic or Locally Advanced Solid Tumors
|
January 2011 | Phase 1 |
| NCT03281369 | Hoffmann-La Roche|Halozyme Therapeutics|BioLineRx, Ltd. |
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
|
October 13, 2017 | Phase 1|Phase 2 |
| NCT04581265 | Sun Yat-sen University |
Extracranial Germ Cell Tumor, Pediatric
|
November 10, 2020 | Phase 2 |
| NCT01444547 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Municipal Science & Technology Commission |
Esophageal Cancer
|
January 2007 | Phase 2 |
| NCT00003133 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter
|
September 1997 | Phase 1 |
| NCT00096668 | Achieve Life Sciences |
Breast Cancer
|
October 2004 | Phase 2 |
| NCT01594177 | German Breast Group|Boehringer Ingelheim |
Unilateral HER2 Positive Breast Cancer
|
May 2012 | Phase 2 |
| NCT05300048 | Faeth Therapeutics |
Advanced Solid Tumor|PIK3CA Mutation|PTEN Loss of Function Mutation
|
April 22, 2022 | Phase 1 |
| NCT03094884 | Fox Chase Cancer Center |
Lung Cancer|Esophageal Cancer
|
February 24, 2017 | Phase 1 |
| NCT02194738 | National Cancer Institute (NCI) |
Lung Adenocarcinoma|Lung Large Cell Carcinoma|Resectable Lung Non-Small Cell Carcinoma|Stage IB Lung Non-Small Cell Carcinoma AJCC v7|Stage IB Lung Squamous Cell Carcinoma AJCC v7|Stage II Lung Non-Small Cell Cancer AJCC v7|Stage II Lung Squamous Cell Carcinoma AJCC v7|Stage IIA Lung Non-Small Cell Carcinoma AJCC v7|Stage IIA Lung Squamous Cell Carcinoma AJCC v7|Stage IIB Lung Non-Small Cell Carcinoma AJCC v7|Stage IIB Lung Squamous Cell Carcinoma AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
|
August 18, 2014 | Not Applicable |
| NCT02183194 | C. R. Bard |
Dysfunctional AV Graft|Dysfunctional AV Fistula
|
July 2014 | Not Applicable |
| NCT00691912 | Claudia Lorenz-Schlüter|University of Magdeburg |
Metastatic Breast Cancer
|
December 2006 | Phase 2 |
| NCT05213312 | Shanghai Zhongshan Hospital|Bristol-Myers Squibb |
Esophageal Squamous Cell Carcinoma
|
June 1, 2022 | Phase 2|Phase 3 |
| NCT02891018 | Shandong Branden Med.Device Co.,Ltd|Fudan University |
In-stent Restenosis
|
December 2015 | Phase 3 |
| NCT03944915 | University of Chicago |
Human Papilloma Virus|Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Head and Neck|HPV-Related Squamous Cell Carcinoma|HNSCC
|
August 26, 2019 | Phase 2 |
| NCT00002684 | Memorial Sloan Kettering Cancer Center |
Bladder Cancer|Urethral Cancer
|
May 1995 | Phase 2 |
| NCT02060253 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Synta Pharmaceuticals Corp.|New York University Cancer Institute |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
April 2014 | Phase 1 |
| NCT00002888 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group |
Head and Neck Cancer
|
March 1997 | Phase 3 |
| NCT01041027 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Endometrial Adenocarcinoma|Stage IA Uterine Corpus Cancer|Stage IB Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer
|
September 2008 | Phase 2 |
| NCT02036164 | Siriwan Tangjitgamol, MD|National Research Council of Thailand|Navamindradhiraj University|Chiang Mai University|Prince of Songkla University|Bhumibol Adulyadej Hospital|Lopburi Cancer Hospital|Ubonratchathani Cancer Hospital|Udonthani Cancer Hospital|Chonburi Cancer Hospital|Lampang Cancer Hospital|Health Intervention and Technology Assessment Program|Rajburi Hospital |
Uterine Cervical Cancer
|
January 2014 | Phase 3 |
| NCT02322814 | Hoffmann-La Roche |
Breast Cancer
|
November 25, 2014 | Phase 2 |
| NCT00655850 | University of Alabama at Birmingham|Genentech, Inc. |
Non-Small Cell Lung Cancer
|
March 2008 | Phase 2 |
| NCT00478361 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Distal Urethral Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Proximal Urethral Cancer|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Urethral Cancer Associated With Invasive Bladder Cancer
|
April 2007 | Phase 2 |
| NCT04974944 | Sun Yat-sen University |
Stage IVB Cervical Cancer|Recurrent Cervical Cancer|Persistent Cervical Cancer
|
July 30, 2021 | Phase 2 |
| NCT01134523 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Breast Cancer
|
May 2010 | Phase 3 |
| NCT05529667 | Yonsei University |
Fibroblast Growth Factors (FGFs)+Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
|
May 27, 2019 | Phase 1|Phase 2 |
| NCT02628613 | Fudan University |
Breast Cancer
|
December 2015 | Phase 2 |
| NCT01011075 | New Mexico Cancer Care Alliance|Fred Hutchinson Cancer Center|Novartis |
Non-small Cell Lung Cancer
|
August 2009 | Phase 2 |
| NCT04282109 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Bristol-Myers Squibb|Apices Soluciones S.L. |
Recurrent Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer Stage IV
|
June 3, 2020 | Phase 2 |
| NCT00748163 | Masonic Cancer Center, University of Minnesota |
Lung Cancer
|
August 2008 | Phase 2 |
| NCT03263741 | Affiliated Hospital of Qinghai University |
Gastric Cancer
|
April 1, 2017 | Phase 2 |
| NCT00655876 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Esophageal Cancer
|
June 2008 | Phase 3 |
| NCT01428414 | Zhimin Shao|Roche Pharma AG|Fudan University |
HER-2 Positive Breast Cancer
|
August 2011 | Phase 2 |
| NCT02794571 | Genentech, Inc. |
Advanced+Metastatic Tumors
|
May 23, 2016 | Phase 1 |
| NCT00883116 | R-Pharm |
Endometrial Cancer
|
August 2009 | Phase 3 |
| NCT01471132 | Peking University |
Gastric Cancer|Metastases to Perineum
|
September 2011 | Phase 2 |
| NCT01918124 | Fan Ming|Fudan University |
Prosthesis Survival
|
January 2008 | Phase 2 |
| NCT00096200 | National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
August 2004 | Phase 2 |
| NCT01796197 | Dana-Farber Cancer Institute |
Breast Cancer
|
August 2013 | Phase 2 |
| NCT04877821 | Guangdong Provincial People´s Hospital |
Triple Negative Breast Cancer
|
September 15, 2021 | Phase 2 |
| NCT00762034 | Eli Lilly and Company |
Non-small Cell Lung Cancer
|
December 2008 | Phase 3 |
| NCT03475615 | Fudan University |
Gastric Cancer|Stomach Neoplasms
|
March 16, 2018 | Phase 3 |
| NCT01216111 | Fudan University|Chinese Anti-Cancer Association |
Triple Negative Breast Cancer
|
January 1, 2011 | Phase 3 |
| NCT00033553 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
March 2002 | Phase 2 |
| NCT00017017 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
February 2001 | Phase 1|Phase 2 |
| NCT00096343 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Breast Cancer
|
October 2002 | Phase 2 |
| NCT01236716 | Chinese Society of Lung Cancer |
Carcinoma, Non-Small-Cell Lung
|
November 2010 | Phase 2 |
| NCT04989283 | National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Superior Sulcus Lung Carcinoma
|
September 9, 2021 | Phase 2 |
| NCT00010257 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Thymoma|Thymic Carcinoma
|
February 2001 | Phase 2 |
| NCT02718742 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Bladder Urothelial Carcinoma|Stage IV Bladder Urothelial Carcinoma
|
June 2016 | Phase 2 |
| NCT01419548 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Neoplasms
|
July 29, 2011 | Phase 1 |
| NCT00331422 | Masonic Cancer Center, University of Minnesota |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
October 2005 | Phase 2 |
| NCT03554109 | ImmunityBio, Inc. |
Triple Negative Breast Cancer (TNBC)
|
September 2018 | Phase 2 |
| NCT02948075 | NewVac LLC|Janssen Pharmaceutica N.V., Belgium |
Ovarian Cancer
|
September 2015 | Phase 2 |
| NCT00050167 | M.D. Anderson Cancer Center|Roche Pharma AG |
Breast Cancer
|
November 2002 | Phase 1 |
| NCT05439993 | Hallym University Medical Center |
Gastric Cancer|Gastroesophageal-junction Cancer
|
March 1, 2022 | Phase 1|Phase 2 |
| NCT00003378 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
August 1998 | Phase 1 |
| NCT00008047 | GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI) |
Esophageal Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT01706120 | National Cancer Institute, Naples|Mario Negri Institute for Pharmacological Research |
Ovarian Cancer
|
October 2012 | Phase 4 |
| NCT02810457 | Centus Biotherapeutics Limited |
Carcinoma, Non-Small-Cell Lung
|
September 7, 2016 | Phase 3 |
| NCT01413750 | National Cancer Institute (NCI) |
Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer
|
November 2010 | Phase 1|Phase 2 |
| NCT05353361 | Jiangsu HengRui Medicine Co., Ltd. |
HER2 Positive Non Resectable or Metastatic Breast Cancer
|
May 15, 2022 | Phase 2 |
| NCT00003050 | University of Southern California|National Cancer Institute (NCI) |
Breast Cancer
|
April 1997 | Phase 2 |
| NCT03852979 | The Netherlands Cancer Institute |
Cervical Cancer
|
November 1, 2018 | Phase 2 |
| NCT00870038 | Ospedale della Misericordia |
Angioplasty, Transluminal, Percutaneous Coronary|Percutaneous Coronary Intervention
|
December 2010 | Phase 4 |
| NCT02591615 | Alliance Foundation Trials, LLC.|Merck Sharp & Dohme LLC |
Non-Small Cell Lung Cancer
|
March 2016 | Phase 2 |
| NCT05009082 | AGO Study Group|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
|
September 13, 2022 | Phase 3 |
| NCT00270491 | ARCAGY+ GINECO GROUP |
Breast Cancer|Neoplasm Metastasis
|
December 2005 | Phase 2 |
| NCT01169870 | National Cancer Center, Korea |
Breast Cancer
|
July 2007 | Phase 2 |
| NCT00003927 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
May 18, 1999 | Phase 1 |
| NCT02761694 | ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) |
Cancer|Solid Tumors
|
June 26, 2016 | Phase 1 |
| NCT00972205 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Cervical|Ovarian|Lung|Breast|Renal
|
December 2007 | Not Applicable |
| NCT03697239 | Hitendra Patel|Cancer Research UK|Stand Up To Cancer|Lustgarten Foundation|Destroy Pancreatic Cancer|Translational Genomics Research Institute|HonorHealth Research Institute|University of California, San Diego |
Metastatic Pancreatic Cancer|Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreatic Metastasis
|
June 2019 | Phase 1|Phase 2 |
| NCT04781088 | Floor Backes|Ohio State University Comprehensive Cancer Center |
Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
September 1, 2021 | Phase 2 |
| NCT00378313 | NSABP Foundation Inc |
Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer|Breast Cancer|Locally Advanced
|
November 2001 | Phase 2 |
| NCT00003449 | University of Southern California|National Cancer Institute (NCI) |
Ovarian Cancer
|
May 1998 | Phase 2 |
| NCT02598687 | Maastricht Radiation Oncology|Threshold Pharmaceuticals|Zuyderland Medical Centre |
Esophageal Cancer
|
December 2015 | Phase 1 |
| NCT01928498 | Centre hospitalier de l´Université de Montréal (CHUM)|Biotronik Canada Inc |
Arteriovenous Fistulae|Arteriovenous Graft
|
October 2013 | Not Applicable |
| NCT00054210 | CTI BioPharma |
Lung Cancer
|
January 2003 | Phase 3 |
| NCT00174434 | Pfizer |
Breast Neoplasms
|
September 2005 | Phase 1 |
| NCT02012192 | Medical University Innsbruck|European Commission |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer
|
July 4, 2014 | Phase 1|Phase 2 |
| NCT00083083 | American College of Radiology Imaging Network|National Cancer Institute (NCI)|Radiation Therapy Oncology Group |
Lung Cancer
|
March 2005 | Phase 2 |
| NCT00131963 | Duke University|National Cancer Institute (NCI) |
Breast Cancer
|
October 2003 | |
| NCT01461915 | Chimerix|Translational Drug Development |
Metastatic Pancreatic Cancer
|
November 2011 | Phase 2 |
| NCT02142790 | Nanjing Luye Sike Pharmaceutical Co., Ltd. |
Breast Cancer
|
May 2014 | Phase 4 |
| NCT00003326 | Theradex|National Cancer Institute (NCI) |
Esophageal Cancer
|
September 1997 | Phase 2 |
| NCT00016315 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
May 2001 | Phase 1 |
| NCT04341883 | Sun Yat-sen University |
Recurrent Cervical Cancer
|
November 13, 2019 | Phase 2 |
| NCT00100789 | Southwest Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
January 2005 | Phase 2 |
| NCT03603184 | Mario Negri Institute for Pharmacological Research|Hoffmann-La Roche |
Endometrial Cancer
|
October 2, 2018 | Phase 3 |
| NCT03045770 | Fujian Cancer Hospital |
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
|
February 10, 2017 | Not Applicable |
| NCT00657878 | National Cancer Institute, Naples |
Ovarian Cancer
|
November 2008 | Phase 3 |
| NCT04284215 | Guizhou Medical University |
Efficacy and Safety
|
September 1, 2019 | Not Applicable |
| NCT03991403 | Samsung Medical Center |
Non-small Cell Lung Cancer
|
August 27, 2019 | Phase 3 |
| NCT04988789 | Singapore General Hospital |
Dialysis Access Malfunction|Kidney Failure
|
April 1, 2020 | |
| NCT03756090 | Zhejiang Cancer Hospital |
Breast Cancer|Breast Diseases|Breast Neoplasms
|
December 1, 2018 | Not Applicable |
| NCT00736619 | Memorial Sloan Kettering Cancer Center|Celgene Corporation|National Comprehensive Cancer Network |
HEAD & NECK Cancer
|
August 2008 | Phase 1 |
| NCT04278092 | Medical University of Vienna |
Head and Neck Squamous Cell Carcinoma
|
February 10, 2020 | Phase 2 |
| NCT04405505 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Triple Negative Breast Cancer
|
June 1, 2020 | Phase 3 |
| NCT04243616 | Medical College of Wisconsin |
Invasive Breast Cancer
|
March 5, 2020 | Phase 2 |
| NCT00411138 | Leiden University|Cancer Research UK|Australia New Zealand Gynaecological Oncology Group|NCIC Clinical Trials Group|Mario Negri Institute for Pharmacological Research|UNICANCER|Leiden University Medical Center |
Endometrial Cancer
|
November 23, 2006 | Phase 3 |
| NCT04551950 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono |
Cervical Cancer
|
October 19, 2020 | Phase 1 |
| NCT01107665 | University of California, Irvine|GlaxoSmithKline |
Stage III Melanoma|Stage IV Melanoma|Unresectable Melanoma
|
August 2010 | Phase 2 |
| NCT03858322 | Dana-Farber Cancer Institute|Mayo Clinic |
Breast Cancer
|
March 21, 2019 | Phase 1 |
| NCT03394885 | Duke University|Johns Hopkins University|Genentech, Inc. |
Ovarian Cancer|Ovarian Neoplasms
|
June 19, 2018 | Phase 1|Phase 2 |
| NCT04704934 | Daiichi Sankyo, Inc.|AstraZeneca |
Gastric Cancer, Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
May 21, 2021 | Phase 3 |
| NCT00251472 | Veeda Oncology|Celgene Corporation |
Metastatic Breast Cancer
|
March 2005 | Phase 2 |
| NCT00003387 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lung Cancer
|
July 1998 | Phase 3 |
| NCT04192253 | The Netherlands Cancer Institute |
Locally Advanced, Squamous Cell Carcinoma of the Vulva
|
January 14, 2020 | Phase 2 |
| NCT00002969 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
May 1997 | Phase 2 |
| NCT03693612 | GlaxoSmithKline|MedImmune LLC |
Neoplasms
|
November 26, 2018 | Phase 1|Phase 2 |
| NCT01248949 | MedImmune LLC |
Advanced Solid Tumors|Advanced Recurrent Ovarian Tumors
|
October 2010 | Phase 1 |
| NCT02593175 | M.D. Anderson Cancer Center |
Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma
|
August 26, 2016 | Phase 2 |
| NCT00006248 | Southwest Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
November 2000 | Phase 2 |
| NCT03057366 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Tumors, Neoplasms, Advanced Solid
|
May 11, 2017 | Phase 1 |
| NCT00991796 | Daiichi Sankyo, Inc. |
Non-small Cell Lung Cancer
|
June 2009 | Phase 2 |
| NCT00034190 | Achieve Life Sciences |
Colorectal Adenocarcinoma
|
March 2002 | Phase 2 |
| NCT03801876 | NRG Oncology|National Cancer Institute (NCI) |
Clinical Stage I Esophageal Adenocarcinoma AJCC v8|Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage I Esophageal Adenocarcinoma AJCC v8|Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Thoracic Esophagus Squamous Cell Carcinoma
|
March 15, 2019 | Phase 3 |
| NCT02159820 | Chinese PLA General Hospital |
Primary Malignant Neoplasm of Ovary|FIGO Stages II to IV
|
June 2014 | Phase 2|Phase 3 |
| NCT02898077 | Eli Lilly and Company |
Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma
|
March 2, 2017 | Phase 3 |
| NCT04047862 | BeiGene |
Locally Advanced and Metastatic Solid Tumors
|
August 26, 2019 | Phase 1 |
| NCT03095001 | Chinese PLA General Hospital |
Peritoneal Adhesion
|
June 1, 2017 | Phase 2 |
| NCT01572727 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
August 2012 | Phase 2|Phase 3 |
| NCT05374512 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Cancer
|
May 16, 2022 | Phase 3 |
| NCT00112489 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Sarcoma
|
May 2005 | Phase 2 |
| NCT00390611 | SCRI Development Innovations, LLC|Bayer |
Ovarian Cancer
|
October 2006 | Phase 2 |
| NCT00003206 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Head and Neck Cancer
|
April 1998 | Phase 2 |
| NCT00075712 | Royal College of Obstetricians and Gynecologists|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
September 2003 | Phase 2|Phase 3 |
| NCT02446652 | National Institute of Cancerología|Psicofarma S.A. de C.V. |
Cervical Cancer
|
July 2015 | Phase 3 |
| NCT04338399 | Adlai Nortye Biopharma Co., Ltd. |
Head and Neck Cancer
|
December 12, 2020 | Phase 3 |
| NCT04647643 | Lahey Clinic|National Evaluation System for health Technology Coordinating Center (NESTcc)|Society for Vascular Surgery Patient Safety Organization |
Peripheral Arterial Disease
|
November 20, 2020 | |
| NCT02307227 | Centro di Riferimento Oncologico - Aviano |
Breast Neoplasms
|
April 2006 | Phase 2 |
| NCT01873326 | Memorial Sloan Kettering Cancer Center|University of Southern California|Mayo Clinic|University of Pittsburgh|University of North Carolina|University of Chicago|Stanford University|University of Texas Southwestern Medical Center |
Germ Cell Tumors
|
June 2013 | Phase 2 |
| NCT00317200 | Hoosier Cancer Research Network|Genentech, Inc.|Walther Cancer Institute |
Small Cell Lung Cancer
|
April 2006 | Phase 2 |
| NCT00004174 | Northwestern University|National Cancer Institute (NCI) |
Breast Cancer
|
October 1999 | Phase 1 |
| NCT02429700 | Beihua Kong|Huazhong University of Science and Technology|Zhejiang University|Sun Yat-sen University|Shandong University |
Ovarian Sex Cord Stromal Tumor|Ovarian Neoplasms|Ovarian Cancer
|
April 2015 | Phase 3 |
| NCT00006374 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
October 1999 | Phase 2 |
| NCT03537690 | University of Southern California|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm
|
May 25, 2018 | Phase 1 |
| NCT01560104 | AbbVie (prior sponsor, Abbott)|AbbVie |
Non-Small -Cell Lung Cancer
|
February 2012 | Phase 2 |
| NCT02106546 | AbbVie |
Squamous Non-Small Cell Lung Cancer
|
April 10, 2014 | Phase 3 |
| NCT01862328 | Millennium Pharmaceuticals, Inc.|Takeda |
Solid Tumors
|
June 10, 2013 | Phase 1 |
| NCT00415961 | Conor Medsystems|Getz Pharma |
Coronary Disease
|
November 2006 | Not Applicable |
| NCT02319889 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage I Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer
|
February 2, 2016 | Early Phase 1 |
| NCT02365935 | Campus Bio-Medico University |
Uterine Cervical Neoplasms
|
February 2007 | Not Applicable |
| NCT05013697 | Henan Cancer Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Esophageal Neoplasms
|
September 2021 | Phase 2 |
| NCT00003401 | University of Maryland, Baltimore |
Multiple Myeloma and Plasma Cell Neoplasm
|
January 1999 | Phase 2 |
| NCT01973660 | SOLTI Breast Cancer Research Group|Novartis |
Breast Cancer
|
October 2013 | Phase 2 |
| NCT00004160 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Lung Cancer
|
February 2000 | Phase 1|Phase 2 |
| NCT01008150 | NSABP Foundation Inc|Puma Biotechnology, Inc. |
Breast Cancer
|
October 2010 | Phase 2 |
| NCT02913274 | Rennes University Hospital |
Stenosis of Arteriovenous Dialysis Fistula
|
March 20, 2017 | Not Applicable |
| NCT03262948 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Non-small Cell Lung Cancer
|
December 1, 2017 | Phase 3 |
| NCT04435652 | Qilu Pharmaceutical Co., Ltd. |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
|
July 1, 2020 | Phase 2|Phase 3 |
| NCT02420314 | Joseph J. Cullen, MD, FACS|National Cancer Institute (NCI)|National Institutes of Health (NIH)|Holden Comprehensive Cancer Center|McGuff Pharmaceuticals, Inc.|University of Iowa |
Carcinoma, Non-Small-Cell Lung
|
April 2015 | Phase 2 |
| NCT03466749 | Xijing Hospital|The First Affiliated Hospital of Zhengzhou University|First Affiliated Hospital of Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Second Hospital of Jilin University|First Affiliated Hospital of Xinjiang Medical University|Tang-Du Hospital|China-Japan Union Hospital, Jilin University|Xuzhou Third People´s Hospital |
Coronary Disease
|
February 22, 2018 | Not Applicable |
| NCT00002679 | Yale University |
Breast Cancer
|
February 1994 | Phase 2 |
| NCT04929041 | National Cancer Institute (NCI) |
Advanced Lung Adenocarcinoma|Advanced Lung Adenosquamous Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Adenocarcinoma|Metastatic Lung Adenosquamous Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
December 21, 2021 | Phase 2|Phase 3 |
| NCT04262869 | Emory University|National Cancer Institute (NCI) |
Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
March 27, 2020 | Phase 2 |
| NCT00603538 | Pfizer |
Carcinoma, Non-Small-Cell Lung
|
January 2008 | Phase 1 |
| NCT02338115 | University of Michigan Rogel Cancer Center |
Breast Cancer
|
May 2014 | |
| NCT03719924 | Federation Francophone de Cancerologie Digestive|Shire |
Squamous Cell Carcinoma
|
March 7, 2019 | Phase 2 |
| NCT00976677 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
January 2010 | Phase 2 |
| NCT01303497 | Centre Oscar Lambret|French Sarcoma Group|Study Group of Bone Tumors |
Angiosarcoma
|
September 10, 2010 | Phase 2 |
| NCT00070278 | Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI) |
Breast Cancer
|
January 2005 | Phase 3 |
| NCT02579564 | Xinqiao Hospital of Chongqing |
Malignant Hydrothorax|Non Small Cell Lung Cancer
|
October 2016 | Phase 3 |
| NCT04879368 | Australasian Gastro-Intestinal Trials Group|Bayer|Bristol-Myers Squibb|University of Sydney|Academic and Community Cancer Research United|Taiwanese Cooperative Oncology Group|Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|National Cancer Center Hospital East |
Gastro-Oesophageal Cancer
|
June 1, 2021 | Phase 3 |
| NCT02640053 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Breast Carcinoma
|
December 23, 2015 | Not Applicable |
| NCT01137994 | GlaxoSmithKline |
Neoplasms, Breast
|
October 2011 | Phase 2 |
| NCT04301375 | David Garcia Cinca|Fundacion Clinic per a la Recerca Biomédica|Hospital Clinic of Barcelona |
Mammary Cancer
|
June 15, 2020 | Phase 2 |
| NCT00838656 | Warwick Medical School|National Cancer Institute (NCI) |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer
|
October 2007 | Phase 2 |
| NCT00459810 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
February 2007 | Phase 2 |
| NCT00316407 | Swedish Medical Center|GlaxoSmithKline |
Ovarian Epithelial Cancer Stage III|Stage IV Ovarian Cancer|Stage IV Breast Cancer
|
August 2005 | Phase 1|Phase 2 |
| NCT00004887 | The Christie NHS Foundation Trust|National Cancer Institute (NCI) |
Lung Cancer
|
January 1999 | Phase 3 |
| NCT00009880 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Esophageal Cancer|Gastric Cancer
|
April 2001 | Phase 2 |
| NCT03206177 | University of Oklahoma|Eli Lilly and Company |
Carcinosarcoma, Ovarian
|
August 20, 2017 | Phase 1 |
| NCT04836728 | Tianjin Medical University Cancer Institute and Hospital |
Non-small Cell Lung Cancer Metastatic|First-line Treatment
|
April 1, 2021 | Phase 2 |
| NCT01606358 | Rennes University Hospital |
Ovarian Cancer
|
||
| NCT01084863 | Celltrion |
Metastatic Breast Cancer
|
February 2010 | Phase 1|Phase 2 |
| NCT00564733 | University of Washington|National Cancer Institute (NCI) |
Malignant Pleural Effusion|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
October 2007 | Phase 2 |
| NCT00518284 | Celgene Corporation|Celgene |
Vascular Disease, Peripheral
|
January 2008 | Phase 2 |
| NCT00320541 | Eli Lilly and Company|Genentech, Inc. |
Breast Cancer
|
May 2006 | Phase 2 |
| NCT01172223 | Prof Dirk Elling|Sana-Klinikum Lichtenberg |
Breast Cancer
|
September 2007 | Phase 1|Phase 2 |
| NCT00848718 | Merck Sharp & Dohme LLC |
Locally Advanced, Metastatic Solid Tumors
|
March 17, 2009 | Phase 1 |
| NCT03725059 | Merck Sharp & Dohme LLC |
Breast Cancer
|
December 27, 2018 | Phase 3 |
| NCT00064077 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer
|
May 2003 | Phase 3 |
| NCT00948675 | Eli Lilly and Company |
Advanced Non-Small Cell Lung Cancer
|
September 1, 2009 | Phase 3 |
| NCT00993655 | Canadian Cancer Trials Group|National Cancer Institute (NCI)|Grupo Español de Investigación en Cáncer de Ovario|Cancer Research UK|Southwest Oncology Group |
Fallopian Tube Cancer|Metastatic Cancer|Ovarian Cancer|Peritoneal Cavity Cancer
|
September 11, 2009 | Phase 2 |
| NCT03223974 | Beijing Hospital |
Coronary Disease
|
November 16, 2017 | Not Applicable |
| NCT00280150 | UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.|Eli Lilly and Company |
Lung Cancer
|
January 2006 | Phase 1|Phase 2 |
| NCT00124943 | Celgene Corporation|Celgene |
Coronary Restenosis
|
July 2005 | Phase 1|Phase 2 |
| NCT01268059 | MedImmune LLC |
Non-small Cell Lung Cancer
|
December 16, 2010 | Phase 1|Phase 2 |
| NCT00110019 | National Cancer Institute (NCI) |
Mucosal Melanoma|Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma
|
June 2005 | Phase 3 |
| NCT00915603 | SCRI Development Innovations, LLC|Novartis |
Metastatic Breast Cancer
|
July 2009 | Phase 2 |
| NCT02297230 | NYU Langone Health |
Breast Cancer
|
June 2002 | Phase 1|Phase 2 |
| NCT00052312 | European Organisation for Research and Treatment of Cancer - EORTC |
Endometrial Cancer
|
September 2002 | Phase 2 |
| NCT05487391 | Qilu Pharmaceutical Co., Ltd. |
Carcinoma, Non-Small-Cell Lung
|
October 1, 2022 | Phase 3 |
| NCT00176254 | Susanne Arnold|Bristol-Myers Squibb|University of Kentucky |
Squamous Cell Carcinoma
|
May 2000 | Phase 2 |
| NCT02066103 | Mercator MedSystems, Inc.|National Cancer Institute (NCI) |
Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer
|
July 2014 | Not Applicable |
| NCT00336791 | M.D. Anderson Cancer Center|Breast Cancer Research Foundation |
Breast Cancer
|
September 2003 | Phase 3 |
| NCT04527991 | Gilead Sciences|Everest Medicines |
Locally Advanced or Metastatic Unresectable Urothelial Cancer
|
January 13, 2021 | Phase 3 |
| NCT04843098 | Suzhou Junde Biotechnology Co., Ltd |
Head and Neck Squamous Cell Carcinoma
|
April 2021 | Phase 1|Phase 2 |
| NCT00538603 | King Faisal Specialist Hospital & Research Center |
Epithelial Ovarian Cancer
|
June 2005 | Not Applicable |
| NCT01497470 | Achieve Life Sciences|Teva Branded Pharmaceutical Products R&D, Inc. |
Cancer
|
April 2012 | Phase 1 |
| NCT04603183 | MedSIR|Eli Lilly and Company |
Breast Cancer Metastatic
|
June 2, 2021 | Phase 2 |
| NCT00403130 | George Albert Fisher|Genentech, Inc.|Eli Lilly and Company|Stanford University |
Breast Cancer|Metastatic Breast Cancer
|
February 2006 | Phase 2 |
| NCT03699449 | Yonsei University|AstraZeneca|Samsung Genomic Institute|Seoul National University Hospital|Samsung Medical Center|Korean Gynecologic Oncology Group |
Platinum-resistant Recurrent Ovarian Cancer
|
November 26, 2018 | Phase 2 |
| NCT02449655 | Samsung Medical Center |
Advanced Gastric Adenocarcinoma
|
February 12, 2015 | Phase 2 |
| NCT00645177 | AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie |
Metastatic Breast Cancer
|
July 2008 | Phase 2 |
| NCT02819518 | Merck Sharp & Dohme LLC |
Triple Negative Breast Cancer (TNBC)
|
July 27, 2016 | Phase 3 |
| NCT00003394 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Prostate Cancer
|
April 1998 | Phase 1|Phase 2 |
| NCT00358163 | Dana-Farber Cancer Institute|Novartis Pharmaceuticals|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Massachusetts General Hospital |
Metastatic Non-hematologic Malignancies
|
April 26, 2006 | Phase 1 |
| NCT04405674 | Shanghai Chest Hospital |
Non Small Cell Lung Cancer
|
July 15, 2020 | Phase 2 |
| NCT00100139 | INSYS Therapeutics Inc |
Neoplasm
|
November 2004 | Phase 1 |
| NCT04802980 | Huabo Biopharm Co., Ltd. |
Solid Tumor
|
April 28, 2020 | Phase 1 |
| NCT01912625 | National Cancer Institute (NCI) |
Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7
|
October 28, 2013 | Phase 1 |
| NCT03430843 | BeiGene |
Esophageal Squamous Cell Carcinoma (ESCC)
|
January 26, 2018 | Phase 3 |
| NCT01730833 | City of Hope Medical Center|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Breast Adenocarcinoma|Inflammatory Breast Carcinoma
|
July 17, 2013 | Phase 2 |
| NCT00004011 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group|Radiation Therapy Oncology Group |
Lung Cancer
|
October 1999 | Phase 3 |
| NCT00499525 | Northwestern University|Amgen |
Breast Cancer
|
June 2007 | Phase 2 |
| NCT00278122 | University of Virginia|National Cancer Institute (NCI) |
Melanoma (Skin)
|
July 2005 | Phase 2 |
| NCT00004013 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
January 1999 | Phase 2 |
| NCT01522768 | Memorial Sloan Kettering Cancer Center|Boehringer Ingelheim|University of Southern California|Dana-Farber Cancer Institute|United States Department of Defense |
Esophageal Cancer|Gastric Cancer
|
March 2012 | Phase 2 |
| NCT00600821 | Pfizer |
Non-Small-Cell Lung Carcinoma|Adenocarcinoma
|
April 2008 | Phase 2 |
| NCT00005581 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|National Cancer Institute (NCI) |
Breast Cancer
|
June 2000 | Phase 3 |
| NCT04238988 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Merck Sharp & Dohme LLC |
Locally Advanced Cervical Cancer
|
February 18, 2021 | Phase 2 |
| NCT01303679 | ARCAGY+ GINECO GROUP |
First Line Metastatic Breast Cancer
|
June 2010 | Phase 3 |
| NCT04611776 | Hoffmann-La Roche |
Carcinoma, Non-Small Cell Lung
|
July 1, 2021 | Phase 2 |
| NCT03977077 | Henan Cancer Hospital |
Advanced Gastrointestinal Tumors
|
June 1, 2019 | Not Applicable |
| NCT00031876 | Swiss Group for Clinical Cancer Research |
Breast Cancer
|
May 2000 | Phase 1|Phase 2 |
| NCT00003881 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
May 1999 | Phase 2 |
| NCT05244837 | Hao Long|Sun Yat-sen University |
Tislelizumab|Safety|Biomarker|Chemotherapy
|
December 22, 2020 | Phase 2 |
| NCT05493995 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pancreatic Neoplasms
|
June 1, 2022 | Phase 2 |
| NCT04585490 | Maximilian Diehn|AstraZeneca|Stanford University |
Non Small Cell Lung Cancer|NSCLC, Stage III|Nsclc
|
August 25, 2021 | Phase 3 |
| NCT03223376 | Hutchison Medipharma Limited|Sun Yat-sen University|Hutchmed |
Advanced Gastric Cancer
|
October 18, 2017 | Phase 3 |
| NCT03169777 | ImmunityBio, Inc. |
Colorectal Cancer
|
August 2018 | Phase 1|Phase 2 |
| NCT01745757 | UNICANCER |
Metastatic|Breast Cancer
|
June 2012 | |
| NCT02892123 | Zymeworks Inc. |
HER2-expressing Cancers
|
September 2016 | Phase 1 |
| NCT00737243 | SCRI Development Innovations, LLC|Genentech, Inc. |
Carcinoma
|
August 2008 | Phase 2 |
| NCT01106898 | University of Nebraska|National Cancer Institute (NCI) |
Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer
|
March 2010 | Phase 2 |
| NCT02272790 | AstraZeneca |
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
|
January 30, 2015 | Phase 2 |
| NCT02059967 | Virginia Commonwealth University|National Cancer Institute (NCI) |
Adenocarcinoma of the Lung|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer
|
March 2014 | Phase 1 |
| NCT04634877 | Merck Sharp & Dohme LLC|European Network for Gynaecological Oncological Trial Groups|Gynecologic Oncology Group |
Endometrial Neoplasms
|
January 10, 2021 | Phase 3 |
| NCT01676649 | Jewish General Hospital |
Untreated Stage III Melanoma or Stage IV Melanoma
|
November 2012 | Phase 2 |
| NCT01031212 | University of California, San Francisco|Novartis Pharmaceuticals |
Tumors
|
January 2010 | Phase 1 |
| NCT04095364 | NRG Oncology|National Cancer Institute (NCI) |
Low Grade Fallopian Tube Serous Adenocarcinoma|Ovarian Low Grade Serous Adenocarcinoma|Primary Peritoneal Low Grade Serous Adenocarcinoma|Stage II Fallopian Tube Cancer AJCC v8|Stage II Ovarian Cancer AJCC v8|Stage II Primary Peritoneal Cancer AJCC v8|Stage IIA Fallopian Tube Cancer AJCC v8|Stage IIA Ovarian Cancer AJCC v8|Stage IIA Primary Peritoneal Cancer AJCC v8|Stage IIB Fallopian Tube Cancer AJCC v8|Stage IIB Ovarian Cancer AJCC v8|Stage IIB Primary Peritoneal Cancer AJCC v8|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8
|
August 26, 2019 | Phase 3 |
| NCT02711137 | Incyte Corporation |
Solid Tumors
|
May 18, 2016 | Phase 1|Phase 2 |
| NCT00811993 | Hoffmann-La Roche |
Neoplasms
|
February 2009 | Phase 1 |
| NCT05342636 | Merck Sharp & Dohme LLC |
Esophageal Squamous Cell Carcinoma (ESCC)
|
July 27, 2022 | Phase 1|Phase 2 |
| NCT04110288 | Lahey Clinic|Society for Vascular Surgery Patient Safety Organization |
Peripheral Vascular Disease
|
January 1, 2017 | |
| NCT00005806 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
September 1999 | Phase 1 |
| NCT04152057 | West China Hospital|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer|HER2 Positive|Combination Chemotherapy
|
November 2019 | Phase 1|Phase 2 |
| NCT02607332 | Asan Medical Center |
Gastrointestinal Stromal Tumors
|
November 2015 | Phase 2 |
| NCT04526470 | Seoul National University Bundang Hospital |
Solid Tumor|Stomach Cancer
|
September 1, 2020 | Phase 1|Phase 2 |
| NCT05543629 | Bristol-Myers Squibb |
Advanced Solid Tumors|Non-small Cell Lung Cancer
|
October 4, 2022 | Phase 1|Phase 2 |
| NCT00559845 | Hoffmann-La Roche |
Breast Cancer
|
February 2008 | Phase 2 |
| NCT01310244 | Acrotech Biopharma Inc.|Onxeo |
Stage IV Non-small Cell Lung Cancer
|
December 2010 | Phase 1|Phase 2 |
| NCT00436709 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 2006 | Not Applicable |
| NCT00290537 | M.D. Anderson Cancer Center|AstraZeneca |
Lung Cancer
|
January 2006 | Phase 2 |
| NCT02725268 | Millennium Pharmaceuticals, Inc.|European Network of Translational Research in Ovarian Cancer - EUTROC|European Network of Individualized Treatment in Endometrial Cancer - ENITEC|Takeda |
Endometrial Neoplasms
|
April 1, 2016 | Phase 2 |
| NCT01739894 | National University Hospital, Singapore |
Gastric Cancer
|
January 2013 | Phase 2 |
| NCT00551733 | CTI BioPharma |
Lung Cancer
|
August 2007 | Phase 3 |
| NCT00005065 | National Cancer Institute (NCI) |
Stage IIIA Non-small Cell Lung Cancer
|
January 2000 | Phase 1 |
| NCT01993810 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7
|
February 3, 2014 | Phase 3 |
| NCT01069328 | Bayer |
Carcinoma, Non-Small-Cell Lung|Lung Cancer
|
July 2006 | Phase 1 |
| NCT04225364 | Guangzhou Institute of Respiratory Disease|BGI-Shenzhen|Jiangsu HengRui Medicine Co., Ltd. |
Esophageal Squamous Cell Carcinoma|Immunotherapy
|
January 17, 2020 | Phase 2 |
| NCT00161278 | University of Michigan Rogel Cancer Center |
Advanced Non-Small Cell Lung Cancer
|
December 2004 | Phase 2 |
| NCT05136846 | Ohio State University Comprehensive Cancer Center |
Locally Advanced Lung Non-Small Cell Carcinoma|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma
|
December 6, 2021 | Phase 1 |
| NCT00369070 | Amgen |
Advanced Non-squamous NSCLC
|
January 31, 2007 | Phase 2 |
| NCT01042925 | Sanofi |
Breast Cancer|Breast Neoplasms
|
February 2010 | Phase 1|Phase 2 |
| NCT00003589 | European Organisation for Research and Treatment of Cancer - EORTC |
Lung Cancer
|
August 1998 | Phase 3 |
| NCT00499083 | University of Nebraska|National Cancer Institute (NCI) |
Breast Cancer
|
May 2006 | Phase 2 |
| NCT01136031 | Seoul National University Hospital |
Advanced Gastric Cancer
|
January 2008 | Phase 1|Phase 2 |
| NCT00434226 | Genentech, Inc. |
Non-Small Cell Lung Cancer
|
March 2007 | Phase 2 |
| NCT04516447 | K-Group Beta |
Solid Tumor|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
|
October 26, 2020 | Phase 1 |
| NCT00668616 | North Eastern German Society of Gynaecological Oncology |
Breast Cancer
|
March 2000 | Phase 3 |
| NCT00566540 | Ohio State University Comprehensive Cancer Center |
Head and Neck Cancer
|
December 11, 2007 | Phase 2 |
| NCT01000896 | AstraZeneca |
Cancer|Non Small Cell Lung Cancer|Epithelial Ovarian Cancer
|
January 2010 | Phase 1 |
| NCT01091428 | Millennium Pharmaceuticals, Inc.|Takeda |
Ovarian Carcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Breast Carcinoma
|
April 16, 2010 | Phase 2 |
| NCT00265733 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
February 2006 | Phase 2 |
| NCT02876302 | Dana-Farber Cancer Institute|Incyte Corporation |
Inflammatory Breast Cancer (IBC)
|
April 26, 2017 | Phase 2 |
| NCT00005078 | City of Hope Medical Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
March 2000 | Phase 1 |
| NCT02437812 | Gynecologic Oncology Associates|University of North Carolina, Chapel Hill |
Epithelial Ovarian Carcinoma
|
January 2014 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
DMSO : 100 mg/mL ( 117.11 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.1711 mL | 5.8554 mL | 11.7108 mL |
| 5 mM | 0.2342 mL | 1.1711 mL | 2.3422 mL |
| 10 mM | 0.1171 mL | 0.5855 mL | 1.1711 mL |
Add each solvent one by one: corn oil
Solubility: 10 mg/mL (11.71 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (2.44 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution